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A B S T R A C T
Background
Mind-body interventions are based on the holistic principle that mind, body and behaviour are all interconnected. Mind-body inter-
ventions incorporate strategies that are thought to improve psychological and physical well-being, aim to allow patients to take an active
role in their treatment, and promote people’s ability to cope. Mind-body interventions are widely used by people with fibromyalgia to
help manage their symptoms and improve well-being. Examples of mind-body therapies include psychological therapies, biofeedback,
mindfulness, movement therapies and relaxation strategies.
Objectives
To review the benefits and harms of mind-body therapies in comparison to standard care and attention placebo control groups for
adults with fibromyalgia, post-intervention and at three and six month follow-up.
Search methods
Electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), EMBASE (Ovid),
PsycINFO (Ovid), AMED (EBSCO) and CINAHL (Ovid) were conducted up to 30 October 2013. Searches of reference lists were
conducted and authors in the field were contacted to identify additional relevant articles.
Selection criteria
All relevant randomised controlled trials (RCTs) of mind-body interventions for adults with fibromyalgia were included.
Data collection and analysis
Two authors independently selected studies, extracted the data and assessed trials for low, unclear or high risk of bias. Any discrepancy
was resolved through discussion and consensus. Continuous outcomes were analysed using mean difference (MD) where the same
outcome measure and scoring method was used and standardised mean difference (SMD) where different outcome measures were used.
For binary data standard estimation of the risk ratio (RR) and its 95% confidence interval (CI) was used.
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Main results
Seventy-four papers describing 61 trials were identified, with 4234 predominantly female participants. The nature of fibromyalgia
varied from mild to severe across the study populations. Twenty-six studies were classified as having a low risk of bias for all domains
assessed. The findings of mind-body therapies compared with usual care were prioritised.
There is low quality evidence that in comparison to usual care controls psychological therapies have favourable effects on physical
functioning (SMD -0.4, 95% CI -0.6 to -0.3, -7.5% absolute change, 2 point shift on a 0 to 100 scale), pain (SMD -0.3, 95% CI
-0.5 to -0.2, -3.5% absolute change, 2 point shift on a 0 to 100 scale) and mood (SMD -0.5, 95% CI -0.6 to -0.3, -4.8% absolute
change, 3 point shift on a 20 to 80 scale). There is very low quality evidence of more withdrawals in the psychological therapy group in
comparison to usual care controls (RR 1.38, 95% CI 1.12 to 1.69, 6% absolute risk difference). There is lack of evidence of a difference
between the number of adverse events in the psychological therapy and control groups (RR 0.38, 95% CI 0.06 to 2.50, 4% absolute
risk difference).
There was very low quality evidence that biofeedback in comparison to usual care controls had an effect on physical functioning (SMD
-0.1, 95% CI -0.4 to 0.3, -1.2% absolute change, 1 point shift on a 0 to 100 scale), pain (SMD -2.6, 95% CI -91.3 to 86.1, -2.6%
absolute change) and mood (SMD 0.1, 95% CI -0.3 to 0.5, 1.9% absolute change, less than 1 point shift on a 0 to 90 scale) post-
intervention. In view of the quality of evidence we cannot be certain that biofeedback has a little or no effect on these outcomes. There
was very low quality evidence that biofeedback led to more withdrawals from the study (RR 4.08, 95% CI 1.43 to 11.62, 20% absolute
risk difference). No adverse events were reported.
There was no advantage observed for mindfulness in comparison to usual care for physical functioning (SMD -0.3, 95% CI -0.6 to
0.1, -4.8% absolute change, 4 point shift on a scale 0 to 100), pain (SMD -0.1, CI -0.4 to 0.3, -1.3% absolute change, less than 1 point
shift on a 0 to 10 scale), mood (SMD -0.2, 95% CI -0.5 to 0.0, -3.7% absolute change, 2 point shift on a 20 to 80 scale) or withdrawals
(RR 1.07, 95% CI 0.67 to 1.72, 2% absolute risk difference) between the two groups post-intervention. However, the quality of the
evidence was very low for pain and moderate for mood and number of withdrawals. No studies reported any adverse events.
Very low quality evidence revealed that movement therapies in comparison to usual care controls improved pain (MD -2.3, CI -4.2
to -0.4, -23% absolute change) and mood (MD -9.8, 95% CI -18.5 to -1.2, -16.4% absolute change) post-intervention. There was
no advantage for physical functioning (SMD -0.2, 95% CI -0.5 to 0.2, -3.4% absolute change, 2 point shift on a 0 to 100 scale),
participant withdrawals (RR 1.95, 95% CI 1.13 to 3.38, 11% absolute difference) or adverse events (RR 4.62, 95% CI 0.23 to 93.92,
4% absolute risk difference) between the two groups, however rare adverse events may include worsening of pain.
Low quality evidence revealed that relaxation based therapies in comparison to usual care controls showed an advantage for physical
functioning (MD -8.3, 95% CI -10.1 to -6.5, -10.4% absolute change) and pain (SMD -1.0, 95% CI -1.6 to -0.5, -3.5% absolute
change, 2 point shift on a 0 to 78 scale) but not for mood (SMD -4.4, CI -14.5 to 5.6, -7.4% absolute change) post-intervention.
There was no difference between the groups for number of withdrawals (RR 4.40, 95% CI 0.59 to 33.07, 31% absolute risk difference)
and no adverse events were reported.
Authors’ conclusions
Psychological interventions therapiesmay be effective in improvingphysical functioning, pain and lowmood for adultswith fibromyalgia
in comparison to usual care controls but the quality of the evidence is low. Further research on the outcomes of therapies is needed
to determine if positive effects identified post-intervention are sustained. The effectiveness of biofeedback, mindfulness, movement
therapies and relaxation based therapies remains unclear as the quality of the evidence was very low or low. The small number of trials
and inconsistency in the use of outcome measures across the trials restricted the analysis.
P L A I N L A N G U A G E S U M M A R Y
Interventions focusing on the link between the mind and body for adults with fibromyalgia
Research question
What are the effects of mind and body therapy for fibromyalgia on pain, physical function, mood and side effects?
What problems does fibromyalgia cause?
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People with fibromyalgia have chronic, widespread body pain, and often have fatigue (feeling tired), stiffness, depression and problems
sleeping.
What are mind-body interventions?
Mind-body interventions include treatments such as biofeedback, mindfulness, movement therapies, psychological therapy and relax-
ation therapies. Biofeedback is when you are connected to electrical sensors that help you receive information about your body to make
subtle changes in your body, such as relaxing. Mindfulness means having awareness of thoughts, feelings and bodily sensations. All
mind-body therapies make the link between thoughts, behaviour and feelings to help people to cope with their symptoms.
Study characteristics
We conducted a review of the effect of mind-body therapies for adults with fibromyalgia. After searching for all relevant studies until
October 2013, we found 61 studies including 4234 adults.
- Many studies only included female participants, but some males were included in a few studies.
- Participants had mild to severe fibromyalgia.
- Mind-body interventions were compared to ’usual care’, such as medication use. Secondary analysis also compared findings in
comparison to an ’attention control therapy’ which involved receiving information for the same amount of time as the mind-body
therapy.
Key results at the end of treatment
- Low quality evidence revealed that psychological therapies improved physical functioning, pain, mood and side effects compared to
usual care. More people withdrew from the psychological therapy group compared to usual care.
- There was little or no difference in physical functioning, pain and mood between people receiving biofeedback and usual care but
this may have happened by chance. More people withdrew from the biofeedback than the usual care group. No studies reported any
side effects.
- There was little or no difference in physical functioning, pain, mood and the number of withdrawals between people receiving
mindfulness therapy and usual care. No studies reported any adverse events.
- We are uncertain whether movement therapies improve physical functioning, pain, mood, side effects or the number of people who
withdrew from the treatment. There were improvements in pain and mood for people receiving movement therapies but the quality of
the evidence was very low. More people withdrew and two participants reported experiencing increased pain in the intervention group.
- We are uncertain whether relaxation therapies improve physical functioning and pain compared to usual care because the quality of
evidence was very low. There was little or no difference in mood and withdrawal from treatment between people receiving relaxation
therapies and those receiving usual care. No adverse events were reported.
Best estimates of what happens at the end of treatment in people with fibromyalgia when they use mind-body therapies
The main findings on the use of psychological therapies are summarised below.
- Physical functioning after 1 to 25 weeks (higher scores mean greater limitations)
People who used psychological therapies rated their physical functioning as 2 points lower on a scale of 0 to 100 compared to those
who received usual care (7.5% absolute improvement).
- Pain after 3 to 14 weeks (higher scores mean worse or more severe pain)
People who used psychological therapies rated their pain as 2 points lower on a scale of 0 to 100 compared to those who received usual
care (3.5% absolute improvement).
- Mood (higher scores mean worse or more severe pain)
People who used psychological therapies rated their mood as 3 points lower on a scale of 20 to 80 compared to those who received
usual care (4.8% absolute improvement).
- Withdrawing from the treatment for any reason
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A total of 204 out of 1000 people withdrew from psychological therapies compared with 148 out of 1000 from usual care (6% absolute
improvement).
- Side effects
Nineteen people out of 1000 who received psychological therapies experienced a side effect compared with 51 out of 1000 who had
usual care (4% absolute improvement). This may have happened by chance.
We do not have precise information about side effects and complications of mind-body therapies. Rare adverse events may include
worsening of pain.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Psychological therapies compared to usual care for fibromyalgia
Patient or population: patients with fibromyalgia
Settings: outpatients
Intervention: psychological therapies
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of p
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Psychological therapies
Functioning as assessed
post-intervention
Fibromyalgia Im-
pact Questionnaire. Scale
from: 0 to 100
Follow-up: 1 to 5 weeks
The mean functioning as
assessed post-interven-
tion in the control groups
was
6.77
The mean functioning as
assessed post-interven-
tion in the intervention
groups was
0.43 standard deviations
lower
(0.57 to 0.28 lower)
733
(10 studies)
⊕⊕©©
low1,2
SMD -0.4 (95% CI -0.6 to -0.
3).
Absolute change -7.5% (95%
CI -9.9 to -4.9), 2 point shift
on a scale of 0-100
Relative improvement -10.
8% (95% CI -5.8 to -14.3)
NNT 5 (95% CI 4 to 7)
Pain as assessed post-
intervention
100 point visual analog
scale. Scale from: 0 to
100
Follow-up: 3 to 14 weeks
The mean pain as as-
sessed post-intervention
in the control groups was
7.48
The mean pain as as-
sessed post-intervention
in the intervention groups
was
0.33 standard deviations
lower
(0.52 to 0.15 lower)
453
(9 studies)
⊕⊕©©
low3,4
SMD -0.3 (95% CI -0.5 to -0.
2)
Absolute change -3.5% (95%
CI -5.4 to -1.6), 2 point shift
on a scale of 0-100 Relative
improvement -5.3% (95% CI
-7.0 to -8.3)
NNT 6 (95% CI 4 to 14)
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Mood as assessed post-
intervention
State Trait Anxiety Inven-
tory - State Scale. Scale
from: 20 to 80
Follow-up: 1 to 25 weeks
The mean mood as as-
sessed post-intervention
in the control groups was
7.8
The mean mood as as-
sessed post-intervention
in the intervention groups
was
0.45 standard deviations
lower
(0.64 to 0.26 lower)
492
(8 studies)
⊕⊕©©
low5,6
SMD -0.5 (95% CI -0.6 to
-0.3). Absolute change -4.
8 (95% CI -6.8 to -2.8), 3
point shift on a scale of 20-
80 Relative improvement -
10.8% (95% CI -2.5 to -6.3)
NNT 5 (95% CI 3 to 8)
All cause attrition post-
intervention
Number of people with-
drawing from the study
before completing the in-
tervention
Follow-up: 1 to 25 weeks
Study population RR 1.38
(1.12 to 1.69)
1687
(22 studies)
⊕©©©
very low7,8
Absolute risk difference 6%
(95% CI 0.0 to 0.1)
Relative per cent change 38%
(95% CI 12 to 69)
NNTH 18 (95% CI 10 to 55)
148 per 1000 204 per 1000
(165 to 249)
Adverse events post-in-
tervention
Number of people report-
ing an adverse event be-
fore completing the inter-
vention
Follow-up: 4 to 6 weeks
Study population RR 0.38
(0.06 to 2.5)
126
(2 studies)
⊕⊕©©
low9,10
Absolute risk difference 4%
(95% CI -0.1 to 0.0)
Relative per cent change 62%
(95% CI -94 to 150)
Not statistically significant
51 per 1000 19 per 1000
(3 to 127)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level due to risk of bias: For some studies allocation concealment was unclear and there was a high risk of selective
reporting in one study
2 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery between studies
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3 Downgraded one level due to risk of bias: For some studies allocation concealment was unclear and there was a high risk of selective
reporting in one study
4 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery between studies
5 Downgraded one level due to risk of bias: For some studies allocation concealment, blinding of participants and selective reporting were
unclear
6 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery between studies
7 Downgraded two levels due to risk of bias: Two studies were classified as having a high risk of outcome data and 3 studies were
classified as having a high risk of selective reporting bias. Some studies were classified as having an unclear risk of sequence generation,
allocation concealment, blinding of outcome assessors and outcome data.
8 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery between studies
9 Downgraded one level due to risk of bias: Some studies were classified as having an unclear risk of sequence generation, allocation
concealment and one study was classified as having a high risk of selective reporting
10 Downgraded one level due to imprecision: There were less than 200 participants in the analysis
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Fibromyalgia (FM) is a complex, chronic condition, which is char-
acterised by widespread persistent pain, fatigue, cognitive impair-
ment and sleep disturbances that make it difficult for people to
engage in everyday activities (Arnold 2011; Bennett 2007; Wolfe
1990). Fibromyalgia has been associated with high individual and
societal healthcare costs (Berger 2007; Sicras-Mainar 2009) with
many patients reporting reduced physical functioning and poor
quality of life (Burckhardt 1991). The term fibromyalgia (FM) is
used in this review in accordance with Cochrane convention.
Estimates suggest that FM affects between 2% to 5% of the gen-
eral population (Branco 2010; Wolfe 1995). There is a higher
prevalence in females (female:male ratio of 9 to 10:1) (MacFarlane
2002; Wolfe 1990; Yunus 2001), with prevalence rising to 8% in
women between 55 and 64 years of age (White 1999). Emerging
evidence suggests that the condition is linked to dysregulation of
the central and sympathetic nervous systems (Mease 2005) that
results from neurochemical imbalances leading to both an ampli-
fication of pain signals and reduced ability to inhibit the pain re-
sponse (Ceko 2011; Clauw 2011).
A diagnosis of fibromyalgia is usually based on the exclusion of
other potential causes of symptoms and through clinical evalua-
tion. The American College of Rheumatology (ACR) criteria stip-
ulate that painmust be distributed across the four quadrants of the
body (that is pain above the waist, below the waist, on the left and
right sides of the body) and in the axial skeleton, with tenderness
in 11 or more of the 18 specific sites known as tender points dur-
ing digital palpation (using 4 kg pressure) or dolorimetry (Wolfe
1990). There has been considerable debate regarding the diagnos-
tic accuracy of FM as the ACR criteria have proven problematic,
with no objective standardised test. Changes to the criteria have
recently been proposed that do not require tender point examina-
tion and include a severity rating scale for fibromyalgia symptoms
(Wolfe 2011). The revised criteria show potential in refining the
diagnostic criteria for FM; however, as the criteria remain prelim-
inary and further evidence of the validity, acceptance reliability
and consistent implementation of the new criteria is required, this
review classified FM based on the ACR criteria that have been
widely implemented since 1990 (Wolfe 2010; Wolfe 2011; Wolfe
2011b).
Description of the intervention
Non-pharmacological interventions have received increasing at-
tention for helping patients to manage the demands of complex
conditions such as FM. Indeed, it has been revealed that people
with neurological conditions use complementary therapies more
than other therapeutic approaches (Wells 2010).Mind-body ther-
apies have been defined as focusing on the interactions among the
brain,mind, body andbehaviour. The aimofmind-body therapy is
to enhance the capacity for self-knowledge, self-care and to provide
tools that can improve coping, mood and quality of life (NCCAM
2005 Appendix 1; Wahbeh 2008). Mind-body interventions are
considered to be a type of approach that falls under the umbrella
of complimentary and alternative medicine, which also includes
manipulative therapies and herbal products. The National Center
for Complementary and Alternative Medicine (NCCAM 2005)
describes mind-body interventions as treatment approaches that
are based on the holistic principle that mind, body and behaviour
are all interconnected, incorporate strategies that are thought to
improve psychological and physical well-being, and aim to allow
patients to take an active role in their treatment and to promote
people’s ability to cope. Mind and body interventions include a
range of treatments (NCCAM2012). Examples of mind and body
therapies include biofeedback (use of technology to give audio or
visual feedback on physiological processes such as heart rate to
assist people in being able to gain more control over their bodies);
mindfulness (a way of looking at the world in a non-judgemental
manner); movement therapies (use of physical movement to stim-
ulate mental clarity, such as yoga, tai chi, qi-gong); psychological
therapies (use of techniques to help people become aware of their
own thoughts and behaviours, such as written emotional disclo-
sure and cognitive behaviour therapy); and relaxation strategies
(techniques to help calm the mind and relax the body, such as
breathing techniques, visual imagery, guided imagery, progressive
muscle relaxation).
How the intervention might work
FM is a complex condition and psychological, social and lifestyle
factors have all been found to play an important role in the symp-
tom experience (Bergman 2005; Nicassio 2002; Theadom 2008).
Interventions that aim to improve well-being, self esteem, coping
ability and reduce stress may therefore improve physical symptoms
and quality of life for people with FM. The relevance of mind-
body interventions to FM is also supported by emerging evidence
of the interactions between the central nervous, endocrine, im-
mune, and peripheral autonomic nervous systems, suggesting “a
mechanism by which mind-body medicine could influence phys-
ical health” (Vitetta 2005).
Why it is important to do this review
Symptom-specific medication has been the primary method of
treatment for FM with many patients prescribed tricyclic an-
tidepressants (TCAs), selective serotonin uptake inhibitors (SS-
RIs), simple analgesics and serotonin norepinephrine reuptake in-
hibitors (SNRIs), which have demonstrated efficacy for reducing
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pain (Dworkin 2003; Hauser 2013; Moore 2009). Medications
previously used in the treatment of epilepsy such as gabapentin
and pregabalin are now more widely used for FM, however many
people report side effects and continue to experience symptoms
despite using the medication (Moore 2009; Moore 2011). Ad-
ditionally, a recent review of guidelines on the management of
FM (Hauser 2010) highlights the need for a multidimensional
approach including a combination of non-pharmacological and
pharmacological therapies.
A reviewonpsychological therapies for themanagement of chronic
pain (excluding headache) in adults revealed that psychological
therapies had weak effects in improving pain but that cognitive be-
haviour therapy and behaviour therapy improved low mood with
some evidence of improvements being maintained at six months,
in comparison to usual care and attention controls. Whilst this
review included participants with FM, the impact of interventions
may vary between different pain populations. Previous Cochrane
reviews have explored the evidence for the use of exercise and resis-
tance training for FM and found that supervised aerobic exercise
and resistance training have beneficial effects on pain and physical
functioning (Busch 2007; Busch 2013). A recent review has also
found that cognitive behaviour therapy shows a small benefit in
comparison to control in reducing pain, negative mood and dis-
ability in people with FM (Bernardy 2013).
There is evidence that mind-body therapies are more effective
in comparison to waiting list or placebo control groups on self
efficacy and quality of life outcomes for FM (Hadhazy 2000).
Since the publication of Hadhazy’s review in 2000, a wealth of
studies have since been published in this area. The present review
aims to provide evidence of the efficacy of mind-body therapies
for adults with FM.
O B J E C T I V E S
To review the benefits and harms of mind-body therapies in com-
parison to standard care and attention placebo control groups for
adults with fibromyalgia (FM), post-intervention and at three and
six month follow-up.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) that aimed to explore the
benefits or harm for people diagnosed with FM who received a
mind-body intervention in comparison tousual care or a treatment
that was not thought to have therapeutic effects but was delivered
by an equivalent therapist and for the same amount of time as
the mind-body therapy group (known as an attention control)
were included in the review. Case studies, clinical observations and
quasi-randomised controlled trials were excluded from the review
in order to minimise bias.
Types of participants
All persons 18 years of age or older with a clinical diagnosis of
FM (as defined by the ACR 1990 criteria) (Wolfe 1990). If people
with FMwere recruited into a trial in addition to participants with
other medical conditions, the study was only included if the data
for people with FM were available separately.
Types of interventions
Interventions incorporating at least one type of mind-body ther-
apy were included. Based on the definition of mind-body inter-
ventions proposed by the Centre for Complementary and Alter-
native Medicine (NCCAM 2005), six criteria were established to
determine whether an intervention met the definition of a mind
and body intervention for this review.
The criteria specified that the intervention must: 1) be based on
the principle that the mind and body are interconnected; 2) aim
to increase self knowledge; 3) aim to increase people’s ability to
self-manage their health and consequences of ill-health; 4) actively
engage and involve the participant in the intervention delivery;
and 5) provide tools to improve coping and self-management of
the condition. As mind and body interventions are often incor-
porated with other techniques the sixth criterion, that 6) at least
80% of the total intervention delivery must include components
meeting the aforementioned five principles, was added to prevent
the findings from trials including only a small mind-body com-
ponent influencing the results.
Due to the wide diversity of available mind-body therapies, inter-
ventions were categorised into broad groups to enable compari-
son.
• Psychological therapies (including cognitive behaviour
therapy (CBT), psychoanalytic and humanistic approaches).
• Biofeedback (providing immediate feedback on bodily
functions, such as muscle tension, to raise the patient’s awareness
and enable the possibility of conscious control of those functions.
• Mindfulness meditation therapies (being aware of the
present moment in a non-judgemental and accepting way).
• Movement therapies (e.g. yoga, tai chi, qi-gong).
• Relaxation based therapies (e.g. breathing techniques, visual
imagery, guided imagery, progressive muscle relaxation).
Interventions delivered in all settings including community, pri-
mary care or hospital were included in the review to facilitate the
generalisability of the reviewfindings. Exercise based interventions
for FM have been subject to their own Cochrane review (Busch
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2007) and were therefore not included. Only movement therapies
that met the definition of a mind-body therapy were included in
the review. Interventions delivered to a participant manually by a
therapist (such as massage, acupuncture, physiotherapy) were not
included within the review as participants are not actively engaged
in the treatment, a key criterion of mind-body interventions ac-
cording to the NCCAM 2005 definition of mind-body therapy.
Eligible comparative interventions includedboth usual care, which
involved the treatment that people would usually receive (such as
medication), or wait-list conditions or attention control interven-
tions involving participants receiving similar levels of contact with
researchers or therapists in a similar format as the experimental
intervention (such as sham therapy or peer group support).
Types of outcome measures
Major outcomes
The five major outcomes for this review were:
• self-reported physical functioning (ability to complete
everyday tasks e.g. scores on the Fibromyalgia Impact
Questionnaire (Bennett 2009));
• self-reported levels of pain (e.g. pain intensity numerical
rating scale). A 30% or two point reduction in a 10 point
numerical rating scale has been reported to be a relevant clinical
outcome in evaluating trials in chronic pain (Farrar 2001);
• mood, encompassing both anxiety and depression (e.g.
Hospital Anxiety and Depression Scale (Zigmond 1983));
• participant withdrawals;
• adverse events (e.g. increased pain).
Data on all outcome measures assessed post-intervention and at
three and six month follow-up were extracted for the review.
Minor outcomes
Minor outcomes were assessed post-intervention and at three and
six month follow-up. These included:
• fatigue (e.g. scores on the Multidimensional Assessment of
Fatigue scale (Smets 1995));
• sleep (e.g. Pissburgh Sleep Quality Index (Buysse 1989));
• self efficacy (perceived ability to manage their overall health
e.g. Chronic Pain Self-Efficacy Scale (Anderson 1995));
• tender point score (measured by dolorimetry or digital
palpitation);
• quality of life (e.g. Short Form Medical Outcome Study
(Hays 1993)).
Search methods for identification of studies
Electronic searches
The electronic searches were conducted by the Trial Search Co-
ordinator of the Musculoskeletal Group: Cochrane Central Reg-
ister of Controlled Trials (CENTRAL) in The Cochrane Library
(2013, Issue 10), MEDLINE (Ovid) (1950 to October 2013),
EMBASE (Ovid) (1974 to October 2013), PsycINFO (Ovid)
(1806 to October 2013), AMED (EBSCO, Allied and Comple-
mentaryMedicine) (1985 toOctober 2013) and CINAHL (Ovid,
1982 to 2008; EBSCO, 2008 to October 2013). The search strat-
egy is shown in Appendix 2.
Searching other resources
The reference lists of relevant articles were searched for additional
relevant trials. Authors were also contacted to identify any other
unpublished or published studies. The lists of identified articles
were then combined and duplicate references were deleted.
Data collection and analysis
Selection of studies
Three review authors (AT,AK, SM) independently assessed all cita-
tions and identified abstracts of relevance to the review against the
core inclusion criteria using a pre-designed study selection form.
Core criteria included being a RCT, inclusion of participants with
FM, diagnosis based on the ACR criteria (Wolfe 1990), included
participants aged over 18 years, inclusion of an intervention likely
to meet the mind-body criteria (for example articles on exercise,
massage, use of treatment devices or medication or supplements
were excluded) and availability of an abstract describing the trial.
Full text articles were acquired for any citations meeting the core
inclusion criteria for the review or where additional information
was required to determine eligibility.
All full text articles were then re-assessed against the core inclu-
sion criteria and against the additional six inclusion criteria defin-
ing what constituted a mind-body intervention for this review
(see criteria described in type of interventions). Reasons for in-
clusion or exclusion were recorded in an electronic spreadsheet
and on the hard copy data extraction form. The results were com-
pared between the review authors and any disagreement resolved
through discussion and consensus. Where resolution was not pos-
sible through discussion, the full review team was consulted un-
til a consensus decision was reached. Where information was not
available in the full article, trial authors were contacted for further
details to clarify eligibility for the review.
Data extraction and management
Three review authors (AT, AK, SM) were involved in extracting
data from the included trials, with two review authors allocated
to each trial to independently extract the data. Any disputes were
resolved through discussion. The data were extracted using a hard
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copy data extraction standard form designed specifically for this
review. The data extraction form recorded information on the
type of intervention (such as length of programme, therapeutic
components and therapist details), setting, study procedures (such
as blinding of outcome assessors and treatment allocation), details
of participants and outcomemeasure data.Where the information
needed was insufficient or incomplete, multiple attempts were
made to contact the trial authors. Data were extracted from graphs
if this could be accurately measured with 100% agreement by
two independent researchers.The data extracted from the included
trials was entered into RevMan 5.
Endpoint versus change data
Continuous data collected from self-report questionnaires were ex-
tracted if the measure explicitly aimed to assess one of the primary
or secondary outcomes andwas used in its standardised form. End-
point scores were extracted from the trial articles. Group means
were used throughout the analysis (Higgins 2011).
Skewed data
Data collected using questionnaires to measure clinical and psy-
chological outcomes often does not reveal a normal distribution.
To avoid the influence of skewed data on the analyses, data were
only analysed if: 1) both means and standard deviations could be
derived from the data provided in the article or provided by the
trial authors; and 2) if the standard deviation was less than half
the mean (Altman 1996).
Assessment of risk of bias in included studies
The studies included in the review were assessed for possible risk
of bias using theCochrane Collaboration tool for assessing the risk
of bias (Higgins 2011). The methods of each study were assessed
independently by two review authors (AT and MC) to ascertain if
the procedures applied in the study were adequate. Any disagree-
ment identified between the review authors was resolved through
discussion or through the involvement of a third review author.
These components of trials forming the risk of bias assessment
included:
1) sequence generation (e.g. was the sequence generation process
truly random);
2) concealment of treatment allocation;
3) blinding of the outcome assessor;
4) completeness of outcome data (e.g. participant attrition rates
post-intervention and withdrawal rates between groups);
5) selective reporting bias (e.g. were all pre-specified outcomes
reported).
Other risks of bias such as design-specific risks were not considered
in this review, which only included randomised controlled trials.
No studies reported early stopping. For each component the trials
were classified as low risk of bias, high risk of bias or unclear (if
there was insufficient information provided in the article to make
a decision). If information on the procedures used within the trial
were unclear, the authors of the article were contacted to yield the
necessary information. If the necessary information could not be
retrieved, the potential risk was classified as unclear. To assess the
direction andmagnitude of the risk of bias and the possible impact
this may have on the findings, sensitivity analysis was conducted.
The ’blinding of participants’ was not applied in this review as it
would be extremely difficult to blind people delivering the inter-
vention or participants in accordance with other Cochrane reviews
(Bernardy 2013; Williams 2012). As mind-body interventions re-
quire the participant to actively participate in the treatment, it
was considered that it was not possible to blind the participant to
their treatment allocation. However, it was considered to be both
feasible and desirable to randomise participants to their treatment
condition, so evidence of randomisation was an important crite-
rion for inclusion in this review. Blinding of the outcome assessors
was considered as part of the risk of bias assessment of the included
studies.
Measures of treatment effect
For continuous data, the weighted mean difference in endpoint
scores between groups (using the same version and scoringmethod
for outcome measure on each of the outcome domains) was calcu-
lated with the 95% confidence interval (CI). Standardised mean
differences (SMD) were used for continuous outcome data mea-
suring the same outcome variable but using different: 1) scales
or subscales; 2) versions published in different languages; or 3)
scored using a different approach, due to the likelihood that there
would be differences in measurement between the outcome mea-
sures (Puhan 2006). For binary data, standard estimation of the
risk ratio (RR) and its 95%CIwere used. The P < 0.05 significance
level and 95% CIs were used as the conventional significance level
(Higgins 2011). All outcome data were transformed, if necessary,
before analysis to ensure that high scores on eachmeasure reflected
poorer health outcomes (by subtracting the mean from the max-
imum score on the measure). Numbers of withdrawals between
the groups post-intervention and adverse events reported were de-
scribed in terms of frequencies.
Unit of analysis issues
Cross-over trials
Cross-over trials were excluded from this review as there is no evi-
dence to suggest a suitable duration of a washout period following
a mind-body intervention and it is likely that some components
(such as increased knowledge) may be sustained or retained over
time.
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Multiple treatment arms
Where a given trial presented relevant control data for more than
one group (for example if a treatment group had both a usual care
and an attention placebo comparison group), each set of data were
used for the respective separate analyses. If an additional treatment
group that met the criteria was presented, this was included sep-
arately in the analysis (as long as the control group data were not
used more than once in a given comparison).
Dealing with missing data
Missing outcome data not reported
Where possible, trial authors were contacted to request any data
of potential relevance to the review that was not presented in the
article. For example, requests were made when the trial authors re-
ported that an outcome measurement was conducted at follow-up
but the data were not presented, or if means or standard deviations
were not able to be derived from the information provided. For
studies where standard deviations were not available for outcome
data but CIs were provided, the lower CI was used in addition to
the mean to calculate the variance, using the Revman calculator.
Attrition
As high rates of attrition can influence the credibility of outcome
data and observation of any treatment effect, any studies with at-
trition rates higher than 40% (calculated as the number of par-
ticipants at follow-up divided by the number of participants ran-
domised x 100) were not included in the analyses but were in-
cluded in the attrition analyses. This decision was based on evi-
dence that overall completion rates of between 50% to 80% are
considered to be acceptable (Altman 2000; Fewtrell 2008). Four
studies were found to have high (above 40%) attrition rates (Astin
2003; Brattberg 2008; Edinger 2005; Vlaeyen 1996) and were ex-
cluded from the analysis.
Assessment of heterogeneity
Statistical heterogeneity
The statistical heterogeneity of trials was assessed using the I2
statistic, calculated using RevMan 5. A cut-off point of I2 > 50%
and a P value of < 0.10 from the Mantel-Haenszel Chi2 test
were used to determine if statistically significant heterogeneity was
found between the trials (Higgins 2011).
Visual inspection of the graphs
All graphs were inspected by the review team to investigate the
possibility of heterogeneity.Where differences in the findings were
evident, the methodology of the studies included in the analysis
were reviewed for potential reasons for heterogenous findings for
example clinical heterogeneity or influence of different subtypes
of therapy.
Assessment of reporting biases
Funnel plots were not reported due to the low numbers of trials
included in the analyses (< 10), which may prevent adequate de-
tection of publication bias (Lau 2006). Approaches to reduce pub-
lication bias such as searching for unpublished studies and setting
clear inclusion and appraisal criteria were implemented to reduce
the impact of possible publication bias on the review findings,
however the possibility of publication bias remained. The risk of
publication bias was considered in the grading of evidence in the
summary of findings tables.
Data synthesis
In the absence of statistical heterogeneity a fixed-effect model of
meta-analysis was used for combining data. If heterogeneity was
found, a sensitivity analysis was completed.
Main comparisons
The main comparisons were conducted at the post-intervention
time point in this review.
• Psychological therapies versus usual care.
• Psychological therapies versus attention control.
• Biofeedback versus usual care.
• Biofeedback versus attention control.
• Mindfulness meditation therapies versus usual care.
• Mindfulness meditation therapies versus attention control.
• Movement therapies versus usual care.
• Movement therapies versus attention control.
• Relaxation based therapies versus usual care.
• Relaxation based therapies versus attention control.
It was evident that some interventions applied more than one
mind-body approach within the intervention, so interventions
were categorised based on the primary focus or the largest compo-
nent of the intervention, or both. In one study (Astin 2003) both
mindfulness and a movement therapy were applied equally within
the intervention and so the data were described but not included
in the analyses as the primary focus could not be determined.
Subgroup analysis and investigation of heterogeneity
Subanalyses of longer-term outcomes of mind-body interventions
including the short-term (one to three months post-intervention,
where data closest to three months were used) and the medium-
term (three to six months post-intervention, where data closest to
six months were used) were calculated where outcome data were
available.
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Heterogeniety was investigated if there was observed inconsistency
in the findings resulting from the main analyses and subanalyses.
If heterogeneity was observed, firstly the accuracy of data entry
was checked. Secondly any outliers were specifically investigated
to determine if there was a possible explanation for the different
findings for example different mode, duration or type of interven-
tion, or risk of bias. Sensitivity analyses were planned to explore
the effect of heterogeneity on the findings, where possible.
Sensitivity analysis
A cut-off point of I2 > 50% and a P value of < 0.10 from the
Mantel-Haenszel Chi2 test were used to determine if statistically
significant heterogeneity was found between the trials (Higgins
2011). Sensitivity analyseswere completed to explore any potential
effect of the intervention content or duration, and inclusion of
studies classified as having a high risk of bias.
Grading of evidence and summary of findings tables
The data are presented in the summary of findings tables (Higgins
2011), conducted using GRADEpro software. The primary out-
comes of self-reported functioning and pain were included in the
summary of findings tables. Data on adverse events were used only
for the groups included in the analysis. Studies were downgraded
based on assessments of risk of bias, inconsistency (for example
differences in treatment duration), indirectness (for example if no
males were included in the analysis to enhance generalisability
to the fibromyalgia population), imprecision (studies were down-
graded -1 if there were < 200 participants in the analysis and -2 if
< 100 participants in the analysis).
R E S U L T S
Description of studies
See: ’Characteristics of included studies’; ’Characteristics of ex-
cluded studies’; ’Characteristics of studies awaiting classification’.
Results of the search
The search elicited 2083 citations, with 2009 citations excluded
as the studies did not meet the inclusion criteria for this review
(Figure 1).
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Figure 1. Study flow diagram.
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Included studies
There were 61 distinct trials identified from 74 publications, each
of which met the inclusion criteria for the review (see ’Character-
istics of included studies’ table). Studies were conducted across 13
countries including; USA (22 studies), Spain (11 studies), Swe-
den (8 studies), Germany (4 studies), Canada (3 studies), Nether-
lands (3 studies), Norway (3 studies), Turkey (2 studies), Brazil (1
study), France (1 study), Italy (1 study), India (1 study), UK (1
study).
Interventions
The types of mind-body interventions encompassed by the iden-
tified articles included in this review were classified into different
mind-body therapy categories.
• There were five biofeedback studies (Babu 2007; Bakker
1995; Baumuller 2009; Kayiran 2010; Van Santen 2002).
• There were three mindfulness studies (Parra-Delgado 2013;
Schmidt 2011; Sephton 2007).
• There were 11 movement therapy interventions in total
including three tai chi studies (Wang 2010; Calandre 2009;Jones
2012), three yoga studies (Carson 2010; Carson 2012; Holmer
2004), three qi-gong studies (Liu 2012; Lynch 2012;
Mannerkorpi 2004), one study on dance therapy
(Bojner-Horwitz 2003) and one study on pilates (Altan 2009).
• The majority of studies (N = 35) were classified as involving
a psychological therapy, which included two emotional freedom
interventions (Brattberg 2008; Connais 2009), one study using
the Resserguier approach (Maddali-Bongh 2010), one study
using the written emotional disclosure paradigm (Gillis 2006),
one study using Accceptance Commitment Therapy (Wicksell
2013) and one study using psychotherapy (Scheidt 2013). There
were 17 studies based on the cognitive behaviour therapy
approach (Alda 2011; Ang 2010; Ang 2013; Castel 2009; Castel
2012; Edinger 2005; Falcao 2008; Garcia 2006; Hamnes 2012;
Jensen 2012; Langford 2009; Lera 2009; Martinez-Valero 2008;
Miro 2011; Thieme 2006; Vlaeyen 1996; Williams 2002;
Woolfolk 2012) and 11 studies based on psychoeducation
(Burckhardt 1994; de Souza 2008; Fontaine 2010; Hammond
2006; Hsu 2010; Luciano 2011; Oliver 2001; Soares 2002;
Stuifbergen 2010; Wigers 1996; Williams 2010).
• Three studies looked at relaxation using the guided imagery
approach (Fors 2000; Menzies 2006; Riedel 2012).
• Four studies included interventions that were not able to be
classified into the pre-determined categories but were deemed to
meet the inclusion criteria for a mind-body intervention
including music therapy (Oneva-Zafra 2010), hypnosis (Picard
2013) and multi-component interventions (Astin 2003; Castel
2009).
The overall length of treatment ranged between 1 day to 25 weeks.
The average treatment duration was 17 hours. Mind-body inter-
ventions were implemented in a range of settings, with over half
of the studies (34 studies, 55.7%) conducted in a healthcare set-
ting such as in a hospital or primary care clinic. Thirteen studies
(21.3%) were conducted in a community setting such as in the
person’s home, with 7 studies (11.5%) conducted in a university
or academic research centre. For 7 studies the type of setting where
the intervention was delivered was not clear.
Most interventions (44.3%) were facilitated by a healthcare pro-
fessional and 27.9% by a trained specialist in the particular ther-
apy. Just over half (54.1%) of the studies included in this review
involved only female participants. The mode of delivery of the
intervention varied between trials with 54.1% of interventions de-
livered within a group based format, 37.7% delivered on an in-
dividual basis, and 6.6% using both a group and individual for-
mat for different elements of the intervention. For 1.6% of the
interventions the mode of administration was unable to be clearly
determined from the intervention description.
One study reported findings on multiple treatment arms (Thieme
2006) which included both a cognitive behaviour therapy inter-
vention group and an operant behavioural therapy experimental
group. Given there were no other studies in the review which also
looked at the effectiveness of operant behavioural therapy and be-
cause both experimental groups would be in the same analysis
(psychological therapies), and only one control group was avail-
able, only the cognitive behavioural group and control group (at-
tention placebo) were included in the analyses.
Excluded studies
There were two studies that met the inclusion criteria of the review
but that were still ongoing at the time of data extraction. These
have be specified in the list of ongoing studies and should be
included in future updates of this review (Garcia-Campayo 2009;
Miles 2010). Articles that met the inclusion criteria of the review
butwere excludedbased on the sixmind-body intervention criteria
for inclusion are outlined in the table ’Characteristics of excluded
studies’, with reasons for exclusion described.
Risk of bias in included studies
Allocation
All trials included in this reviewwere described as randomised con-
trolled trials or it was stated that a random component of partici-
pant allocation to the treatment group had been implemented. As
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shown in Figure 2, one study utilising a randomisation approach
was classified as having a high risk of bias in accordance with the
recommendations by Higgins 2011. As shown in Figure 3, a num-
ber of studies (13.0%) were classified as having an unclear risk of
selection bias as insufficient details of the randomisation proce-
dure were provided. Two studies (Connais 2009; Holmer 2004)
were classified as having a high risk for allocation concealment as
participants were alternately allocated to treatment groups and the
researchers may have been able to foresee treatment allocation.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Blinding
Due to the nature of delivering mind and body interventions,
where it would be clear to participants which group they were in,
it was not expected that the included studies would be able to be
double blinded (blinding of participants). With regard to blinding
of outcome assessors most studies were rated as having a low risk
of bias. Six trials (Calandre 2009; Fontaine 2010; Holmer 2004;
Lera 2009; Parra-Delgado 2013; Picard 2013) were classified as
having a high risk of detection bias as the outcome assessors were
not blind to treatment allocation.
Incomplete outcome data
Additional data or clarification of study procedures were obtained
from the authors of 36 studies included in this review (Altan 2009;
Astin 2003; Babu 2007; Bakker 1995; Baumuller 2009; Brattberg
2008; Burckhardt 1994; Calandre 2009; Carson 2010; Carson
2012; Castel 2007; Castel 2009; Connais 2009; de Souza 2008;
Falcao 2008; Fontaine 2010; Gillis 2006; Holmer 2004; Hsu
2010; Kayiran 2010; Lera 2009; Lynch 2012; Maddali-Bongh
2010; Mannerkorpi 2004; Martinez-Valero 2008; Menzies 2006;
Miro 2011;Oliver 2001;Oneva-Zafra 2010; Parra-Delgado 2013;
Scheidt 2013; Soares 2002; Stuifbergen 2010;Wang 2010;Wigers
1996; Williams 2010).
Most included studies (N = 48, 78.7%) were rated as having a
low risk of attrition bias. Six studies (Bakker 1995; Burckhardt
1994; Connais 2009; Garcia 2006; Lynch 2012; Williams 2002)
were rated as having a high risk of attrition bias since we were
unable to extract the means and standard deviations from the
information provided, precluding inclusion in the meta-analysis.
Three studies (Astin 2003; Edinger 2005; Vlaeyen 1996) were
classified as having a high risk of attrition bias as they reported
attrition rates over 40%. One study (Brattberg 2008) was classified
as being at high risk of bias as a large number of participants
(40%) did not undertake or complete the intervention sessions
but completed the outcome assessments. Details of reasons for
attrition were often not provided.
Selective reporting
Forty-seven (77.0%) studies were classified as having a low risk
of reporting bias as data on the outcome measures of relevance to
the review were provided. Seven studies (Bojner-Horwitz 2003;
Jones 2012; Liu 2012; Luciano 2011; Soares 2002;Williams 2002;
Woolfolk 2012) were classified as having a high risk of reporting
bias as data were not reported on specified outcome measures.
It was not always clear from the reports whether measures were
planned on being used as outcome measures or that their purpose
was solely to provide baseline information or to act as covariates
in the analysis.
Effects of interventions
See: Summary of findings for the main comparison
Psychological therapies compared to usual care for fibromyalgia;
Summary of findings 2 Biofeedback compared to usual care for
fibromyalgia; Summary of findings 3 Mindfulness compared to
usual care for fibromyalgia; Summary of findings 4 Movement
therapies compared to usual care for fibromyalgia; Summary of
findings 5 Relaxation compared to usual care for fibromyalgia
The primary outcome assessment time point was post-interven-
tion (up to one month following intervention delivery). This
would provide the greatest opportunity to determine if any treat-
ment effect was evident as any effects were most likely to be at
their strongest immediately following a mind-body intervention.
Outcomes were also assessed in the short term (within one to three
months post-intervention) and medium term (greater than three
to six months post-intervention). If an outcome assessment was
made at three months this was classified as a short-term outcome.
Comparison 1. Psychological therapies versus usual
care
Therewere 18 studieswith data available for this comparison.Data
were unable to be extracted from eight trials (Burckhardt 1994;
Connais 2009; Edinger 2005; Garcia 2006; Martinez-Valero
2008; Vlaeyen 1996; Williams 2002; Woolfolk 2012) exploring
psychological therapies in comparison to usual care or were unable
to be incorporated due to very high attrition rates (> 40%). Two
studies (Falcao 2008; Soares 2002) revealed standard deviations
that were more than half the mean on a specific outcome mea-
sure, indicating that themean was unlikely to accurately reflect the
centre-point of the distribution for that variable (Altman 1996).
As skewed data is less likely to be problematic if the data set is
large, the sample sizes of these two studies were considered. As
both studies had sample sizes of less than 100 participants it was
decided to exclude the data from the analyses for variables where
the standard deviation was more than half the mean. The data
from a trial were included in the analyses for variables where this
was not the case.
Major outcomes
1.1 Self-reported physical functioning
Ten trials explored psychological therapies in comparison to usual
care on physical functioning outcomes (Alda 2011; Castel 2009;
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Castel 2012; Falcao 2008;Hamnes 2012; Luciano 2011;Maddali-
Bongh 2010; Scheidt 2013; Soares 2002; Wicksell 2013). There
was an advantage for psychological therapies observed post-inter-
vention (N = 733, SMD -0.43, 95% CI -0.57 to -0.28, Analysis
1.1), at 3 month follow-up (N = 148, SMD -0.54, 95% CI -0.87
to -0.21, Analysis 1.2) and at 6 month follow-up (N = 112, MD
-3.66, 95% CI -7.29 to -0.03, Analysis 1.3).
1.2 Self-reported pain
Data from nine trials (Alda 2011; Castel 2009; Castel 2012;
de Souza 2008; Hsu 2010; Jensen 2012; Maddali-Bongh 2010;
Soares 2002; Wigers 1996) revealed a difference between groups
receiving psychological therapy and usual care that favoured psy-
chological therapy post-intervention (N = 453, SMD -0.33, 95%
CI -0.52 to -0.15, Analysis 1.4). The advantage for psychological
therapies over usual care was not observed at 3 month follow-up
(Falcao 2008; Castel 2012) (N = 115, MD -0.85, 95% CI -1.76
to -0.06, Analysis 1.5) but was observed at 6 months (N = 371,
SMD -0.51, 95% CI -0.72 to -0.30, Analysis 1.6).
1.3 Mood
There was an advantage for psychological therapies in comparison
to usual care post-intervention, evident in eight trials (Alda 2011;
Castel 2012; Falcao 2008; Hamnes 2012; Jensen 2012; Scheidt
2013; Wicksell 2013; Wigers 1996) (N = 492, SMD -0.45, 95%
CI -0.64 to -0.26, Analysis 1.7). There was high heterogeneity
between studies; removing the study by Castel 2012, which had
a longer intervention delivery, reduced the I2 value to 7%. The
advantage of psychological therapies post-intervention remained
(SMD -0.29, 95% CI -0.48 to -0.10). The advantage of psycho-
logical therapies was still evident at 3 months (N = 182, SMD -
1.15, 95% CI -1.50 to -0.80). There was high heterogeneity ob-
served. Removing the study by Castel 2012 reduced the I2 value
to 0%. The advantage for psychology over usual care remained. At
6 months there was no advantage of psychological therapies over
usual care (N = 213, SMD -0.17, 95% CI -0.44 to 0.10, Analysis
1.9).
1.4 Participant withdrawals
The RR of withdrawing from the study was statistically higher
in the psychological therapy group in comparison to the control
group (RR 1.38, 95% CI 1.12 to 1.69, Analysis 1.10).
1.5 Adverse events
There was no difference between the number of adverse events
in the psychological therapy and control groups (RR 0.38, 95%
CI 0.06 to 2.50, Analysis 1.11). Only one study reported one
person experiencing aworsening of symptoms in the psychological
therapy group but it was not clear if this was directly related to the
intervention or not (Vlaeyen 1996).
Minor outcomes
1.6 Fatigue
Only two studies presented data on fatigue following intervention
delivery (Hsu 2010; Williams 2010). There was no advantage for
psychological therapies in comparison to usual care at post-inter-
vention (N = 82, SMD -0.09, 95% CI -0.53 to 0.34, Analysis
1.12) nor at 6 month follow-up (N = 160, SMD -0.07, 95% CI -
0.38 to 0.24, Analysis 1.13). No follow-up data were available for
the 3 month follow-up time point. Moderate heterogeneity was
observed in the findings post-intervention; neither study included
in the analysis had a high risk of bias and the heterogeneity may
have been reflective of the different psychological interventions
included in the analysis, with one trial implementing a self-aware-
ness intervention and the other a stress management intervention
(Analysis 2.3).
1.7 Sleep
Data on sleep outcomes were presented by five trials (Castel 2012;
Hsu 2010; Maddali-Bongh 2010; Soares 2002; Wigers 1996).
There was an advantage observed for psychological therapies in
comparison to usual care for sleep post-intervention (N = 222,
SMD -0.52, 95% CI -0.80 to -0.25, Analysis 1.19). High hetero-
geneity was observed. Removing the study by Castel 2012, which
was delivered over a much longer duration than the other trials,
reduced the heterogeneity however the advantage of psychological
therapies over usual care was no longer observed (N = 158, SMD
-0.18, 95% CI -0.50 to 0.13). At 3 month follow-up, one study
revealed an advantage for psychological therapy over usual care (N
= 64, MD -11.30, 95% CI -15.44 to -7.16). At 6 month follow-
up three studies provided data for analysis. No advantage for psy-
chological therapies was observed (N = 224 , SMD -0.15, 95% CI
-0.42 to 0.12, Analysis 1.21). High heterogeneity was observed
within the data. Removing the study with a longer intervention
duration (Castel 2012) reduced the heterogeneity, however there
remained no advantage of psychological therapies over usual care
(N = 160, SMD = 0.22, 95% CI -0.09 to 0.53, Analysis 2.4).
1.8 Self efficacy
There were four trials that assessed self efficacy as an outcome
(Brattberg 2008; Hamnes 2012; Soares 2002;Wicksell 2013). No
advantage was found for psychological therapy in comparison to
usual care post-intervention (N = 255, SMD -0.25, 95% CI -0.50
to -0.00, Analysis 1.14). One study (Wicksell 2013) conducted a
3 month follow-up and found that no difference between groups
was observed (N = 23, MD -15.10, 95% CI -44.95 to 14.75).
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1.9 Tender points
No data were able to be extracted from trials assessing tender point
count post-intervention or at 3 month follow-up. One trial (Hsu
2010) presented data at 6 month follow-up. There was no advan-
tage for psychological therapies over usual care at 6 months (N =
42, MD 0.38, 95% CI -0.12 to 0.88, Analysis 1.15).
1.10 Quality of life
Six trials presented data on quality of life post-intervention
(Brattberg 2008; Falcao 2008; Hsu 2010; Maddali-Bongh 2010;
Scheidt 2013; Wicksell 2013). There was no difference between
groups on quality of life post-intervention (N = 276, SMD -0.19,
95%CI -0.44 to 0.06, Analysis 1.16).Moderate heterogeneity was
observed. Removing the study by Scheidt 2013 (that had a longer
intervention delivery period) reduced the I2 value to 28% and an
advantage of psychological therapies was observed (Analysis 1.18).
At 3 months only one study provided data and the advantage for
psychological therapies remained (N = 33, MD -15.16 95% CI
-21.90 to -8.30). At 6 months the advantage for psychological
therapies was no longer evident (N = 42, MD -2.50, 95% CI -
7.95 to 2.95).
Comparison 2. Psychological therapies versus
attention control
There were seven studies with data available for this comparison
(Fontaine 2010; Gillis 2006; Langford 2009; Lera 2009; Miro
2011; Stuifbergen 2010; Thieme 2006).
Major outcomes
2.1 Self-reported physical functioning
Seven studies reported data on functioning as an outcome
(Fontaine 2010; Gillis 2006; Langford 2009; Lera 2009; Miro
2011; Stuifbergen 2010; Thieme 2006). There was no advantage
of psychological therapy in comparison to an attention control
post-intervention (N = 561, SMD -0.10, 95% CI -0.27 to 0.07,
Analysis 3.1) or in the short term (3 months) (N = 447, SMD
0.02, 95% CI -0.17 to 0.20, Analysis 3.2) or medium term (6
month follow-up) (N = 326, SMD 0.00, 95% CI -0.22 to 0.23,
Analysis 3.3). Moderate heterogeneity was observed within the
findings for functioning post-intervention; removing the study at
high risk of bias for blinding of outcome assessors reduced the het-
erogeneity (Analysis 4.1). High heterogeneity was also observed
at 6 month follow-up, and a review of the forest plot indicated
that the findings by Thieme 2006 were outliers. This may reflect
that risk of bias was categorised as unclear as there was insufficient
information in the article to determine level of risk, which may be
reflective of trial quality. Removing the findings by Thieme 2006
reduced the heterogeneity; there remained no difference between
groups at 6 month follow-up (Analysis 4.2).
2.2 Self-reported pain
An advantage was found when psychological therapy was com-
pared to an attention control post-intervention (N = 324, SMD -
0.28, 95%CI -0.51 to -0.06, Analysis 3.4), however this advantage
was not sustained in the short term (N = 115, SMD 0.13, 95% CI
-0.24 to 0.50, Analysis 3.5), or medium term (N = 60, MD -0.34,
95% CI -0.89 to 0.21, Analysis 3.6). Moderate heterogeneity was
observed within the data for pain outcomes post-intervention. On
review of the type of interventions incorporated within the anal-
ysis it became apparent that three trials implemented CBT and
one trial implemented written emotional disclosure as an inter-
vention. Removing the written emotional disclosure intervention
(Gillis 2006) from the analysis reduced the heterogeneity. An ad-
vantage for psychological therapy remained consistent following
the sensitivity analysis (Analysis 4.3).
2.3 Mood
No advantage was observed for psychological therapy post-inter-
vention (N = 330, SMD -0.12, 95% CI -0.33 to 0.10, Analysis
3.7) and at 3 month follow-up (N = 115, SMD 0.24, 95% CI -
0.13 to 0.61, Analysis 3.8). No follow-up data were available at 6
month follow-up to explore the medium-term outcomes.
2.4 Participant withdrawals
The RR of withdrawing from the study for any reason was statisti-
cally higher in the control group than the psychological therapies
group (RR 0.68, 95% CI 0.54 to 0.87, Analysis 3.9).
2.5 Adverse events
No studies reported data on any adverse events observed.
Minor outcomes
2.6 Fatigue
Only two studies reported data on fatigue (Fontaine 2010; Gillis
2006). No advantage was observed for psychological therapy post-
intervention (N = 153, SMD -0.12, 95% CI -0.44 to 0.20,
Analysis 3.10) or at 3 month follow-up (N = 69, MD -0.18, CI -
0.73 to 0.37, Analysis 3.11). No studies reported data at 6 month
follow-up.
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2.7 Sleep
No differences were observed in group outcomes for sleep when
assessed post-intervention (N = 109, SMD -0.12, 95% CI -0.50
to 0.25, Analysis 3.19) and at 3 month follow-up (N = 69, MD
0.01, 95%CI -0.45 to 0.47, Analysis 3.20). No data were available
for analysis at 6 month follow-up. Moderate heterogeneity was
observed in the findings for sleep outcomes. The two trials utilised
different interventions, which may explain the heterogeneity, with
one trial implementing CBT and one trial implementing a written
emotional disclosure intervention (Analysis 4.4).
2.8 Self efficacy
Only Langford 2009 reported outcomeswith regard to self efficacy
post-intervention. No advantage was observed for psychological
therapy in comparison to attention control (N = 105, MD 0.48,
95% CI -0.27 to 1.23, Analysis 3.12). Further data were available
at the 3 month follow-up time point (Hammond 2006; Langford
2009), however no differences in group outcomes were observed
(N = 151, SMD -0.27, 95%CI -0.59 to 0.05, Analysis 3.13). One
trial reported outcomes at 6 month follow-up with no differences
between the groups observed (N = 36, MD 0.01, 95% CI -1.31
to 1.33, Analysis 3.14).
2.9 Tender points
There was no advantage observed for psychological therapies in
comparison to attention control with regards to the tender point
count post-intervention (N = 150, MD -0.80, 95% CI -1.62 to
0.02, Analysis 3.15). No short or medium-term follow-up data
were available.
2.10 Quality of life
Three trials reported data on quality of life (Langford 2009; Lera
2009; Stuifbergen 2010). No advantage was observed for psycho-
logical therapies at any endpoint: post-intervention (N = 308,
SMD -0.13, 95% CI -0.35 to -0.10, Analysis 3.16), 3 month fol-
low-up (N = 218, SMD -0.05, 95% CI -0.31 to 0.22, Analysis
3.17), 6 month follow-up (N = 171, SMD -0.04, 95% CI -0.34
to 0.26, Analysis 3.18).
Comparison 3. Biofeedback versus usual care
There were two studies with data available for this comparison
(Baumuller 2009; Van Santen 2002).
Major outcomes
3.1 Self-reported physical functioning
Two studies provided data post-intervention. No advantage was
observed when biofeedback was compared to usual care post-
intervention (N = 106, SMD -0.06, 95% CI -0.44 to 0.33,
Analysis 5.1). Only one study provided data at 3 month follow-
up (Baumuller 2009) revealing no advantage for biofeedback in
the short to medium term (N = 36, MD -0.41, 95% CI -8.88 to
8.06, Analysis 5.2).
3.2 Self-reported pain
Only one study provided data on pain post-intervention (Van
Santen 2002). It was revealed that there was no effect of biofeed-
back on pain in comparison to usual care (N = 65, MD -2.60,
95% CI -91.29 to 86.09, Analysis 5.3).
3.3 Mood
There was no overall effect favouring biofeedback when compared
to usual care post-intervention (N = 104, SMD 0.13, 95% CI -
0.26 to 0.52, Analysis 5.4) and at 3 month follow-up (N = 36,
MD 4.61, 95% CI -0.16 to 9.38, Analysis 5.5).
3.4 Participant withdrawals
The RR of withdrawing from the study for any reason was statisti-
cally lower in the control group than the intervention group (RR
4.08, 95% CI 1.43 to 11.62, Analysis 5.6).
3.5 Adverse events
No studies reported data on any adverse events observed.
Minor outcomes
3.6 Fatigue
No data were available for analysis
3.7 Sleep
No data were available for analysis.
3.8 Self efficacy
No data were available for analysis.
3.9 Tender points
No effect in favour of biofeedback was observed post-intervention
(N = 101, MD -0.92, 95% CI -2.29 to 0.45, Analysis 5.7) or at
3 month follow-up (N = 36, MD -0.09, 95% CI 0.09 to 0.62,
Analysis 5.8).
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3.10 Quality of life
Only one study (Baumuller 2009) presented data on quality of
life as an outcome, as assessed by the German version of the Short
Form36 (SF36). There was an overall effect for the vitality domain
post-intervention (N = 36, MD -13.43, 95% CI -24.06 to -2.80,
Analysis 5.13) but this was not sustained at 3 month follow-up
(Analysis 5.22).
There was no overall effect for biofeedback over usual care post-
intervention on seven out of the eight outcome domains (Analysis
5.9; Analysis 5.10; Analysis 5.11; Analysis 5.12; Analysis 5.14;
Analysis 5.15; Analysis 5.16), nor at 3 month follow-up (Analysis
5.17; Analysis 5.18; Analysis 5.19; Analysis 5.21 Analysis 5.20;
Analysis 5.23; Analysis 5.24). There was an overall effect for the
vitality domain post-intervention (N = 36, MD -13.43, 95% CI
-24.06 to -2.80, Analysis 5.13) but this was not sustained at 3
month follow-up (Analysis 5.22).
Comparison 4. Biofeedback versus attention control
Only one study presented data using an attention placebo control
group (Babu 2007). Outcome assessments were only completed
post-intervention for this study therefore three and six month data
were not available.
Major outcomes
4.1 Self-reported physical functioning
There was a difference in Fibromyalgia Impact Questionnaire
scores between biofeedback and sham attention control post-in-
tervention favouring biofeedback (N = 30, MD 13.60, 95% CI
1.05 to 26.13, Analysis 6.1).
4.2 Self-reported pain
An advantage was observed for biofeedback in comparison to sham
attention control post-intervention on a 100 point visual analog
scale for pain post-intervention (N = 30, MD 2.66, 95% CI 1.21
to 5.71, Analysis 6.2).
4.3 Mood
No data were available for analysis.
4.4 Participant withdrawals
The RR of withdrawing from the study for any reason did not
differ between the biofeedback group and control group (RR 3.46,
95% CI 0.44 to 27.19, Analysis 6.3).
4.5 Adverse events
No studies reported data on any adverse events observed.
Minor outcomes
4.6 Fatigue
No data were available for analysis.
4.7 Sleep
No data were available for analysis.
4.8 Self efficacy
No data were available for analysis.
4.9 Tender points
Data available for the tender point count post-intervention re-
vealed an advantage for biofeedback over a sham attention control
group (N = 30, MD 2.93, 95% CI 0.15 to 5.71, Analysis 6.4).
4.10 Quality of life
No data were available for analysis.
Comparison 5. Mindfulness meditation therapies
versus usual care
Only three studies reported data that could be extracted for this
analysis (Parra-Delgado 2013; Schmidt 2011; Sephton 2007).
Major outcomes
5.1 Self-reported physical functioning
Two studies reported data relating to self-reported physical func-
tioning following a mindfulness intervention in comparison to a
usual care control group (Parra-Delgado 2013; Schmidt 2011).
There were no differences between the mindfulness and the wait-
list control groups post-intervention (N = 128, SMD -0.26, 95%
CI -0.60 to 0.09, Analysis 7.1) or at short-term follow-up (N =
103, MD -0.06, 95% CI -1.78 to 0.66, Analysis 7.2). No statisti-
cal or clinical heterogeneity was observed in this comparison.
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5.2 Self-reported pain
Two studies reported data on pain as an outcome measure
(Parra-Delgado 2013; Schmidt 2011). There was no advantage of
mindfulness in comparison to a wait-list control group post-inter-
vention (N = 128, SMD -0.09, 95% CI -0.44 to 0.26, Analysis
7.3) and at short-term follow-up (N = 103, MD -0.28, 95% CI -
2.37 to 1.81, Analysis 7.4). No statistical or clinical heterogeneity
was observed in this comparison.
5.3 Mood
Three trials reported data relating to mood as an outcomemeasure
(Parra-Delgado 2013; Schmidt 2011; Sephton 2007). There was
nodifference between themindfulness andwait-list control groups
post-intervention (N = 218, SMD -0.24, 95% CI -0.51 to 0.03,
Analysis 7.5) and at short-term follow-up (N = 193, SMD -0.21,
95% CI -0.50 to 0.07, Analysis 7.6). There was a moderate level
of heterogeneity observed at the 3 month follow-up for mood.
On review of the included studies it became evident that one
study (Parra-Delgado 2013) was classified as having a high risk
of bias for outcome assessment. Following removal of this study
there remained no difference between participants receiving the
mindfulness intervention and controls (Analysis 4.3).
5.4 Participant withdrawals
There was no difference in participant withdrawals between the in-
tervention and control groups (RR 1.07, CI 0.67 to 1.72, Analysis
7.7), however as the CI included one there was uncertainty in the
estimate.
5.5 Adverse events
No studies reported data on any adverse events observed.
Minor outcomes
5.6 Fatigue
No data were available for this analysis.
5.7 Sleep
Only one study (Schmidt 2011) reported on sleep as an outcome
(assessed using the Pittsburgh Sleep Quality Index). There was
no advantage of mindfulness in comparison to usual care post-
intervention (N = 97, MD -0.64, 95% CI -2.27 to 0.99, Analysis
7.8) or at short-term follow-up (N = 103, MD -0.36, 95% CI -
1.91 to 1.19, Analysis 7.9).
5.8 Self efficacy
No data were available for this analysis.
5.9 Tender points
No data were available for this analysis.
5.10 Quality of life
No data were available for this analysis.
Comparison 6. Mindfulness meditation therapies
versus attention control
There was no data available for this comparison.
Comparison 7. Movement therapies versus usual care
Data were available for four studies exploring a movement therapy
in comparison to a usual care control group (Carson 2010; Carson
2012; Holmer 2004; Mannerkorpi 2004).
Major outcomes
7.1 Self-reported physical functioning
Four studies providing data on functioning post-intervention
(Carson 2010; Carson 2012; Holmer 2004; Mannerkorpi 2004).
There was an advantage formovement therapies over usual care (N
= 124, SMD -0.19, 95% CI -0.5 to -0.2, Analysis 9.1). However,
high statistical heterogeneity was observed. To explore reasons for
this heterogeneity two sensitivity analyses were completed, one to
explore the effect of removing one trial classified as having a high
risk of bias (Holmer 2004) and the other to explore potential dif-
ferences between movement therapy types by removing the two
studies looking at qi-gong interventions (as the other three studies
looked at the effect of yoga). Despite completing these two sensi-
tivity analyses high heterogeneity remained and no other reasons
for the heterogeneity were observed. In the short and medium-
term follow-ups, there remained an advantage for movement ther-
apies over usual care (N = 143, MD -0.65, 95% CI -1.08 to -0.22,
P < 0.01 at 3 months; MD -11.21, 95% CI -19.13 to -3.29, P <
0.01 at 6 month follow-up).
7.2 Self-reported pain
One study (Holmer 2004) reported data on pain post-interven-
tion. There was an advantage for movement therapies in compar-
ison to usual care (N = 28, MD -2.30, 95% CI -4.19 to -0.41,
Analysis 9.2).
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7.3 Mood
Data were available for one study that assessed mood post-inter-
vention (Holmer 2004). An overall effect was observed for move-
ment therapy over usual care (N = 29, MD -9.84, 95% CI -18.51
to -1.17, P = 0.03, Analysis 9.3).
7.4 Participant withdrawals
The RR of withdrawing from the study for any reason was sta-
tistically lower in the control group than the movement therapy
group (RR 1.95, 95% CI 1.13 to 3.38, Analysis 9.4).
7.5 Adverse events
There was no difference between adverse events in the movement
therapy and control group (RR 4.62, 95% CI 0.23 to 93.92,
Analysis 9.5). The CIs were large, which may reflect that only one
study (Lynch 2012) reported on adverse events that occurred. In
this study two people reported experiencing increased pain in the
intervention group.
Minor outcomes
7.6 Fatigue
The data presented on fatigue (Holmer 2004), as assessed using
the Multidimensional Assessment of Fatigue scale, revealed that
there was an advantage of movement therapy in comparison to
usual care (N = 29, MD -10.80, 95% CI -18.57 to -1.17, Analysis
9.6).
7.7 Sleep
One study reported data assessing sleep post-intervention (Holmer
2004). Sleepwas assessed using the Pittsburgh SleepQuality Index.
There was a difference observed in sleep quality post-intervention,
with those receiving a movement therapy intervention revealing
improved outcomes (N = 29, MD -4.68, 95% CI -8.14 to -1.22,
Analysis 9.8).
7.8 Self efficacy
No data were available.
7.9 Tender points
Data were only available for two studies which incorporated a
tender point count as an outcome measure (Carson 2010; Carson
2012). There was no advantage observed for movement therapy
over usual care (N=93, SMD0.18, 95%CI -0.25 to 0.60, Analysis
9.7). High heterogeneity was observed (91%) but no reasons for
the heterogeneity were apparent in terms of intervention delivery
or study quality.
7.10 Quality of life
No data were available.
Comparison 8. Movement therapies versus attention
control
There were three studies with data available for this comparison.
One study (Wang 2010) revealed standard deviations that were
more than half themean on a specific outcomemeasure, indicating
that the mean was unlikely to accurately reflect the centre-point
of the distribution for that variable (Altman 1996). Due to the
low number of studies that could be analysed for each outcome
domain, it was not possible to complete a sensitivity analyses with
and without these data, as planned. As skewed data were less likely
to be problematic if the data set was large, and the study had a
sample size of less than 100 participants, it was decided to exclude
the data from the analyses for variables where the standard devia-
tion was more than half the mean (but the data from the trial were
included in the analyses for variables where this was not the case).
Major outcomes
8.1 Self-reported physical functioning
There was an advantage observed from three studies (Altan 2009;
Calandre 2009; Wang 2010) for movement therapy over an at-
tention control group on functioning post-intervention (N = 191,
SMD -0.65, 95% CI -0.94 to -0.35, Analysis 12.1) and this was
sustained at 3 month follow-up (N = 189, SMD -0.53, 95% CI
-0.82 to -0.23, Analysis 12.2). Removing the data from one trial
with inadequate blinding of outcome assessors (Calandre 2009)
reduced the heterogeneity and the advantage for movement ther-
apy remained (Analysis 13.1; Analysis 13.2).
8.2 Self-reported pain
Three studies assessed pain as an outcome using a 10 point visual
analog scale (Altan 2009; Calandre 2009; Wang 2010). An ad-
vantage was revealed for movement therapy over attention control
post-intervention (N = 172, MD -1.45, 95% CI -2.08 to -0.81,
Analysis 12.3) that was sustained at 3 month follow-up (N = 165,
MD -1.19, 95% CI -1.87 to -0.52, Analysis 12.4). When one
trial (Calandre 2009) showing inadequate blinding of outcome
assessors was removed from the analysis statistical heterogeneity
was reduced and an advantage for movement therapies remained
(Analysis 13.3; Analysis 13.4).
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8.3 Mood
Two studies presented data on mood as an outcome (Calandre
2009;Wang 2010). There was a difference inmood scores between
movement therapy and the attention control groups favouring
movement therapy post-intervention (N = 141, SMD -0.49, 95%
CI -0.83 to -0.15, Analysis 12.5). The group difference remained
evident at 3 months (N = 140, SMD -0.35, 95% CI -0.69 to -
0.01, Analysis 12.6). After removing one trial from the analysis
due to the high risk of bias identified (due to inadequate blinding
of outcome assessors) differences in group outcomes remained,
favouring movement therapy (Analysis 13.5; Analysis 13.6).
8.4 Participant withdrawals
There was no difference between the rates of participant with-
drawals for the movement therapy and control groups (RR 1.16,
95% CI 0.65 to 2.09, Analysis 12.7).
8.5 Adverse events
There was no difference between the number of adverse events
in the movement therapy and control groups (RR 7.00, 95% CI
0.37 to 131.17, Analysis 12.8). The CIs were large, which may
reflect that only one study (Calandre 2009) reported on adverse
events. In this study three people experienced adverse events in
the intervention group including one person who reported being
hypersensitive to chlorine (as the intervention was conducted in a
pool) and two participants who reported increased pain.
Minor outcomes
8.5 Fatigue
No studies reported data that could be used in this analysis.
Calandre 2009 reported data on the fatigue questions of the Fi-
bromyalgia Impact Questionnaire, but as these data was included
in the total score for self-reported physical functioning variable
the data were not presented here.
8.7 Sleep
The Pittsburgh SleepQuality Index was used to assess sleep quality
in two trials (Calandre 2009;Wang 2010). There was an advantage
for movement therapy in comparison to attention control for sleep
post-intervention (N = 141, MD -1.88, 95% CI -3.27 to -0.48,
Analysis 12.15), but this was not evident at 3 month follow-up
(N = 140, MD -1.35, 95% CI -2.77 to 0.07, Analysis 12.16).
8.8 Self efficacy
One trial presented data on self efficacy for movement therapy
versus an attention control group (Wang 2010). There was an
advantage observed for movement therapies post-intervention (N
= 60, MD -45.20, 95% CI -46.14 to -44.22, Analysis 12.9) and
this was sustained at 3 month follow-up (N = 59, MD 1.20, 95%
CI 0.15 to 2.25, Analysis 12.10).
8.9 Tender points
There was no advantage revealed for movement therapies in the
short (N =130, MD 0.09, 95% CI -1.16 to 1.33, Analysis 12.11)
or medium term (N = 130, MD -0.39, 95% CI -1.63 to 0.85,
Analysis 12.12) across two trials (Altan 2009; Calandre 2009).
8.10 Quality of life
Two studies presented data from quality of life assessments (Altan
2009; Wang 2010). An advantage was observed for movement
therapies in comparison to attention control post-intervention (N
= 109, SMD -0.70, 95% CI -1.09 to -0.31, Analysis 12.13) and
at 3 month follow-up (N = 108, SMD -0.52, 95% CI -0.91 to -
0.14, Analysis 12.14).
Comparison 9. Relaxation based therapies versus
usual care
There were two studies with data available for this comparison
(Menzies 2006; Riedel 2012).
Major outcomes
9.1 Self-reported physical functioning
Two trials (Menzies 2006; Riedel 2012) presented data relating
to functioning post-intervention, which was assessed using the
Fibromyalgia Impact Questionnaire. There was an advantage for
relaxation in comparison to usual care (N =67,MD-8.34, 95%CI
-10.14 to -6.53, Analysis 14.1).No follow-updatawere available to
determine short and medium-term effectiveness and no statistical
heterogeneity was observed.
9.2 Self-reported pain
Menzies 2006 and Riedel 2012 reported on pain as an outcome
following a relaxation intervention in comparison to usual care.
There was an advantage observed for relaxation post-intervention
(N = 67, SMD1.02, 95%CI -1.55 to 0.50, Analysis 14.2). No fol-
low-up data were available. Statistical heterogeneity was observed
between the two studies but nomajormethodological reasonswere
identified.
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9.3 Mood
Riedel 2012 presented data on depression following intervention
delivery as assessed by the Center for Epidemiological Studies De-
pression Scale. There were no differences observed between the
experimental and control groups post-intervention (N = 19, MD
-4.44, 95% CI -14.46 to 5.58).
9.4 Participant withdrawals
There was no difference between participant withdrawal rates for
the relaxation and control groups (RR4.40, 95%CI0.59 to 33.07,
Analysis 14.4).
9.5 Adverse events
No studies reported data on any adverse events observed.
Minor outcomes
9.6 Fatigue
Only one study (Riedel 2012) presented data on fatigue post-in-
tervention. There were no differences observed between relaxation
and control participants (N = 19, MD -0.82, 95% CI -2.91 to
1.27).
9.7 Sleep
The study by Riedel 2012 presented information on sleep quality
as assessed by the Pittsburgh Sleep Quality Index. There were no
differences observed between the experimental and control groups
post-intervention (N = 19, MD 1.03, 95% CI -2.23 to 4.29).
9.8 Self efficacy
There was an advantage observed for relaxation over usual care on
self efficacy as assessed by two studies post-intervention (Menzies
2006; Riedel 2012) (N = 67, SMD -1.54, 95% CI -2.13 to -0.95,
Analysis 14.5). No follow-up data were available.
9.9 Tender points
No data were available for this analysis.
9.10 Quality of life
No data were available for this analysis.
Comparison 10. Relaxation based therapies versus
attention control
There was only one study with data available for this comparison
(Fors 2000).
Major outcomes
10.1 Self-reported physical functioning
No data were available for this analysis.
10.2 Self-reported pain
One trial presented data onpain,whichwas assessed by a 100 point
visual analog scale (Fors 2000). There was an advantage identified
for the relaxation group in comparison to an education control
group (N = 39, MD -23.17, 95% CI -36.73 to -9.61, Analysis
15.1). No follow-up assessment data were available.
10.3 Mood
The data presented by Fors 2000, which assessed mood using a
100 point visual analog scale for anxiety, found an improvement
with the use of relaxation based therapies in comparison to an
education control (N = 39,MD -32.10, 95%CI -46.35 to -17.85,
Analysis 15.2). No follow-up data were available.
10.4 Participant withdrawals
As no participants were reported to have withdrawn from the Fors
2000 study estimates could not be derived for this outcome.
10.5 Adverse events
No studies reported data on any adverse events observed.
Minor outcomes
10.6 Fatigue
No data were available for this analysis.
10.7 Sleep
No data were available for this analysis.
10.8 Self efficacy
No data were available for this analysis.
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10.9 Tender points
No data were available for this analysis.
10.10 Quality of life
No data were available for this analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Biofeedback compared to usual care for fibromyalgia
Patient or population: patients with fibromyalgia
Settings: outpatients
Intervention: biofeedback
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Biofeedback
Functioning as assessed
post-intervention
Fibromyal-
gia Impact Questionnaire
Revised. Scale from: 0 to
100
Follow-up: 8 to 24 weeks
The mean functioning as
assessed post-interven-
tion in the control groups
was
17.16
The mean functioning as
assessed post-interven-
tion in the intervention
groups was
0.06 standard deviations
lower
(0.44 lower to 0.33
higher)
106
(2 studies)
⊕©©©
very low1,2,3
SMD -0.1 (95% CI -0.4 to
0.3)
Absolute change -1.2%
(95% CI -8.8 to 6.6) Rel-
ative improvement 2.2%
(95% CI -16.3 to12.2)
Not statistically signifi-
cant
Pain as assessed post-
intervention
100 point visual analog
scale. Scale from: 0 to
100
Follow-up: mean 8 weeks
The mean pain as as-
sessed post-intervention
in the control groups was
1.3
The mean pain as as-
sessed post-intervention
in the intervention groups
was
2.6 lower
(91.29 lower to 86.09
higher)
65
(1 study)
⊕©©©
very low4,5
MD -2.6 (95% CI -91.3 to
86.1)
Absolute change -2.6%
(95% CI -91.0 to 86.0)
Relative improvement -4.
0% (95% CI -1.0 to1.0)
Not statistically signifi-
cant
Mood as assessed post-
intervention
The Symptom Checklist-
90 Revised. Scale from:
The mean mood as as-
sessed post-intervention
in the control groups was
7.3
The mean mood as as-
sessed post-intervention
in the intervention groups
was
104
(2 studies)
⊕©©©
very low6,7,8
SMD 0.1 (95% CI -0.3 to
0.5)
Absolute change 1.9%
(95% CI -3.7 to 7.4)2
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0 to 90
Follow-up: 8 to 24 weeks
0.13 standard deviations
higher
(0.26 lower to 0.52
higher)
Relative improvement 3.
6% (95% CI -7.2 to 14.5)
Not statistically signifi-
cant
All cause attrition post-
intervention
Number of people with-
drawing from the study
before completing the in-
tervention
Follow-up: 4 to 24 weeks
Study population RR 4.08
(1.43 to 11.62)
125
(3 studies)
⊕©©©
very low9,10,11
Absolute risk difference
20% (95% CI 0.8 to 0.3)
Relative per cent change
308% (95% CI 43 to
1062)
NNTH 7 (95% CI 3 to 41)63 per 1000 259 per 1000
(91 to 738)
Adverse events post-in-
tervention - not reported
See comment See comment Not estimable - See comment Not estimable
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level due to risk of bias: Random sequence generation and allocation concealment was unclear for one study
2 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery
3 Downgraded one level due to imprecision: There were less than 200 participants in this analysis
4 Downgraded one level due to risk of bias: Random sequence generation and allocation concealment was unclear for one study
5 Downgraded one level due to imprecision: There were less than 100 participants in the analysis
6 Downgraded one level due to imprecision: Downgraded one level due to risk of bias: Random sequence generation and allocation
concealment was unclear for one study
7 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery
8 Downgraded one level due to imprecision: There were less than 200 participants in the analysis
9 Downgraded one level due to risk of bias: Random sequence generation and allocation concealment was unclear for one study
10 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery
11 Downgraded one level due to imprecision: There were less than 200 participants in the analysis2
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Mindfulness compared to usual care for fibromyalgia
Patient or population: patients with fibromyalgia
Settings: outpatients
Intervention: mindfulness
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Mindfulness
Functioning as assessed
post-intervention
Fibromyalgia Im-
pact Questionnaire. Scale
from: 0 to 100
Follow-up: mean 8 weeks
The mean functioning as
assessed post-interven-
tion in the control groups
was
17.22
The mean functioning as
assessed post-interven-
tion in the intervention
groups was
0.26 standard deviations
lower
(0.6 lower to 0.09 higher)
128
(2 studies)
⊕⊕©©
low1
SMD -0.3 (95% CI -0.6 to
0.1)
Absolute change -4.8%
(95% CI -11.2 to 1.7%)
Relative improvement -8.
5% (95% CI -19.3 to 3.5)
Not statistically signifi-
cant
Pain as assessed post-
intervention
Visual analog scale 0 to
100. Scale from: 0 to 10.
Follow-up: mean 8 weeks
The mean pain as as-
sessed post-intervention
in the control groups was
0.21
The mean pain as as-
sessed post-intervention
in the intervention groups
was
0.09 standard deviations
lower
(0.44 lower to 0.26
higher)
128
(2 studies)
⊕⊕©©
low2,3
SMD -0.09 (95% CI -0.4
to 0.3)
Absolute change -1.28%
(95% CI -6.2 to 3.7)
Relative improvement -2.
3% (95% CI -11.1 to 6.6)
Not statistically signifi-
cant
Mood as assessed post-
intervention
State Trait Anxiety Inven-
tory State Scale. Scale
from: 0 to 60.
The mean mood as as-
sessed post-intervention
in the control groups was
10.28
The mean mood as as-
sessed post-intervention
in the intervention groups
was
0.24 standard deviations
218
(3 studies)
⊕⊕⊕©
moderate4
SMD -0.24 (95% CI -0.5
to 0.0)
Absolute change -3.7%
(95% CI -7.9 to 0.5)
Relative improvement -8.3
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Follow-up: mean 8 weeks lower
(0.51 lower to 0.03
higher)
7% (95% CI -18.5 to 1.2)
Not statistically signifi-
cant
All cause attrition post-
intervention
Number of people with-
drawing from the study
before completing the in-
tervention
Follow-up: mean 8 weeks
Study population RR 1.07
(0.67 to 1.72)
195
(3 studies)
⊕⊕⊕©
moderate5
Absolute risk difference
2% (95% CI -0.10 to 0.
14)
Relative per cent change
98% (95% CI -90 to -86)
Not statistically signifi-
cant
223 per 1000 239 per 1000
(150 to 384)
Adverse events post-in-
tervention - not reported
See comment See comment Not estimable - See comment Not reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded two levels due to imprecision: There were less than 200 participants in the analysis
2 Downgraded one level due to risk of bias: One study was classified as having a high risk of blinding of the outcome assessors
3 Downgraded one level due to imprecision: There were less than 200 participants in the analysis
4 Downgraded one level due to risk of bias: One study was classified as having a high risk of blinding of the outcome assessors
5 Downgraded one level due to risk of bias: One study was classified as having a high risk of blinding of the outcome assessors with one
study classified as having an unclear risk of sequence generation, allocation concealment and blinding of the outcome assessors
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Movement therapies compared to usual care for fibromyalgia
Patient or population: patients with fibromyalgia
Settings: outpatients
Intervention: movement therapies
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Movement therapies
Functioning as assessed
post-intervention
Fibromyalgia Impact
Questionnaire - Revised.
Scale from: 0 to 100.
Follow-up: 8 to 14 weeks
The mean functioning as
assessed post-interven-
tion in the control groups
was
13.3
The mean functioning as
assessed post-interven-
tion in the intervention
groups was
0.19 standard deviations
lower
(0.53 lower to 0.15
higher)
143
(4 studies)
⊕©©©
very low1,2,3
SMD -0.19 (95% CI -0.5
to 0.2).
Absolute change -3.4%
(95% CI -9.4 to 2.7) 2
point change on 0 to 100
scale
Relative improvement -6.
8% (95% CI -19.1 to 5.5)
Not statistically signifi-
cant
Pain as assessed post-
intervention
10 point visual analog
scale. Scale from: 0 to 10
Follow-up: mean 8 weeks
The mean pain as as-
sessed post-intervention
in the control groups was
-0.37
The mean pain as as-
sessed post-intervention
in the intervention groups
was
2.3 lower
(4.19 to 0.41 lower)
28
(1 study)
⊕©©©
very low4,5
MD -2.3 (95% CI -4.2 to
-0.4)
Absolute change -23.0%
(95% CI -42.0 to -4.0)
Relative improvement -3.
0% (95% CI -6 to -0.6)
NNT 3 (95% CI 2 to 41)
3
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Mood as assessed post-
intervention
Center for Epidemio-
logic Studies Depression
Scale. Scale from: 0 to 60
Follow-up: mean 8 weeks
The mean mood as as-
sessed post-intervention
in the control groups was
0.41
The mean mood as as-
sessed post-intervention
in the intervention groups
was
9.84 lower
(18.51 to 1.17 lower)
29
(1 study)
⊕©©©
very low6,7
MD -9.8 (95% CI -18.5 to
-1.2)
Absolute change -16.4%
(95% CI -31.0 to -2.0)
Relative improvement -0.
7% (95% CI -1.3 to -0.1)
NNT 3 (95% CI 2 to 34)
All cause attrition post-
intervention
Number of people with-
drawing from the study
before completing the in-
tervention
Follow-up: 8 to 24 weeks
Study population RR 1.95
(1.13 to 3.38)
240
(5 studies)
⊕©©©
very low8,9
Absolute risk difference
11% (95% CI 0.0 to 0.2)
Relative per cent change
95% (95% CI 13 to 238)
NNTH 13 (95% CI 5 to
105)106 per 1000 206 per 1000
(119 to 357)
Adverse events post-in-
tervention
Number of people report-
ing an adverse event be-
fore completing the inter-
vention
Follow-up: 8 to 24 weeks
Study population RR 4.62
(0.23 to 93.72)
98
(1 study)
⊕©©©
very low11,12,13
Absolute risk difference
4% (95% CI -0.0 to 0.1)
Relative per cent change
362% (95% CI -77 to
9272)
Not statistically signifi-
cant
0 per 1000 40 per 100010
(0 to 0)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level due to risk of bias: One study was classified as having a high risk of allocation concealment and blinding of
outcome assessors
2 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery
3 Downgraded one level due to imprecision: There were less than 200 participants in the analysis
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4 Downgraded one level due to risk of bias: One study was classified as having a high risk of allocation concealment and blinding of
outcome assessors
5 Downgraded one level due to imprecision: There were less than 100 participants in the analysis
6 Downgraded one level due to risk of bias: One study was classified as having a high risk of allocation concealment and blinding of
outcome assessors
7 Downgraded one level due to imprecision: There were less than 200 participants in the analysis
8 Downgraded one level due to risk of bias: One study was classified as having a high risk of allocation concealment and blinding of
outcome assessors and one study had a high risk of selective reporting
9 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery
10 Absolute effect calculated from risk difference
11Downgraded one level due to risk of bias: One study was classified as having a high risk of selective reporting and unclear sequence
generation and allocation concealment
12 Downgraded one level due to inconsistency: There was diversity in the duration of intervention delivery
13 Downgraded one level due to imprecision: There were less than 200 participants in the analysis
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Relaxation compared to usual care for fibromyalgia
Patient or population: patients with fibromyalgia
Settings: outpatients
Intervention: relaxation
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of p
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Relaxation
Functioning as assessed
post-intervention
Fibromyalgia Im-
pact Questionnaire. Scale
from: 0 to 80
Follow-up: 6 to 10 weeks
The mean functioning as
assessed post-interven-
tion in the control groups
was
3.16
The mean functioning as
assessed post-interven-
tion in the intervention
groups was
1.63 standard deviations
lower
(10.14 to 6.53 lower)
67
(2 studies)
⊕©©©
very low1,2
MD -8.3 (95% CI -10.1 to -6.
5).
Absolute change -10.4%
(95%CI -13.0 to -8.0), 5 point
shift on 0 to 80 scale
Relative improvement -20.0%
(95% CI -0.2 to -0.2)
NNT 2 (95% CI 1 to 2)
Pain as assessed post-
intervention
Short Form - McGill
Pain Questionnaire Total
Score. Scale from: 0 to
78
Follow-up: 6 to 10 weeks
The mean pain as as-
sessed post-intervention
in the control groups was
1.86
The mean pain as as-
sessed post-intervention
in the intervention groups
was
1.02 standard deviations
lower
(1.55 to 0.5 lower)
67
(2 studies)
⊕©©©
very low3,4
SMD -1.0 (95% CI -1.6 to -0.
5).
Absolute change -3.5% (95%
CI -5.3 to -1.7), 2 point shift
on a scale of 0 to 8
Relative improvement -9.5%
(95% CI -14.5 to -4.8)
NNT 2 (95% CI 1 to 4)
Mood as assessed post-
intervention
Center for Epidemio-
logic Disease Depression
Scale. Scale from: 0 to 60
The mean mood as as-
sessed post-intervention
in the control groups was
-1.9
The mean mood as as-
sessed post-intervention
in the intervention groups
was
4.44 lower
19
(1 study)
⊕©©©
very low5,6
MD -4.4 (95% CI -14.5 to 5.
6)
Absolute change -7.4% (95%
CI -24 to 9)
3
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Follow-up: mean 6 weeks (14.46 lower to 5.58
higher)
Relative improvement -27%
(95% CI -0.9 to -0.3)
Not statistically significant
All cause attrition post-
intervention
Number of people with-
drawing from the study
before completing the in-
tervention
Follow-up: mean 6 weeks
Study population RR 4.4
(0.59 to 33.07)
21
(1 study)
⊕©©©
very low7,8
Absolute risk difference 31%
(95% CI -0.0 to 0.7)
Relative per cent change
340% (95% CI -41 to 3207)
Not statistically significant
91 per 1000 400 per 1000
(54 to 1000)
Adverse events post-in-
tervention - not reported
See comment See comment Not estimable - See comment Not estimable
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level due to risk of bias: One study was classified as having an unclear risk of blinding of outcome assessors
2 Downgraded one level due to imprecision: There were less than 100 participants in the analysis
3 Downgraded one level due to risk of bias: One study was classified as having an unclear risk of blinding of outcome assessors
4 Downgraded one level due to imprecision: There were less than 100 participants in the analysis
5 Downgraded one level due to risk of bias: One study was classified as having an unclear risk of blinding of outcome assessors
6 Downgraded one level due to imprecision: There were less than 100 participants in the analysis
7 Downgraded one level due to risk of bias: One study was classified as having an unclear risk of blinding of outcome assessors
8 Downgraded one level due to imprecision: There were less than 100 participants in the analysis
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D I S C U S S I O N
Summary of main results
Moderate, low or very low quality of evidence from 61 trials (in-
cluding a total of 4234 participants) was analysed. Mind-body in-
terventionswere analysed based on the type of intervention includ-
ing biofeedback, movement therapies, psychological therapies, re-
laxation based therapies and mindfulness.
There was no advantage observed for biofeedback in comparison
to usual care controls and no studies reported any adverse events,
however the quality of the evidence was very low so we cannot be
certain if there is any effect or not. There was also no advantage
observed for mindfulness in comparison with usual care, There
was no difference in withdrawals between groups. Adverse events
were not reported.
There was no advantage observed for mindfulness in comparison
to usual care for physical functioning, pain or mood post-inter-
vention. However the quality of the evidence was very low. There
was uncertainty as to whether there were statistical differences in
withdrawals between the two groups. No studies reported any ad-
verse events.
There were improved outcomes formovement therapies over usual
care and attention controls for physical functioning, pain and
mood post-intervention. However the risk of increased pain re-
ported by one trial suggests caution is needed in interpreting the
results and we cannot be certain of any effect due to the very low
quality of evidence.
Results for the main analyses on the use of psychological thera-
pies in comparison to usual care controls revealed low quality evi-
dence from 10 trials (733 participants) suggesting that psychologi-
cal therapies provide a small improvement in physical functioning,
pain and mood at the end of treatment. Low quality evidence re-
vealed that improvements in physical functioning and mood were
sustained at three month follow-up and at six month follow up
for physical functioning. There was very low quality evidence for
the secondary outcomes resulting from psychological therapies.
Relaxation based therapies showed an advantage over usual care
for physical functioning and pain outcomes post-intervention; for
pain however the quality of the evidence was very low. No differ-
ences in withdrawals or adverse events were reported for relaxation
based therapies.
The small number of studies that provided short to medium-term
(three to six month follow-up) data in this review is a concern and
limited evidence was available to determine the short to medium-
term impact of mind-body interventions for adults with FM.
Overall completeness and applicability of
evidence
Overall completeness
In the search strategy we included efforts to identify and include
unpublished data to reduce the possible impact of publication bias.
Whilst some unpublished data have been included in the review,
we cannot rule out the possibility that negative study results may
not have been published or identified for inclusion by this review.
The applicability of the evidence included in this review is con-
sidered to be strong for a number of reasons. Firstly, the review
includes a number of mind-body interventions delivered across a
range of contexts including hospital settings, primary care centres
and in the community. Secondly, many samples included both
male as well as female adults with FM, which is important as al-
though FM predominantly affects women it can affect men; how-
ever, due to the low numbers no study performed a subgroup anal-
ysis for male participants. Thirdly, many trials included partici-
pants with additional co-morbidities (not serious or life-threaten-
ing), such as depression, which commonly occur in adults with
FM.
Due to the diversity of symptoms experienced by people with FM,
this review analysed the evidence on a wide range of outcomes
including the major outcomes of self-reported physical function-
ing, pain, withdrawals and adverse events, and minor outcomes
such as fatigue and self efficacy. Outcomes such as walk time, self
confidence, use of medication and healthcare visits may be impor-
tant but we were not able to incorporate them within the scope of
this review as there is a limit to the number of outcomes that can
reliably be studied within the context of a Cochrane review.
This review aimed to quantitatively summarise the effects ofmind-
body interventions for FM. Whilst this review was targeted at
one specific population (adults with FM), the findings may have
relevance to other populations where complex symptomology
presents. Within the context of current practice, many chronic
pain programmes already implement components of mind-body
therapies, such as the use of guided imagery. Mind-body interven-
tions that require specialist expertise to deliver, such as tai chi or
cognitive behaviour therapy (CBT), may be more challenging to
incorporate into practice without additional resources.
Quality of the evidence
The evidence presented in this review was extracted from trials
published in academic journals and was requested from the trial
authors. The overall quality of the evidence was moderate, low
or very low (see summary of findings tables). Trial quality was
reduced by unclear details or high risk of allocation concealment,
non-blinding of outcome assessors or risk of bias from selective
reporting; however, sensitivity analyses revealed that the findings
were not influenced by the removal of studies with a high risk of
bias from the analyses. The sample size of the included trials was
often small and even in the meta-analyses participant numbers
were as low as N = 19, increasing to N = 733. Few studies reported
information on any adverse events arising from the interventions.
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It is important to record any instances where there is a decrease
in health or well-being, such as increased levels of pain or fatigue,
that may have been exacerbated by the intervention.
Potential biases in the review process
Despite efforts to reduce the impact of publication bias in the
review, the possibility remains that some studies (with positive
or negative findings) may not have been identified by the search.
Where further clarification of study methodology could not be ob-
tained from the authors, there is the possibility that the risk of bias
for the studies may have been overestimated. Whilst contacting
authors for additional information assisted in the accuracy of the
information reported in most cases, this may have introduced a
’response bias’ into the risk of bias assessment. Some values needed
to be imputed for missing data (such as variability estimates when
the lower confidence interval was used) using the Revman calcu-
lator. Data were unable to be extracted accurately for several trials
that presented their findings graphically, thus limiting the gener-
alisability of the findings. The small number of trials included in
some analyses further reduces the robustness of these findings.
Inmany cases determining the assessment time point was difficult,
as it was not always clear if the timeframe was post-randomisation
or intervention delivery and the window within which assessments
were completed was rarely documented.
Agreements and disagreements with other
studies or reviews
One previous systematic review of mind-body therapies for adults
with FMwas found (Hadhazy 2000). The review included13 trials
of 802 participants and searched the literature until 1999. The
findings of the review support the findings of this current review
suggesting that there is some limited evidence of the effectiveness
of mind-body therapies in comparison to placebo or attention
control for self-reported pain and physical functioning.
Reviews examining different types of mind-body interventions in-
clude a Cochrane review of cognitive behaviour therapy (CBT)
for adults and children with FM, conducted until August 2013
(Bernardy 2013). The results from this current review were more
negative than for the review conducted by Bernardy 2013, which
revealed small effects for pain, mood and disability that were sus-
tained at follow-up. By including CBTs in comparisons of treat-
ment effect with other psychological therapies may have obscured
unique effects of different types of interventions. The inclusion of
children in the other review may also have increased the observed
treatment effect.
Another systematic review explored the effectiveness of qi-gong
interventions for adults and children with FM (Chan 2012). The
review completed a search of studies until February 2011 and re-
vealed that it was too early to draw conclusions as to the efficacy of
qi-gong and that further robust RCTswere warranted. The current
review supports these findings that there is currently insufficient
evidence on movement therapies to draw any firm conclusions.
The authors of a Cochrane review on psychological therapies for
chronic pain (excluding headache) searched the literature until
September 2011 (Williams 2012). This review revealed that peo-
ple receiving psychological therapies experienced small improve-
ments in functioning, pain and mood when compared to usual
care but not when compared to attention control participants.
These findings are comparable to the findings in the current re-
view.
Other systematic reviews in this field have been published outside
of The Cochrane Library. Findings revealed some inconsistencies
which may be due to differences in the inclusion criteria set and
outcomes domains explored. In a review of mindfulness based re-
laxation studies for FM (Lauche 2013) the authors revealed that
mindfulness group participants showed reductions in pain and im-
proved quality of life post-intervention in comparison to controls.
In contrast, this review found no difference between the experi-
mental and control groups on any of themajor outcomes including
pain and quality of life. This disparity in the findings may reflect
the inclusion of non-randomised trials in the review by Lauche
2013. A review of guided imagery for FM that was conducted by
Bernardy 2011 revealed similar findings to the relaxation analysis
conducted as part of this Cochrane review, where both studies in-
cluded in the relaxation analysis used a guided imagery interven-
tion. Both reviews revealed that participants receiving guided im-
agery showed reductions in pain but not quality of life post-inter-
vention. This Cochrane review also identified that participants re-
ceiving biofeedback demonstrated improved physical functioning
post-intervention compared to controls. In a review of biofeed-
back for people with FM conducted by Glombiewski 2013, it was
revealed that participants receiving biofeedback reported reduc-
tions in pain post-intervention in comparison to controls. This
Cochrane review was unable to detect a difference between par-
ticipants receiving biofeedback and controls. This may be due to
the inclusion of trials using additional interventions such as cog-
nitive strategies or exercise. In contrast, for inclusion in this review
biofeedback needed to be the primary focus of the intervention
(constituting at least 80% of the intervention) to ensure any ef-
fects detected were due to the biofeedback rather than inclusion of
other treatments. A consistent finding between these three reviews
published outside of Cochrane and the current review is that the
quality of the available evidence in this area is poor.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Mind-body interventions are becoming increasingly incorporated
into treatment programmes for fibromyalgia (FM). The findings
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of this review indicate that psychological therapies may improve
physical functioning, pain and mood following treatment but
highlight that the quality of evidence is low. The observed effects
were not sustained at six months follow-up. There was wide vari-
ation in intervention mode of delivery and there were an insuffi-
cient number of trials to enable calculation of the effect of differ-
ent modes of delivery on outcomes. Psychological therapies were
delivered over a period of between one and 25 weeks (mean 11
weeks), with greater effects observed with longer duration. There
was low reporting on the presence or absence of adverse events,
however equivalent rates of dropout between the treatment and
control groups indicate that the risks to people receiving psycho-
logical interventions are low.
There is insufficient evidence to determine the use of biofeedback,
mindfulness, movement therapies or relaxation based therapies for
adults with FM.
Implications for research
Evidence
The evidence for outcomes in this review was limited by the low
or very low quality of the trials identified. To enable recommen-
dations on the use of mind-body therapies for adults with fi-
bromyalgia to be determined, robust randomised controlled tri-
als are needed. Following the findings of this review, trials should
take into account the need to accurately report on randomisation
procedures and allocation concealment processes and to clearly
report data including measures of variance for all outcomes at all
time points assessed. There is no need for further low quality trials
(trials with high risk of bias) in this area.
Population
As fibromyalgia predominantly affects females, many studies only
included female participants in order to reduce heterogeneity,
however this limits the applicability of the findings for males with
fibromyalgia. Subgroup analyses could help explore the impact of
gender on treatment effect and future studies should consider in-
clusion of male and female participants. This study only presents
data for adults over 18 years and future reviews are needed to re-
view the evidence of mind-body therapies for children.
Intervention
There waswide heterogeneity in the interventions deliveredwithin
the groups specified, this was particularly evident within the sensi-
tivity analyses of the data. For example, psychological therapies en-
compassed written therapies, educational based approaches as well
as specific therapeutic techniques such as the Resseguier approach.
There was also variability in the mode of intervention delivery
with therapies being self-administered or delivered by a therapists
on an individual basis or within a group. Future reviews would
benefit from having a narrower focus to ensure that the effective
elements of the specific components of mind-body therapies can
be identified.
Comparison
Trials used a combination of usual care and attention control
groups for comparison. Greater differences between groups were
observed when the intervention was compared to usual care, sug-
gesting that therapeutic attention or a placebo effect may have
been observed.
Outcomes
It was often difficult to determine why participants withdrew from
the included trials and at which time point. Higher numbers of
withdrawals from the intervention group can indicate difficulties
with the feasibility of the intervention or mode of delivery and
should be reported; although this was not found to be the case
for studies in our analyses where this information could be de-
termined. CONSORT diagrams outlining reasons for withdrawal
between groups over time are a useful way of presenting this in-
formation for future studies.
Few studies described any adverse events experienced by partici-
pants and this information is critical for ensuring the safety and
feasibility of interventions in clinical practice, and should be re-
ported. Declarations that no adverse events were experienced, if
this was the case, would also facilitate interpretation of the results.
A wide range of outcomes and outcome measures were reported
between trials. As recommended by Choy 2009 and Bernardy
2013, a core set of outcome measures that should be assessed and
reported across clinical trials needs to be established by consensus
to facilitate pooling of trial data and the comparison of study find-
ings. As recommended by Choy 2009, the Fibromyalgia Impact
Questionnaire should be considered to be the primary outcome
measures for all fibromyalgia randomised controlled trials, with
secondary outcomes of self-reported pain, fatigue and sleep.
Time
This review presents data identified up to October 2013, and fur-
ther updates will be required as new evidence emerges. More trials
with follow-up at three and six months are needed to determine
if the effects of mind-body interventions are sustained.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alda 2011
Methods Randomised controlled multi-centre trial
Participants Participants who fulfil (ACR) criteria for primary fibromyalgia were recruited by doctors
working in primary care centres
Aged 18 to 65 years
Total participants N = 169 randomised (141 completed)
N = 159 female, N = 10 male
Exclusions: unable to understand or read Spainish; undergone psychological treatment
in previous two years, receiving pharmacological treatment or unwilling to discontinue
treatment two weeks before start of study; no informed consent provided; patients with
severe axis I or axis II disorders and other medical disorders that from the clinician’s point
of view prevented the patient from following the treatment protocol; women who were
pregnant or nursing and those declining to participate
Interventions 1) Cognitive behavioural therapy consisting of two components; cognitive restructuring
and coping
90 minute sessions, held weekly for 10 weeks, delivered by trained therapists
2) Treatment as usual
3) Pharmacological treatment (data not included in this review)
Outcomes Measures relevant to this review: Fibromylagia impact questionnaire, pain visual analog
scale, Hamilton rating scale for depression and EuroQol 5D
Assessment time points: baseline, post-intervention and 6 month follow-up
Notes The study was funded by a grant from the Carlos III Health Institute of the Spainish
Ministry of Health and Consumption (ETES P107/90959). The authors declared no
competing interests
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the se-
quence generation process used
Allocation concealment (selection bias) Low risk “Each patient was assigned to one of the
three groups by a computer-generated ran-
domnumber sequence.” “The allocation se-
quence was generated by a member of the
research group who was not involved in the
study.”
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Alda 2011 (Continued)
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk “Study personnel who conducted psycho-
logical assessments (RM and YLdH) were
blinded to participants’ treatment condi-
tions”
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 16% total attrition rate was reported. No
indication of imbalance evident between
groups at follow-up
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and
secondary) outcomes that are of interest in
the review have been reported in the pre-
specified way
Altan 2009
Methods Randomised prospective controlled trial
Participants Women who had a diagnosis of fibromyalgia according to the ACR criteria and who had
admitted to rheumatology clinic were invited to participate in the study
Aged 24 to 63 years
Total participants N = 50 randomised (49 completed)
N = 50 female
Exclusions: rheumatoid disease; unstable hypertension; severe cardiopulmonary prob-
lems; any other psychiatric disorder that could affect patient compliance. All participants
were instructed to discontinue nonsteroidal anti-inflammatory drugs during the study
period. Patients were able to continue taking antidepressant or sedative drugs
Interventions 1) Pilates exercise programme consisting of postural education, antalgic and stretching
exercises, and breathing education 1 hour sessions, delivered 3 x per week for 12 weeks,
by a certified trainer
2) Relaxation and stretching home exercise programme consisting of active and passive
stretching
Conducted for 1 hour 3 x per week for 12 weeks
Outcomes Measures relevant to this review: pain visual analog scale, Fibromyalgia impact Ques-
tionnaire, tender point count, Nottingham health profile
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes The authors report no financial interest in the results of the research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the se-
quence generation process used
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Altan 2009 (Continued)
Allocation concealment (selection bias) Low risk A random number table was used
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Assessors were blinded to treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant withdrew due to medical
reasons (2% total attrition rate)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and
secondary) outcomes that are of interest in
the review have been reported in the pre-
specified way
Ang 2010
Methods Randomised controlled trial
Participants Female participants who met the ACR classification criteria for fibromyalgia confirmed
by a rheumatologist. To be eligible participants needed to be experiencing moderate
symptoms (FIQ pain score > 3 and FIQ physical impairment score of ≥ 2)
Total participants = 32 randomised (29 completed)
Exclusions: non-stable doses of pain-related medication; peripheral neuropathy, diabetes
mellitus, demyelinating disorders and inflammatory rheumatic diseases
Interventions 1) Cognitive behaviour therapy delivered by telephone by a trained therapist (psychology
graduate student) with an accompanying workbook
Components included: time-contingent activity, pacing, activity scheduling, relaxation,
automatic thoughts and cognitive restructuring and stress management 30 to 40 minute
sessions, delivered weekly, for 6 weeks
2) Usual care as provided by treating physicians
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Patient Health
Questionnaire
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes Dr Ang reports to have received consulting fees (less than ($100,000) from Eli Lilly
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated that participants were randomised, but no details
of the random component provided
Allocation concealment (selection bias) Unclear risk No details of the randomisation procedure provided
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Ang 2010 (Continued)
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Outcome assessors were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 13% total attrition rate with reasons for attrition pro-
vided. No clear imbalance between groups
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Ang 2013
Methods Randomised controlled trial
Participants Participants who met the ACR classification criteria for fibromyalgia were referred into
the study by a rheumatology clinic. To be eligible participants needed to have a weekly
average pain intensity score more than or equal to 4, to be on a stable medication regime
for over one month and be between 18 and 65 years old
Total participants = 58 randomised (49 completed)
Exclusions: current use of selective serotonin reuptake inhibitor, milnacipran or tricyclic
antidepressant, uncontrolled hypertension, suicidal ideation, planned elective surgery,
inflammatory rheumatic condition, active psychosis, pregnancy and previous cognitive
behavioural therapy
Interventions 1)Cognitive behavioural therapy delivered by telephone by psychology graduate students
including education, progressive muscle relaxation, cognitive restructuring, pacing and
anger management 8 x 35 minute sessions
2) Usual care (treatment with milnacipran)
Outcomes Measures relevant to this review: Fibromyalgia impact questionnaire, 10 point visual
analog scale for pain, Patient Health Questionnaire Depression Scale
Assessment time-points: Baseline 3 months and 5 month follow-up
Notes The study was funded by the National Institute of Arthritis and Musculoskeletal and
Skin Diseases (Grant number: 1R21AR056046-01A2). The Forest Research Institute
provided the active drug and placebo. The authors report no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified in the manuscript and no other details able
to be obtained
Allocation concealment (selection bias) Unclear risk Not specified in the manuscript and no other details able
to be obtained
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Ang 2013 (Continued)
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk Not specified in the manuscript and no other details able
to be obtained
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 15.5% attrition rate with reasons for withdrawal pro-
vided
Selective reporting (reporting bias) Unclear risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Astin 2003
Methods Randomised controlled trial
Participants Individuals with a diagnosis of fibromyalgia were recruited by newspaper and radio
advertising and local physicians
Aged 18 to 70 years
Total participants N =128 randomised (65 completed)
N = 63 female, N = 2 male
Exclusions: unable to read and speak English fluently, unable to attend group ses-
sions;unable to give informed consent; pregnancy, substance abuse; major psychiatric
disorder, involvement in impending litigation; uncontrolled hypertension; diabetes, con-
gestive heart failure; or other severe medical condition judged by the clinician to place
the patient at risk of possible severe consequences of his or her disease
Interventions 1) Mindfulness based stress reduction and qi-gong. Mindfulness involved learning two
meditation practices (a body scan and meditation) and application of mindfulness in
context of chronic pain. Qi-gong consisted of physical postures, breathing techniques
and focused intention taught by a qi-gong master 2.5 hour sessions, delivered weekly for
8 weeks, in a group based format
2) Education control 2.5 hour sessions, delivered weekly, for 8 weeks in a group based
format
Short lectures of stress, exercise, pain, emotions, sleep, work intimacy and review of
current research in addition to group discussion
Outcomes Measures relevant to this review; Fibromyalgia Impact questionnaire, SF36 pain subscale,
Beck depression inventory, tender point count
Assessment time points: baseline, post-intervention and 4 month follow-up
Notes The study was funded by a grant from the National Center for Complementary and
Alternative Medicine, National Institutes for Health (5 P50AT00084-03)
Risk of bias
Bias Authors’ judgement Support for judgement
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Astin 2003 (Continued)
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Blocks of 2, 4 or 6 groups randomly assignedby computer
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Outcome assessors were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rate (49% total attrition rate)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Babu 2007
Methods Randomised controlled trial
Participants Participants attending the outpatient department who fulfilled the ACR criteria were
recruited
Mean age = 39 years
Total participants N = 30 randomised (30 completed)
N = 21 female, N= 9 male
Exclusions: major psychiatric disorders, malignancies, osteomalacia, recent stroke or
myocardial infarction, renal failure or neuropathic pain
Interventions 1) Biofeedback 45 minute sessions, delivered daily, for 6 consecutive days
2) Sham control. Participants were provided with constant visual feedback irrespective
of muscle activity
At the end of both group interventions participants received a home programme of gentle
stretching and aerobic training
Outcomes Measures relevant to this review; Fibromyalgia Impact Questionnaire, pain visual analog
scale, number of tender points
Assessment time points: baseline and post-intervention
Notes The study was funded by a Fluid Research Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
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Babu 2007 (Continued)
Allocation concealment (selection bias) Low risk Participants were randomly allocated to groups through
concealed envelopes prepared using block randomisation
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Study was described as being a double-blinded placebo
controlled trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data was reported in figure 1 (0% attrition
rate)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review were reported
in the pre-specified way
Bakker 1995
Methods Randomised controlled trial
Participants Female participants meeting the ACR criteria
Total participants = 85 randomised (74 completed)
Aged 18 to 60 years
Interventions 1) Biofeedback 20 minutes sessions, held twice weekly, for 8 weeks
2) Attention control included personal communications with participants
3) Low impact fitness training including aerobic and stretching exercises (data not in-
cluded in review)
Outcomes Measures of relevant to this review; Sickness Impact profile, Dutch AIMS, Health As-
sessment Questionnaire, 100 mm VAS pain scale
Assessment time points: baseline and post-intervention
Notes The study was supported in part by ’Het Nationaal Reumafonds’ of the Netherlands
and the Health Insurance Executive Board (Investigations in Medicine, Grant number
0G90-018)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Random numbers generated by computer confirmed in
an e-mail
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Asessors were blind to treatment allocation
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Bakker 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk A 13% total attrition rate. Unable to extract means and
standard deviations from data reported
Selective reporting (reporting bias) Unclear risk Findings on all outcomes reported but unable to extract
means and standard deviations from data reported
Baumuller 2009
Methods Randomised controlled trial
Participants Female participants diagnosed with fibromyalgia according to the ACR criteria were
recruited from a list of patients referred to a hospital rehabilitation programme
Age range = 18 to 65 years
Total participants = 40 randomised (36 completed)
Exclusions: unable to read or understand German, to provide informed consent or have
major comorbid medical disorders including cancer, chronic heart failure, psychosis
of major affective disorders, substance abuse, co-medication with opiates or benzodi-
azepines, shift-work or trans-meridian flight in last weeks
Interventions 1) Biofeedback 15 minute sessions, three sessions per week for the first 3 weeks followed
by one sessions per week for the following five weeks
2) Usual care
Outcomes Measures relevant to this review; SF36 health related quality of life, Beck Depression
Inventory, SCL-90, tender point score, Fibromyalgia Impact Questionnaire
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Randomised by a block randomisation of two or four to
treatment or control group using computer and placed
into sealed envelopes
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Assessor blinded controlled trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 10% total attrition rate and no clear imbalance evident
between groups
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Baumuller 2009 (Continued)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Bojner-Horwitz 2003
Methods Randomised controlled trial
Participants Female participants met the ACR criteria for fibromyalgia
Total participants = 36 randomised (number withdrawn not stated)
Mean age 57 years (SD 7.2 years)
Interventions 1) Dance and movement therapy consisted of four main themes including; awareness
of the body; movement expressions; movement, feeling, image; and differentiation of
feelings and integration 1 hour session, held weekly for 6 months
2) Control group participants received the intervention on completion of the study
Outcomes Measures relevant to this review; VAS 0 to 100 pain scale, Montgomery Asberg Depres-
sion Rating Scale
Follow-up time points: baseline and month 14 (not able to be included in the review)
Notes The study was funded by the Order of Carpenters in Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated that patients were randomly allocated but details
not provided
Allocation concealment (selection bias) Unclear risk Details of randomisation procedure not provided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk Details not provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details not provided
Selective reporting (reporting bias) High risk Outcome data not reported for pain VAS and the Mont-
gomery Asberg Depression Rating Scale
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Brattberg 2008
Methods Randomised controlled trial
Participants Women with a diagnosis of fibromyalgia for less than 5 years and who had been on sick
leave for at least 3 months for the condition were included in the study. Other require-
ments were access to the Internet and willingness to train in and perform emotional
freedom techniques
Aged 20 to 65 years
Total participants = 86 randomised (66 completed)
Exclusions: individuals undergoing or having received rehabilitation in the previous 6
months
Interventions 1) Emotional freedom involved holding a disturbing memory, emotion or sensation in
focus and simultaneously using the fingers to tap on a series of 13 specific points on the
body that correspond to meridians used in Chinese medicine
The intervention comprised of a set up phase to build acceptance and affirmation, a
tapping phase and the ganut procedure which involves performing brain stimulating
actions (such as moving the eyes)
Emotional freedom was practiced daily by participants for 8 weeks
2) Waiting list control
Outcomes Measures relevant to the review: SF36 health related quality of life, Hospital Anxiety and
Depression Scale, General Self-efficacy scale
Assessment time points: baseline and post-intervention
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Unclear risk A lottery drawing by study leader who was blindfolded
but exact details of procedure unclear
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Self administered outcome assessments so non-blinding
of assessors not deemed to bias outcome
Incomplete outcome data (attrition bias)
All outcomes
High risk A 23% total attrition rate. A high number (40%) of par-
ticipants did not complete the intervention
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Burckhardt 1994
Methods Radomised controlled clinical trial
Participants Women who had been diagnosed with fibromyalgia by physicians using the ACR criteria
through occupational health and primary health clinics
Total participants = 99 randomised (86 completed)
Age range = 24 to 69 years
Exclusions: unable to understand the Swedish language or have a severemedical condition
(e.g. severe osteoarthiritis)
Interventions 1) Multi-component psychological intervention focusing on self-management; 1.5 hour
sessions were held weekly for 6 weeks in a group based format
2) Waiting list control
3) Education and physical therapy (data not included in this review)
Outcomes Measures relevant to this review: Fibromyalgia ImpactQuestionnaire, quality of life scale,
self efficacy scale, tender point count, Beck Depression Inventory
Assessment time points: baseline and 3 months
Notes Funding was provided by Riksforbundet mot Reumatism and the Ragnar och Lisa Sten-
berg’s fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence
generation process used
Allocation concealment (selection bias) Low risk Confirmed in e-mail that an independent person
randomly assigned participants after pre-testing
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk E-mail confirmation received that outcome asses-
sors were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk A 13% total attrition rate. No measure of variance
for outcome measures provided
Selective reporting (reporting bias) Unclear risk Means for all outcome measures were reported but
no standard deviations
Calandre 2009
Methods Prospective randomised controlled trial
Participants Patients who had a diagnosis of fibromyalgia according to the ACR criteria were recruited
through a University Hospital Pain Unit
Total participants = 81 randomised (57 completed)
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Calandre 2009 (Continued)
N = 73 female, N = 8 male
Age range 32 to 69 years
Exclusions: patients who had never attended a swimming pool as well as those suffering
any co-concomitant disease susceptible toworsenwithwarmwater exercisewere excluded
Interventions 1) Tai chi was performed in a pool with water heated at 36 ° and was preceded by a
shower with warmwater to condition patients’ bodies. A trained physiotherapist adjusted
the movement intensity to meet individual needs and participants were taught the 16
movements which constitute tai chi therapy
2) Stretching was facilitated using supportive aids such as long wooden sticks, flexible
strings and tubes to stretch muscles in the cervical, upper and lower extremities and
trunk
Both groups received 18 sessions of 60 minutes, delivered 3 times per week for 6 weeks
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Pittsburgh Sleep
Quality Index, Beck Depression Inventory, State and Trait Anxiety Inventory, SF12
Health Survey, tender point count
Assessment time points: baseline, post-intervention, one and three month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the se-
quence generation process used
Allocation concealment (selection bias) Low risk Computer generated table of random num-
bers
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
High risk Assessors were not blind to treatment alloca-
tion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A 29% total attrition rate; 3 adverse events
were reported in the intervention group par-
ticipants but not for controls, unclear if pain
exacerbations directly related to intervention
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the
review have been reported in the pre-specified
way
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Carson 2010
Methods Pilot randomised controlled trial
Participants Women who had been diagnosed with fibromyalgia according to the ACR criteria for at
least one year and were on a stable regimen of treatment
Total participants = 53 randomised (48 completed)
Mean age = 53.7 (SD 11.5) years
Exclusions: residing > 70 miles from the research site, unavailable to attend the interven-
tion at one of the schedule times, currently engaged in yoga practice, actively contem-
plating suicide, currently undergoing disability application, or litigation, schedule for
elective surgery during the study period, physically disabled in a manner that precluded
meaningful participation in the intervention, unwilling to forgo changing any voluntary
treatments for the length of this study and those unable to speak English
Interventions 1) Yoga consisted of 2 hour sessions, held weekly for 8 weeks in a group based format led
by a certified, experienced yoga teacher. The intervention included meditation, breath-
ing exercises, study of the application of yoga principles to optimal coping and gentle
stretching poses and group discussions
2) Usual care, wait list
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, tender point score
Assessment time points: baseline and post-intervention
Notes The study was supported by a grant from the Oregan Health and Science University
Medical Research Foundation and resources supplied by the Fibromyalgia Information
Foundation. The authors report no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence
generation process used
Allocation concealment (selection bias) Low risk Randomised assignments were generated by an in-
dividual not involved in the study using a random
numbers table
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk The outcome assessors were blinded to treatment
allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 9% total attrition rate. There was no imbalance
evident between groups
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and sec-
ondary) outcomes that are of interest in the review
have been reported in the pre-specified way
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Carson 2012
Methods Randomised controlled trial
Participants Female participants who had been diagnosed according to the ACR criteria for fibromyal-
gia syndrome for at least one year. To be eligible participants needed to be on a stable
regimen of pharmacological or non-pharmacological treatment for more than or equal
to 3 months before study enrolment
Total participants = 53 randomised (39 completed)
Exclusions: residing > 70 miles from research site or unable to attend the intervention,
engaged in intensive yoga practice, actively contemplating suicide, Undergoing disability
assessment, or litigation, scheduled for elective surgery, physically disabled as to preclude
meaningful participation in the intervention, unwilling to change treatment for duration
of the study and non-English speaking
Interventions 1) Yoga deliveredwithin group sessions by a certified yoga instructor 120minute sessions,
delivered weekly over 8 weeks
2) Wait-list control group
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire Revised, tender
point score
Assessment time points: baseline and post-intervention
Notes The studywas supported by a grant from theOreganHealth and ScienceUniversityMed-
ical Research Foundation and resources supplied by Fibromyalgia Information Founda-
tion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk “Randomisation assignments were generated by an indi-
vidual not involved in the study using a random num-
ber table. Assignments were concealed in envelopes until
completion of the baseline assessment”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk “Research Assistants who collected assessment data were
kept blind with regard to condition”
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 24% total attrition rate, no imbalance evident between
groups post-intervention
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Castel 2007
Methods Randomised controlled trial
Participants Patients attending the University Hospital diagnosed with fibromyalgia by a rheumatol-
ogist following the ACR criteria were recruited if they had experienced pain for at least
6 months
Total participants = 45 randomised (45 completed)
Age range = 25 to 68 years
N = 39 female, N = 6 male
Exclusions: non-specified
Interventions 1) Hypnosis with relaxation. Participants were invited to lie down on a comfortable,
reclining chair with arm rests and engaged in hypnosis and relaxation strategies were
facilitated by a trained therapist. The hypnosis session lasted for 20 minutes and was a
single session. Participants were asked to stare at an external stimulus and at a particular
moment to close their eyes. A chain of suggestions were made using palpebral catalepsy,
catalepsy of the vocal chords and the raising of an arm
2) Relaxation comprised of participants being shown how to relax various parts of the
body beginning with the feet and finishing with the head followed by diaphragmatic
breathing. The session lasted for 20 minutes and was a single session
3) Hypnosis with analgesia (data not included in this review)
Outcomes Measures relevant to this review: McGill Pain Questionnaire, pain 10 point visual analog
scale
Assessment time points: baseline and post-intervention
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Participants were randomised using a 1:1:1 ratio based
on a random numbers tables generated by computer
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Confirmation that outcome assessors were blind to treat-
ment allocation received by e-mail
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data were reported at follow-up (0% total
attrition rate)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Castel 2009
Methods Randomised pilot controlled trial
Participants Participants who had been experiencing pain for at least 6 months and had a diagnosis
of fibromyalgia based on the ACR criteria were recruited
Total participants = 47 randomised (39 completed)
Age range = 18 to 60 years
N = 37 female, N = 2 male
Exclusions: 6 years education, severe chronicmedical pain conditions, significant suicidal
ideation, severe psychopathology, moderate to severe cognitive impairment and presence
of pending litigation
Interventions 1) Cognitive behaviour therapy (CBT) sessions were delivered in groups and included
didactic presentations on fibromyalgia and the theory of pain perceptions, cognitive re-
structuring, assertiveness training, behavioural goal setting, problem solving and main-
taining gains. This was followed by 20 minutes of relaxation training beginning with
the feet and ending with the head by means of sensation awareness and diaphragmatic
breathing. Sessions were supported by an audio relaxation exercise for practice at home
90 minutes sessions, held weekly, for 12 weeks
2) CBT = hypnosis (data not included in review)
3) Usual care
Outcomes Measures relevant to review: Fibromyalgia Impact Questionnaire, pain 10 point visual
analog scale, McGill Pain Questionnaire
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence
generation process used
Allocation concealment (selection bias) Unclear risk Participants were assigned a number and ran-
domised using a 1:3 ratio by exact randomisation
procedure unclear
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Confirmed in an e-mail that the outcome assessor
was blind to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 17% total attrition rate. There was an indication
of higher withdrawal in the control group with less
participants reported as attending the second ses-
sion. This may possibly be due to lack of efficacy of
the control intervention
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Castel 2009 (Continued)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and sec-
ondary) outcomes that are of interest in the review
have been reported in the pre-specified way
Castel 2012
Methods Randomised controlled trial
Participants Participants aged between 18 and 65 years old with a diagnosis of FMS according to the
ACR criteria
Total participants = 93 randomised (71 completed)
Exclusions: 1 or more additional severe chronic medical pain conditions or moderate to
severe cognitive impairment
Interventions 1)Cognitive behaviour therapy delivered using group and individual sessions 120minute
sessions, delivered weekly for 14 weeks
2) Usual care
Outcomes Measures relevant to the review: Fibromyalgia ImpactQuestionnaire, 10pointNumerical
Pain Rating Scale, Hospital Anxiety and Depression Scale, Medical Outcomes Study
Sleep Scale
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes The authors report no conflicts of interest with this study. No sources of funding were
declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk It was confirmed in an e-mail from the author that “pa-
tients were randomly assigned in a 1:1:1 ratio in blocks of
18 according to a computer-generated random number
table”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk “All outcome measures were administered by a Psychol-
ogist who was blinded to the participant’s group assign-
ment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 19% attrition rate with equal balance between groups
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Connais 2009
Methods Randomised controlled trial
Participants Female participants were recruited via flyers and word of mouth and referrals from
treating practitioners
Total participants = 6 randomised (6 completed)
Age range = 48 to 60 years
Exclusions; non-specified
Interventions 1) Emotional freedom was delivered by research team members trained in delivering the
intervention. The concept of energy in the body and how pain be a manifestation of the
body’s energy being out of alignment and included a tapping sequence of a series of 13
specific points on the body whilst focusing on a disturbing thought or traumatic memory
and included the four steps of emotional freedom including the setup, the sequence, the
gamut procedure (tapping og the meridian points) followed by the sequence again. The
practice took approximately 5 minutes
2) Wait-list control
Outcomes Measures relevant to the review: Fibromyalgia Impact Questionnaire, tender point scores
Assessment time points: baseline and post-intervention
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Sequence generated by rule based on attendance
Allocation concealment (selection bias) High risk Alternate nature of allocation to treatment groups could
lead to investigators being able to foresee treatment allo-
cation
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Confirmation that outcome assessors were blind to treat-
ment allocation received by e-mail
Incomplete outcome data (attrition bias)
All outcomes
High risk Nomissing data were reported at follow-up (0% total at-
trition rate). Means and standard deviations were unable
to be extracted accurately from the graphs provided and
no measure of variance provided
Selective reporting (reporting bias) Unclear risk Data were reported on all outcome measures relevant
to review but unable to be extracted from the graphs
provided
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de Souza 2008
Methods Randomised controlled trial
Participants Women were recruited who had been diagnosed with fibromyalgia for > 6 months and
who were had been on a stable treatment regime for > 3 months
Total participants = 60 randomised (59 completed)
Age range = 20 to 65 years
Exclusions: pregnancy or breast feeding, cancer, serious depression associated with sui-
cidal thoughts, rheumatic arthritis and uncontrolled cardiopatia
Interventions 1) The Interdisciplinary group intervention was delivered in a group based format by
allied health professionals. The sessions included information provision on symptoms
and the cycle of pain, exercise, relaxation techniques, pacing, nutrition, negative thoughts,
and maintenance 9 x 2 hour sessions were delivered over 11 weeks
2) Usual care
Outcomes Measures relevant to this review: Multidimensional Pain Inventory, pain visual analog
scales on intensity, affective and interference
Notes Financial agencies included the Co-ordination of Improvement of People of (Castrate)
and Canadian Institutes of Health Research (CIHR)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Concealed allocation by block randomisation stratified
by FIQ score
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Confirmation that outcome assessors were blind to treat-
ment allocation received by e-mail
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low total attrition (8.3%) rate unlikely to influence out-
come data
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Edinger 2005
Methods Randomised parallel group clinical trial
Participants Participants diagnosed with fibromyalgia according to the ACR criteria with sleep distur-
bance as assessed by a structured interview criteria for insomnia were recruited through
newspaper advertisements
Total participants = 47 randomised (20 completed)
Age range = 21 to 65 years
N = 41 female, N = 6 male
Exclusions: pregnancy or breastfeeding, co-morbid sleep disruptive medical condition,
Axis I depressive, anxious or substance abuse disorder, severe hypnotic dependence,
diagnosed sleep disorder as assessed by polysomnography
Interventions 1) Cognitive behaviour therapy was delivered by two experienced male clinical psychol-
ogists. Individual sessions included cognitive restructuring, stimulus control, sleep re-
striction and sleep education 60 minute sessions, were delivered weekly for 6 weeks
2) Wait-list control. Participants met weekly with a study co-ordinator to provide sleep
logs and actigraphy data
Outcomes Measures relevant to review: McGill Pain Questionnaire, Profile of Mood States, SF36
health related quality of life, Insomia Symptoms Questionnaire, Brief Pain inventory
Assessment time points: baseline, post-intervention and 6 month follow-up
Notes The study was supported by a grant from theNational Institute of Arthritis andMusucu-
loskeletal and Skin Diseases. Dr Edinger reports to have received honoraria from Fisson
Communications, Sepracor and Axis Healthcare.Dr Rice reports having provided expert
testimony and medical record review as a defence expert in FM for several attorneys
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study claimed tobe a randomised clinical trial
but no details of sequence generation process
provided
Allocation concealment (selection bias) Unclear risk No details of the randomisation procedure
provided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk Study presented as a single blind study and
unclear if single blind referred to participants
or assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk A 57% total attrition rate at 6 months
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the
review have been reported in the pre-specified
way
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Falcao 2008
Methods Randomised controlled trial
Participants Female patients diagnosed with fibromyalgia based on the ACR criteria were consecu-
tively recruited from university outpatient clinics
Total participants = 60 randomised (51 completed)
Age range = 18 to 65 years
Exclusions: < 4 years of elementary school, receiving no other treatment, rheumatic
disease, hypersensitivity to amitriptyline, cyclobenzaprine or paracetamol, use of psy-
chotropic medication or psychiatric disease
Interventions 1) Cognitive behavioural therapy was delivered in a group based format combining
progressivemuscle relaxation, diaphragmatic breathing, cognitive restructuring and stress
management, facilitated by keeping of a diary 3 hour sessions were held weekly for 10
weeks
2) Usual care
Both groups were prescribed amitriptyline 12.5 mg per day increasing to 25 mg the
following week and were seen by a medical practitioner weekly for 10 weeks
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, 10 point visual
analog pain scale, Medical Outcomes Survey, SF36, State and Trait Anxiety Inventory,
Beck Depression Inventory
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Randomized by drawing lots with concealed allocation
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Confirmation that outcome assessors blind to treatment
allocation received by e-mail
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 15% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Fontaine 2010
Methods Randomised controlled trial
Participants Minimally active people diagnosed with fibromyalgia according to the ACR criteria
were recruited through advertisements in newsletters, newspapers and via clinical trial
recruitment websites
Total participants = 84 randomised (73 completed)
N = 88 female, N = 8 male
Mean age = 47.7 years (SD 10.7)
Exclusions: cancer, coronary heart disease, those where there was intended change of
medication planned that might affect mood and those unwilling to make the required
time commitment
Interventions 1) Cogniitve behaviour therapy based Lifestyle Physical Activity encompassed dealing
with pain and fatigue, fear of physical activity, self monitoring, goal setting problem
solving and identifying ways of increasing short bouts of physical activity throughout
the day. Six, 60 minute group based sessions were delivered over 12 weeks
2) Education control consisted of monthly group meetings of 90 to 120 minutes over 3
months. Sessions included presentations on fibromyalgia, facilitating time to discussion
and the opportunity for question and answer
Outcomes Measures relevant to this review: 100 visual analog pain scale, Fatigue Severity Scale,
Center for Epidemiologic Studies Depression Scale, tender point count
Assessment time points: baseline and post-intervention
Notes The study was funded by a NIH/NIAMS grant number AR053168. Dr Clauw reports
acting as a consultant for Pfizer, Lilly, Forest Laboratories, Cyprus Biosciences, Pierre
Fabre, UCB and Wyeth and has received grant support from Pfizer, Cypress Bioscience
and Forest. The other authors report no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Randomised via a coin toss at 1:1 allocation ratio
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
High risk Assesors not blind to treatment allocation (confirmed by
e-mail)
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 13% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Fors 2000
Methods Randomised clinical trial
Participants Female participants were recruited through the fibromyalgia association and had been
diagnosed with fibromyalgia by medical specialists
Total participants = 58 randomised (58 completed)
Age range = 21 to 68 years
Exclusions: male gender
Interventions 1) Guided imagery was delivered via an audio recording that guided participants through
a visual imagery exercise that encouraged visualisation of the natural environment with
a focus on relaxation without the presence of a researcher
2) Education group (data excluded from this review) listened to an audio recording
guiding them to visualise functioning pain killing systems in the body
3) Pain related talk group attended one session talking about their fibromyalgia with a
therapist
Outcomes Measures relevant to this review: visual analog scale 0 to 100 for pain and anxiety
Assessment time points: baseline and post-intervention
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomcomponent is included in the sequence generation
process used
Allocation concealment (selection bias) Low risk Participants were randomised after a lottery with 3 possibil-
ities
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Confirmation that outcome assessors were blinded to treat-
ment outcome received by e-mail
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 0% total attrition rate reported
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary) out-
comes that are of interest in the review have been reported
in the pre-specified way
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Garcia 2006
Methods Randomised controlled clinical trial
Participants Participants were identified through searching case records of people from a pain treat-
ment unit. All patients had their diagnosis of fibromyalgia verified by a rheumatologist
before commencing the study
Total participants = 28 randomised (28 completed)
N = 27 female, N = 1 male
Age range = 30 to 76 years
Exclusions: being treated by medication, in process of lawsuit for disability, unable to
participate in the sessions due to psychological or physical impairments
Interventions 1) Multi-component treatment programme based on cognitive behaviour therapy which
included education about stress, developing coping skills and cognitive techniques and
relaxation training
2) Usual care
Outcomes Measures relevant to this review: Fibromyalgia ImpactQuestionnaire, tender point count
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence
generation process used
Allocation concealment (selection bias) Unclear risk Homogenous blocks method used to randomise
participants but exact details of procedure unclear
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Physician blinded to treatment allocation for
assessment of tender points. Other outcomes
self administered and therefore non-blinding not
considered to bias results
Incomplete outcome data (attrition bias)
All outcomes
High risk Data were unable to be accurately extracted from
the graphs provided and no measure of variance
was provided. No missing data or attrition re-
ported (0% total attrition rate)
Selective reporting (reporting bias) Unclear risk All of the study’s pre-specified (primary and sec-
ondary) outcomes that are of interest in the re-
view have been reported in the pre-specified way
(although no measure of variance provided)
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Gillis 2006
Methods Randomised controlled trial
Participants Participants diagnosedwith fibromyalgiawere recruited via flyers in rheumatology clinics,
patient support organisations and newsletters
Total participants = 83 randomised (72 completed)
N = 70 female, N = 2 male
Age range = 23 to 72 years
Exclusions: autoimmune rheumatic disease, unable to read or write in English
Interventions 1) Written emotional disclosure. Participants were sent a writing pack including instruc-
tions to identify a stressful experience that continues to bother them and to write about
that situation and their deepest feelings about the experience
2) The control writing condition also received a writing pack which included instructions
towrite about different time periods of the day including what they did and their planned
actions
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Arthritis Impact
Measurement Scale-II Fatigue severity scale, 10 point sleep visual analog scale, Positive
and Negative Affect Scale
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes The studywas fundedby a dissertation grant from theBlueCross Blue Shield ofMichigan
Foundation and in part by a Postdoctoral Fellowship Award and Cinical Science Award
from the Arthritis Foundation and by a National Institute of Health grant number R01
AR049059
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Pre-prepared packs numbered with a unique identifier
and randomised via a random numbers table
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Outcome measures were self-administered and therefore
non-blinding unlikely to bias results
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 13% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Hammond 2006
Methods Randomised controlled trial
Participants People diagnosed with fibromyalgia according to the ACR critiera were recruited through
a hospital based rheumatology clinic
Total participants = 183 randomised (133 completed)
N = 120 female, N = 13 male
Mean age = 48.53 (10.89) years
Exclusions: alternative medical diagnosis could explain symptoms, undergoing current
medical investigation, ongoing psychological problems requiring the care of a mental
health practitioner or severemedical conditions affecting the person’s ability to participate
in exercise safely
Interventions 1) Cognitive behavioural group based exercise and education intervention. 2 hour ses-
sions, were heldweekly for 10 weeks and included information on the physiological basis
of symptoms, activity pacing, sleep hygiene, relaxation, problem solving, pain and stress
management, cognitive restructuring, postural training, stretching exercises and tai chi.
A tai chi DVD was provided to facilitate practice at home
2) Relaxation group based programme (which acted as an attention control), 1 hour
sessions were held weekly for 10 weeks. Information on fibromyalgia and relaxation
techniques were outlined with time allocated for group discussion
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Arthritis Self-
efficacy Scale
Assessment time points: baseline, 3 and 6 months
Notes The study was funded by the Derbyshire Royal Infirmary Rheumatology Charitable
Trust Fund (Derby Hospitals NHS Foundation Trust). The authors declare no conflicts
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Computer generated random numbers in pre-prepared
sealed numbered envelopes
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Self administered outcome measures used, assessor not
believed to be able to bias findings
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 27% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Hamnes 2012
Methods Randomised controlled trial
Participants Participants aged between 20 and 70 years, diagnosed with FMS according to the ACR
criteria were recruited through the Lillehammer Hospital for Rheumatic Diseases. To
be eligible participants needed to be able to speak Norweigen and be willing to give
informed consent
Total participants = 147 randomised (118 completed)
Exclusions: previous participation in a self-management programme, cognitive impair-
ment or hearing problems or serious mental health disorders
Interventions 1) Self-management programme based on cognitive behaviour therapy run by a multi-
disciplinary team using group based sessions in hospital
2) Wait-list control
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, General Health
Questionnaire, Arthritis Self-Efficacy Scale
Assessment time points: baseline and post-intervention
Notes The study was funded by the Hospital for Rheumatic Diseases, Lillehammer and was
also supported by the Norwegian Rheumatism Association, The Norwegian Nurses
Organisation and Per Ryghs Legacy, University of Oslo. The authors declare no conflicts
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Unclear risk No details specified
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Questionnaires were self administered
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 20% attrition rate with equal balance of withdrawals
between groups
Selective reporting (reporting bias) Unclear risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Holmer 2004
Methods Randomised controlled trial
Participants Participants had been diagnosed with fibromyalgia based on the ACR criteria
Total participants = 28 randomised (22 completed)
Age range 18 to 65 years
N = 26 female, N = 3 male
Exclusions: none specified
Interventions 1) Yoga delivered by a certified yoga instructor
2) Waiting list control
Outcomes Measures relevant to this review:Multidimensional Assessent of Fatigue Scale, Fibromyal-
gia Impact Assessment - pain scale, Arthritis Impact Measuresment Scale - II, anxiety
subscale, Center for Epidemiology Scale - Depression, Pittsburgh Sleep Quality Index,
visual analog scale for pain
Assessment time points: baseline and post-intervention
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) High risk Alternate group assignment method was employed (in-
formed by e-mail)
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
High risk Outcome assessors were not blind to treatment allocation
(confirmed by e-mail)
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 21% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Hsu 2010
Methods Randomised controlled trial
Participants Female participants were recruited through advertisements distributed in the local area
and to physicians and through presentations to patient support groups. Diagnosis of
fibromyalgia based on the ACR criteria was confirmed by an assessment by a rheuma-
tologist
Total participants = 45 randomised (42 completed)
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Hsu 2010 (Continued)
Age range = 25 to 66 years
Exclusions: serious co-morbid medical conditions that could confound results in the next
6 months e.g. cancer, heart disease, current serious psychiatric disorder, recent suicide
risk or substance abuse and changes in pain medication within 1 month
Interventions 1) Mulit-component group based intervention following an initial 90 min individual
consultation. 2 hour group sessions were heldwere heldweekly for 3 weeks and consisted
of education, written emotional disclosure, affective awareness and re-engagement in
previously avoided activities
2) Wait-list control group
Outcomes Measures relevant to this review: Medical Outcome Study SF36, Brief Pain Inventory,
tender point count, MOS sleep scale, Multidimensional Fatigue Inventory
Assessment time points: baseline, post-intervention and 6 month follow-up
Notes The study was supported in part by the Scott F Nadler DO, Research Grant (Psychiatric
Association of Spine, Sports and Occupational Rehabilitation), Michigan Institute of
Clinical and Health Research grant number U020912, NICHD/NIH grant numbers
T32-HD007422, K12HD001097, NIAMS/NIH AR049059 and Department of De-
fence DAMD 17-00-2-0018. Dr Schubiner reports developing the programme which
is used in the Providence Hospital and on the Internet. The other authors report no
conflicts of interests
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process
Allocation concealment (selection bias) Low risk Random assignment of information sheets in opaque
sealed envelopes generated by computer confirmed by e-
mail
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Confirmation received by e-mail that outcome assessors
were blind to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 6% total attrition rate, the 3 participants whowithdrew
were all in the intervention group but withdrew due to
scheduling difficulties rather than as a direct result of the
intervention
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Jensen 2012
Methods Randomised controlled trial
Participants Participants were referred to the study by their primary care physicians. To be eligible
for the study participants needed to be diagnosed with fibromyalgia syndrome (FMS) in
accordance with the ACR criteria, have an average weekly pain intensity of at least 40
mm
Total participants = 43 randomised (34 completed)
Exclusions: being left-handed, pregnant or breast feeding, those with metal implants or
claustrophobia due to fMRI requirements
Interventions 1) Cognitive behaviour therapy and acceptance and commitment therapy. The inter-
ventions was delivered in group based sessions by psychologists and clinicians in a pain
clinic 90 minute sessions, delivered weekly for 12 weeks
2) Wait-list control
Outcomes Measure relevant to this review: 100 point visual analog scale for pain, Beck Depression
Inventory and State-Trait Anxiety Inventory
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes The study was funded Swedish Council for Working LIfe and Social Research and the
Swedish Research Council, grant number K2009-53x-21070-01-3. The authors report
no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk “Presentedwith the content of a randomisation envelope”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk “An independent researcher (KJ) with no insight or in-
volvement in the treatment intervention performed all
pre and post treatment assessments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 21% attrition rate
Selective reporting (reporting bias) Unclear risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Jones 2012
Methods Randomised controlled trial
Participants Participants aged 40 years diagnosed with fibromyalgia syndrome or over were recruited
with approval of a healthcare practitioner
Total participants = 101 randomised (98 completed)
Exclusions: practice of of tai chi within past 6 months, exercised more than 30 minutes
three times weekly for past 3 months, unable to ambulate without assistive devices, pain
severity or interference scores less than5, planned elective surgery in study period, actively
involved in healthcare litigation, unwilling to keep all treatments stable throughout the
study duration
Interventions 1) Tai chi delivered in a group based format 90 minute sessions delivered twice weekly
for 12 weeks
2) Education sessions delivered in a group based format on fibromyalgia , healthy eating,
education based CBT strategies, sleep hygiene and lifestyle management 90 minute
sessions delivered twice weekly for 12 weeks
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Brief Pain In-
ventory, Numerical Rating Scale for pain, Arthritis Self-Efficacy Scale, Pittsburgh Sleep
Quality Index
Assessment time points: baseline and post-intervention
Notes The study was funded by the National Institutes of Health/NIAMS grant number 5R21
AR053506, NIH/NCCAM1K23 AT006392-01. The authors report no conflicts of
interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk “computer generated table of random numbers with
block stratification using age in 5-year intervals”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 3% attrition rate although all withdrawals occurred in
the control group
Selective reporting (reporting bias) High risk Means and standard deviations not reported
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Kayiran 2010
Methods Randomised, controlled, rater blind clinical trial
Participants Consecutive female patients who met the ACR criteria for fibromyalgia admitted to
outpatient clinic were recruited
Total participants: 40 randomised (36 completed)
Age range = 16 to 49 years
Exclusions: not currently receivingmedication;major health conditions including stroke,
diabetes mellitus, coronary heart disease; alcohol abuse and any abnormality in routine
laboratory tests
Interventions 1) Neurofeedback was provided using Brain Feedback -3 EEG biofeedback software.
patients were informed about the system and told to follow the continuous feedback
process and try to maximise their scores, 20 sessions of 30 minutes in duration of neuro
feedback were received over 4 weeks
2) Escitalopram (10 mg) per day for 8 week duration
Outcomes Measures relevant to this review: SF36, 10 point visual analog pain and fatigue scales,
Hamilton Depression Scale, Hamilton Anxiety Scale, Beck Anxiety Scale
Assessment time points: baseline, post-intervention, 3 and 6 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the
sequence generation process used
Allocation concealment (selection bias) Low risk Participants randomised by a coin toss
(confirmed by e-mail)
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Study described as “rater-blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 10% total attrition rate, no clear imbal-
ance between groups observed
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and
secondary) outcomes that are of interest in
the review have been reported in the pre-
specified way
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Langford 2009
Methods Randomised controlled trial
Participants Female participants diagnosed with fibromyalgia by a rheumatologist were recruited
Total participants = 105 randomised (99 completed)
Mean age = 52.44 years (SD 9.39)
Exclusions: co-comitant rheumaticmedical conditions or other serious illness or unstable
medication regime for < 2 months
Interventions 1) Cognitive behavioural and interpersonal therapy was delivered in group sessions. Ses-
sions included a review of the gate-control theory, sleep difficulties, relaxation strategies,
identifying and changing cognitions and problem solving techniques. Sessions lasted for
2 hours and were held weekly for 8 weeks
2) Attention control participants received phone calls from a researcher over the course
of the 8 week intervention period
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, 0 to 100 numer-
ical pain rating scale, Health Assessment Questionnaire, Arthritis Self-Efficacy Scale,
Symptom Checklist 90-R, Quality of Life Scale (QoLS)
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk A coin toss was used to determine which member of the
matched pair was assigned to which group
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Self administered outcome measures used, assessor not
believed to be able to bias findings
Incomplete outcome data (attrition bias)
All outcomes
Low risk An 11% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Lera 2009
Methods Randomised controlled trial
Participants Female participants were recruited from a hospital rheumatology unit based on a diag-
nosis of fibromyalgia according to the ACR criteria
Total participants = 83 randomised (56 completed)
Mean age = 51.1 years (SD 8.7)
Exclusions: male gender, severe depression, psychosis or delusional disorder
Interventions 1) The multidisciplinary group received multidisciplinary treatment including an ap-
pointments with a rheumatologist for pharmacological management of symptoms, and
group sessions including information on fibromyalgia, postural advice, exercise and ac-
tivity pacing led by a physiotherapist. There were 14 group based sessions held for 1
hour per week over 4 months
2) The second group received the multidisciplinary intervention described above in
addition to 15 group based sessions of 90 minutes on cognitive behaviour therapy.
The sessions were led by a clinical psychologist which included techniques to reduce
physiological arousal, improve sleep,well-being, self esteem, goal planning andmodifying
negative thoughts
Outcomes Measures relevant to this review: Fibromyalgia ImpactQuestionnaire,MedicalOutcomes
Study SF36, Symptom Checklist 90-Revised, tender point count
Assessment time points: baseline, post-intervention and 6 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Random sequence generated by a coin toss (confirmed
by e-mail)
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
High risk The psychologist completing outcome assessments was
not blind to treatment allocation (confirmed by e-mail)
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 32% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
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Liu 2012
Methods Randomised controlled trial
Participants Participants aged between 18 and 70 years with a diagnosis of FMS according to the
ACR criteria were recruited from a neurology clinic and support group
Total participants = 14 randomised (12 completed)
Exclusions: severe psychiatric illness, significant suicide risk, alcohol abuse, use of benzo-
diazepines, history of behaviour that would prohibit compliance for the duration of the
study, co-morbid medical conditions, severe sleep apnoea, pregnancy or breastfeeding
Interventions 1) Qi-gong delivered in a group based format with home practice in between sessions
15 to 20 minute sessions, held weekly for 6 weeks
2) Sham qi-gong delivered in a group based format with no meditation or healing sounds
15 to 20 minute sessions, held weekly for 6 weeks
Outcomes Measures relevant to the review: Fibromyalgia Impact Questionnaire, McGill Pain Ques-
tionnaire, Mulitidimensional Fatigue Inventory, Pittsburgh Sleep Quality Index
Assessment time points: baseline and post-intervention
Notes The authors report no conflicts of interest. No sources of funding were declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Unclear risk No details provided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk No details provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 14% attrition, both withdrawals were in the treatment
group
Selective reporting (reporting bias) High risk Means and standard deviations for outcomemeasures not
reported
Luciano 2011
Methods Randomised controlled trial
Participants Participants were recruited from a database of patients diagnosed with fibromyalgia
confirmed by a rheumatologist
Total participants = 216 randomised (185 completed)
Age range = 18 to 75 years
Exclusions: diagnosis not based on the ACR criteria, cognitive impairment, presence of
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Luciano 2011 (Continued)
physical, psychiatric limitations that impeded participation in the study assessments, life
expectancy of less than 12 months, absence of schooling
Interventions 1) Autogenic training and education comprised of 9 sessions with a clinical psychologist.
The link between emotions and bodily reactions was highlighted and use of distraction
explained and encouraged in addition to use of relaxation techniques that could be
practiced at home
2) Usual care
Outcomes Measures relevant to this review: Fibromyalgia ImpactQuestionnaire, State-Trait Anxiety
Inventory
Assessment time points: baseline and post-intervention
Notes The study was funded by a grant from the Agencia d/Avaluacio de Technologia i Recerca
Mediques grant number AATRM 0077/25/06. Dr Luciano received a postdoctoral con-
tract from the Instituto de Salud Carlos III RD06/0018/0017
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random component is included in randomisation pro-
cedure used
Allocation concealment (selection bias) Low risk Computer generated randomisation list
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk The Research Assistant was bind to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 14% total attrition rate
Selective reporting (reporting bias) High risk Two measures taken at baseline only (MCSDS, STAI)
Lynch 2012
Methods Randomised controlled trial
Participants Participants were recruited through advertisements in local newspapers. To be eligible
participants were required to have a diagnosis of FMS according to the ACR criteria,
have had a stable medication regime in the past 2 weeks, have an average weekly pain
score more than 4 on an 11 point rating scale
Total participants = 100 randomised (89 completed)
Exclusions: significant medical disorder
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Lynch 2012 (Continued)
Interventions 1) Qi-gong delivered by a psychologist in a group based format in the community 3.5
day workshops held weekly with additional refresher sessions
2) Wait-list control
Outcomes Measures relevant to the review: Fibromyalgia ImpactQuestionnaire, 11 point numerical
rating scale for pain, SF36 Health Survey, Pittsburgh Sleep Quality Index
Assessment time points: baseline, post-intervention and 6 month follow-up
Notes The study was funded by a Pfizer Neuropathic Pain Research Award. Authors CH and
DM provide qi-gong interventions in the community. The other co-authors report no
conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was described as a randomised controlled trial but
no details of the sequence generation process provided
Allocation concealment (selection bias) Low risk “participants were assigned using computer generated
numbers to an immediate Qigong training group or to a
control group. Assignments were sealed in opaque white
envelopes”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk No details specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk An 11% attrition although more withdrawals occurred
in the treatment group in comparison to control
Selective reporting (reporting bias) High risk Data were presented as change scores and were not able
to be included in the analyses
Maddali-Bongh 2010
Methods Randomised controlled trial
Participants Consecutive participants diagnosed with FMS were recruited
Total participants = 44 randomised (41 completed)
N = 38 females, N = 3 males
Mean age 45.5 (SD 11.79) years
Exclusions: none specified
Interventions 1) The Ressegiuer method. Patients are asked to describe painful areas of the body in
terms of weight, consistency and symmetry. Themethod aims to obtain patient awareness
and control of bodily perceptions, thus reaching a modulation of responses to pain.
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Maddali-Bongh 2010 (Continued)
Throughout the intervention sessions, the therapist controlled the patient’s attention and
perception by verbal and manual contacts. and leads to perform bodily and respiratory
active and conscious movements “petite gymnastique” of different areas of the body
tailored on the patients needs. Sessions were delivered for 60 minutes, once per week for
8 weeks delivered by a trained physiotherapist
2) Waiting list control group
Outcomes Measures relevant to this review: Medical Outcomes Survey SF36, Fibromyalgia Impact
Questionaire, numerical pain rating scale
Assessment time points: baseline and post-intervention (no data available for the control
group at 6 month follow-up)
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Sequentially numbered sealed envelopes prepared by an
independent person
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk All assessment examinations were performed by an oper-
ator blinded to group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 6% total attrition rate. Three participants withdrew
from the control group as they did not accept their group
allocation which is unlikely to affect the outcome
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Mannerkorpi 2004
Methods A controlled randomised pilot study
Participants Women fulfilling the ACR criteria for fibromyalgia were recruited
Total participants = 36 randomised (22 completed)
Age range = 18 to 65 years
Exclusions: unable to speak Swedish
Interventions 1) Qi-gong + relaxation, 14 group sessions of 1.5 hours, were held weekly, delivered by a
physiotherapist. The treatment included various breathing, relaxation and concentration
techniques conducted in a supine or standing position including qi-gong movements.
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Mannerkorpi 2004 (Continued)
The movements were individually modified to match the functional limitations of the
patients and there was an opportunity for discussion about the movements with the
therapist. Participants were encouraged to practice the movements in between sessions
2) Usual care
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire
Assessment time points: baseline and post-intervention
Notes The study was supported by grants from the Swedish Rheumatism Association and the
Swedish Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the se-
quence generation process used
Allocation concealment (selection bias) Low risk Independent person allocated patients to groups
using sealed envelopes
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Outcome assessor was blinded to patients group
membership
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 39% total attrition rate, fell just below cut-off
of 40% used to indicate high risk of attrition bias
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and sec-
ondary) outcomes that are of interest in the re-
view have been reported in the pre-specified way
Martinez-Valero 2008
Methods Randomised controlled trial
Participants Female participants whowere between one and three years post-diagnosis of fibromyalgia
were recruited by a clinician at the hospital
Total participants = 6 randomised (6 completed)
Age range = 25 to 60 years
Exclusions: receiving psychological treatment, co-morbid psychiatric or medical pathol-
ogy, receipt of compensation for fibromyalgia
Interventions 1) Cognitive behavioural therapy (CBT) was delivered in 1 hour sessions, held weekly
for 10 weeks. Each session consisted of a review of homework from previous session,
introduction and practice of strategies and new homework exercises. Information about
fibromyalgia, coping skills, cognitive restructuring, pacing and planning activities and
training in social skills and problem resolution was included
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Martinez-Valero 2008 (Continued)
2) Usual care
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Plates Coop/
Wonca, numerical rating scales for pain, fatigue, sleep
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Randomised by recruiting doctor using pre-prepared
sealed envelopes
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Post treatment and follow ups were administered by an
experienced, masked, independent rater
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition or missing data apparent (0% total attrition
rate)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Menzies 2006
Methods Longitudinal, prospective, two-group, randomised controlled clinical trial
Participants Participants were recruited through outpatient clinics
Total participants = 48 randomised (48 completed)
N = 47 female, N = 1 male
Mean age = 49.9 years (SD 12.9)
Exclusions: Mini-Mental Status examination score < 25, Fibromyalgia Impact Score of
< 20, presence of other systemic rheumatologic conditions or major communicative
disorder
Interventions 1) Guided imagery was administered using 3 guided imagery audio tapes ranging in
length between 12 and 22minutes. The audio tapes introduced participants to relaxation
and release of tension and encouraged an overall sense of well-being. Participants were
also trained to learn a conditioned response to the signal breath to elicit relaxation and
were to use techniques such as progressive muscle relaxation and guided imagery of a
pleasant scene. Participants were advised to use the tapes at least daily during the 10
week treatment period
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Menzies 2006 (Continued)
2) Usual care
Outcomes Measures relevant to this review: Short form McGill Pain Questionnaire, Fibromyalgia
Impact Questionnaire, Arthritis Self-Efficacy Scale
Assessment time points: baseline, post-intervention and 1 month follow-up
Notes The study was funded by a National Center for Complementary and Alternative
Medicine T32-AT-00052 and K30-AT-00060 and the National Institute of Nursing
Research F31-NR-007696
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the
sequence generation process used
Allocation concealment (selection bias) Low risk Randomnumber tablewas used to generate
the order of the group assignments
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk E-mail received from author confirming as-
sessors were blind to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition or missing data apparent (0%
total attrition rate)
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and
secondary) outcomes that are of interest in
the review have been reported in the pre-
specified way
Miro 2011
Methods Pilot randomised controlled trial
Participants Female participants meeting the ACR criteria for fibromyalgia and Ameican Psychiatric
Association (2000) criteria for insomnia were recruited through a hospital pain unit
Total participants = 44 randomised (31 completed)
Age range = 25 to 60 years
Exclusions: pregnancy, having a significant history of head injury of neurological dis-
order, major concomitant medical conditions, major depressive disorder with suicidal
ideation or other major Axis I diagnoses, symptoms of sleep disruptive co morbidities
with insomnia, apnea, hypopnea index or periodic limbmovement arousal index of≥ 15
per hour of sleep, severe hypnotic dependence, being treated with another psychological
or physical therapy during the course of the study
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Miro 2011 (Continued)
Interventions 1) Cognitive behavioural therapy (CBT) was delivered in groups for 90 minutes, once
a week for 6 weeks by a CBT trained expert based on a treatment manual. Participants
received information on sleep and sleep hygiene education, sleep restriction and stim-
ulus control instructions, relaxation training and cognitive restructuring in addition to
planning to prevent relapses
2) The sleep hygiene control group received information on environmental and lifestyle
factors related to sleep held in groups for 90 minutes, once a week for 6 weeks
Outcomes Measures relevant to this review: McGill Pain Questionnaire, Hospital Anxiety and
Depression Scale, Pittsburgh Sleep Quality Index, Fibromyalgia Impact Questionnaire
Assessment time points: baseline and post-intervention
Notes The study was funded by the Spainish Ministry of Science and Innovation (SEJ2006-
07513, PSI2008-03595PSIC and PSI2009-1365PSIC). The authors report no conflicts
of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence
generation process used
Allocation concealment (selection bias) Low risk Simple randomisation (1:1) was implemented by a
researcher with no clinical involvement in the trial
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Performed by an examiner (CD) who was blinded
to group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 29% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and sec-
ondary) outcomes that are of interest in the review
have been reported in the pre-specified way
Oliver 2001
Methods Randomised controlled trial
Participants Participants were recruited through members of a health maintenance organisation,
advertisements in newspaper, with flyers advertised in waiting rooms, and e-mails sent
to physicians asking them to refer patients into the study. Diagnosis was confirmed by a
trained examiner
Total participants = 600 randomised (492 completed)
Mean age = 54 (SD 11) years
Exclusions: not meeting the ACR criteria for fibromyalgia
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Oliver 2001 (Continued)
Interventions 1) Social support and education was delivered for 2 hours, held weekly for 10 weeks,
followed by 10 monthly meetings. Sessions included group discussions prompted by
assigned tasks aimed at promoting empathy and sharing of coping techniques between
participants and education provided by a health educator
2) Usual care control group
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Arthritis Self-
Efficacy Scale, Center for Epidemiological Studies - Depression Scale and Quality of
Wellbeing Scale
Assessment time points: baseline (12 month follow-up not included in this review)
Notes The study was funded by a National Institutes of Health Grant AR-44020
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk E-mail from author received confirming use of random
generated numbers placed in sealed envelopes. Partici-
pants were asked to select an envelope from a box
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk E-mail from author confirmed that assessors were blind
to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk An 18% attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Oneva-Zafra 2010
Methods Randomised controlled clinical trial
Participants Participants who had experienced fibromyalgia ≥ 3 years were recruited through three
fibromyalgia associations
Total participants = 60 randomised (55 completed)
Age range = 45 to 65 years
N = 106 female, N = 4 male
Exclusions: major psychiatric condition, inability to understand or follow instructions,
inability to read or write Spanish, and deafness
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Oneva-Zafra 2010 (Continued)
Interventions 1) Music therapy was delivered for 1 hour on a compact disc (CD). Participants were
asked to play the CD at home ≥ 4 days in the first week and every day in the second
week. A second CD with a different compilation was provided for the following two
weeks
2) Usual care
Outcomes Measures relevant to this review: visual analog scale 0 to 10 for pain, Beck Depression
Inventory, McGill Pain Questionnaire - long form
Assessment time points: baseline and post-intervention
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence
generation process used
Allocation concealment (selection bias) Low risk Computer generated random numbers table by
independent researcher. Sealed envelopes chosen
on allocation
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk Not clear if outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk An 8% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and sec-
ondary) outcomes that are of interest in the re-
view have been reported in the pre-specified way
Parra-Delgado 2013
Methods Randomised controlled trial
Participants Women were recruited through the Spanish Fibromyalgia Association. To be eligible
people needed to be diagnosed with FMS according to the ACR criteria and willing to
commit to daily mindfulness practice
Total participants = 33 randomised (31 completed)
Exclusions: diagnosiswith alcohol or substance abuse problems or receivingpsychological
therapy
Interventions 1) Mindfulness based cognitive therapy delivered by rehabilitation clinicians in a group
format 2.5 hour sessions held weekly for 8 weeks
2) Usual care
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Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, 10 point visual
analog scale, Beck Depression Inventory
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk “randomly assigned to the MBCT intervention single
group or the treatment as usual group using the random
number generator programme”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
High risk Outcome assessors were not blind to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 6% attrition, 2 participants withdrew from the treat-
ment group
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Picard 2013
Methods Randomised controlled trial
Participants Female participants referred to a pain clinic who had experienced FMS for at least 6
months and who had been diagnosed by a rheumatologist according to the ACR criteria
were recruited
Total participants = 62 randomised (59 completed)
Exclusions: diagnosed with chronic inflammatory arthritis or peripheral or central neu-
ropathic pain, taking opioids, severe psychiatric illness or history of substance abuse
Interventions 1) Hypnosis delivered by a clinician within a pain clinic and including home practice in
between sessions 60 minute sessions held weekly for 5 weeks
2) Wait-list control
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Hospital Anxiety
and Depression Scale, Medical Outcomes Study Sleep Scale, Mulitdimensional Fatigue
Invenory
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Assessment time points: baseline, post-intervention and 3 month follow-up
Notes The study was funded by the Foundation de France UB 032115
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk A random component appears to be included in the se-
quence generation process but details are not provided
Allocation concealment (selection bias) Unclear risk “preparing envelopes”; it was unclear from the informa-
tion provided as to whether the investigators would have
been able to foresee group assignment
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
High risk “Follow up assessments were then performed during a
consultation, 3 and 6 months post-randomisation by the
same medical doctor who was not blind to study condi-
tion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 5% attrition with equal distribution between groups
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Riedel 2012
Methods Randomised controlled trial
Participants Adult participants (aged over 18 years) diagnosed with FMS were referred by clinicians
into the study. To be eligible participants were required to have a diagnosis of FMS based
on the ACR criteria, be able to read, write, and understand English and to be available
for weekly telephone contact
Total participants = 24 randomised (17 completed)
Exclusions: current or regular use of guided imagery within the last 6 months, Mini-
Mental State Examination (MMSE) score < 25, unstable or severe psychiatric illness
Interventions 1) Guided imagery. Audio recording listened to using an MP3 player at the person’s
home. Audio recordings were of 20 minutes duration and were listened to daily for 14
days
2) Usual care
Outcomes Measures relevant to this review: Fibromyalgia ImpactQuestionnaire, Short FormMcGill
Pain Questionnaire, Lees Fatigue Inventory, State-Trait Anxiety Inventory, Center for
Epidemiologic Studies Depression Scale, Arthritis Self-Efficacy Scale, Pittsburgh Sleep
Quality Index
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Assessment time points: baseline and post-intervention
Notes The study was funded by the National Center for Complimentary and Alternative
Medicine, National Institutes for Health grant number 5-T32-AT000052
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk “table of random numbers with probabilities in a ratio of
1:1”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk Details not specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 27% attrition
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Scheidt 2013
Methods Randomised controlled trial
Participants Women aged 18 to 70 years diagnosed with FMS according to the ACR criteria were
recruited
Total participants = 47 randomised (35 completed)
Exclusions: severe or life threatening illness, cognitive impairment, suicidal ideation,
current psychotherapy or participation in other clinical trials
Interventions 1) Psychodynamic psychotherapy delivered by a psychologist on an individual basis
within a hospital setting 50 to 60 minute sessions, held weekly for 25 weeks
2) Wait-list control
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Hospital Anxiety
and Depression Scale, Symptom Checklist-27 and Medical Outcome Study SF36
Assessment time points: baseline, post-intervention and 12 month follow-up
Notes The study was funded as part of an Interdisciplinary Research Project by the Freiberg
Institute of Advanced Studies
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk “Randomised in blocks of 10 to treatment or control
group according to a 1;1 schedule”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Outcome assessors were blind to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk An 11% attrition, equal distribution of withdrawals be-
tween groups
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Schmidt 2011
Methods Randomised controlled trial
Participants Women diagnosed with fibromyalgia defined by the ACR criteria were eligible for the
trial
Total participants = 177 randomised (168 completed)
Age range = 18 to 70 years
Exclusions: unable to speak or understand German, life-threatening disease, evidence of
suppressed immune functioning, participation in other clinical trials
Interventions 1) Mindfulness was delivered based on the Mindfulness Based Stress Reduction struc-
tured programme by Kabat-Zinn 1990. Groups of up to 12 patients took part in 2.
5 hour sessions, held weekly and an additional all-day session on a weekend day for
8 weeks. Sessions included mindful awareness of dynamic yoga postures, mindfulness
during stressful situations and social situations. Participants were encouraged to practice
techniques in-between the weekly sessions at home
2) Wait-list control group
Outcomes Measures relevant to this review: Center for Epidemiological Studies - Depression Scale,
State-Trait Anxiety Inventory, tender point count, Pittsburgh Sleep Quality Index, Pain
Perception Scale, Fibromyalgia Impact Questionnaire, The Quality of Life Profile for
the Chronically Ill
Assessment time points: baseline and post-intervention
Notes The studywas supported by the Amueli Institute and theManfredKohnlechner Stiftung,
Munich, Germany. The authors report no conflicts of interest
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Patients were randomised in blocks using a computer
generated algorithm
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk All personnel handling data or interacting with the pa-
tients stayed blinded until the final analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 5% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Sephton 2007
Methods Randomised clinical trial
Participants Women diagnosed with fibromyalgia according to the ACR criteria were recruited
through media broadcasts and newspaper advertisements
Total participants = 91 randomised (68 completed)
Mean age = 48.2 (SD 10.6) years
Exclusions: no confirmationof diagnosis, declining to participate, unavailability to attend
8 week intervention
Interventions 1) Mindfulness was delivered based on the Mindfulness Based Stress Reduction pro-
gramme. Weekly sessions lasted for 2.5 hours and were facilitated by a licensed clinical
psychologist. Participants were encouraged to practice the techniques at home daily for
3 to 45 minutes in-between sessions. A day long meditation retreat was held in addition
to 7 weekly sessions
2) Wait list
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Beck Depression
Inventory, Stanford Sleep Questionnaire
Assessment time-points: Baseline, post-intervention and 2 month follow-up
Notes This study was supported by an intramural research grant from the University of
Louisville, School of Medicine and Office of the Vice President for Research
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is stated that participants were randomly assigned but no
details of randomisation procedure provided
Allocation concealment (selection bias) Unclear risk No information on the actual randomisation procedure used
provided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk Only stated that data entry personnel were blinded, not out-
come assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 25% total attrition rate
Selective reporting (reporting bias) Low risk Two measures were used to yield covariate variables, All of
the study’s pre-specified outcomes that are of interest in the
review have been reported in the pre-specified way
Soares 2002
Methods Randomised controlled trial
Participants Female participants diagnosed with fibromyalgia within the previous 2 years were re-
cruited through general practitioners
Total participants = 60 randomised (53 completed)
Age range 18 to 64 years
Exclusions: serious illness (e.g. other rheumatic disease, ongoing alcohol or drug abuse,
receipt of other therapies)
Interventions 1) The behavioural intervention consisted of five individual sessions of 1 hour each and
15 group sessions of 2 hours delivered by a licensed psychologist or cognitive behavioural
specialist. The sessions included training in relaxation, biofeedback, pain and stress
management, cognitive restructuring, problem solving and self-management
2) Wait-list control group
Outcomes Measures relevant to this review: Fibromyalgia ImpactQuestionnaire,McGill PainQues-
tionnaire, Symptom Checklist Revised, Arthritis Self-Efficacy Scale, Karolinska Sleep
Questionnaire
Assessment time points: baseline and post-intervention (no control group data available
at 6 months as wait-list control group used)
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Computerised random procedure reported to have been
used so unlikely investigators would have been able to
foresee group assignment but exact details unclear
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Authors confirmed that the outcome assessors were blind
to treatment allocation in an e-mail
Incomplete outcome data (attrition bias)
All outcomes
Low risk An 11% total attrition rate evident
Selective reporting (reporting bias) High risk Data were not reported for social support or the SCL-90
measures
Stuifbergen 2010
Methods Randomised controlled trial
Participants Female participants were recruited through advertisements in local newspapers, websites,
physician’s offices, community sites and support groups
Total participants = 234 randomised (165 completed)
Age range = 20 to 75 years
Exclusions: diagnosis of fibromyalgia within 6 months, unable to attend 8 week inter-
vention, enrolled in other pain management programmes, pregnant, taking medication
for which changes in diet and exercise are contraindicated
Interventions 1) Lifestyle intervention. The lifestyle counts interventionwas adapted from theWellness
Intervention for Women with Multiple Sclerosis programme, 2 hour group sessions
were held weekly for 8 weeks, delivered by a clinical nurse specialist. Sessions included
information on health promotion, enhancing self efficacy, stress management, intimacy
and personal relationships and engaging participants in individualised goal setting and
monitoring
2) The attention control group received received 8 sessions on topics related to disease
management including informationonmedication, secondary outcomes of fibromyalgia,
enhancing memory and health insurance
Outcomes Measures relevant to this review: Medical Outcomes Study short form health survey
(SF36), Self-ratedAbilities forHealth Practices scale, Fibromyalgia ImpactQuestionnaire
Assessment time points: baseline, post-intervention, 3 and 6 month follow-up
Notes This study was supported by the National Institutes of Health, National Institute of
Child Health and Human Development, Center for Medical Rehabilitation Research
R01HD035047. The authors report no conflicts of interest
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk Womenwithin each cohort were randomised using a coin
toss witnessed by an office staff member
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk The staff member was blinded to the class to which the
person was assigned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A 29% total attrition rate. It was reported that 11 women
did not attend the intervention sessions and were ex-
cluded from the analysis. Reasons for non-attendance not
presented
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Thieme 2006
Methods Randomised controlled trial
Participants Consecutive female patients diagnosed with fibromyalgia were recruited from outpatient
rheumatology clinics
Total participants = 125 randomised (100 completed)
Age range = 21 to 67 years
Exclusions: diagnosis not in accordance with ACR criteria, pain for < 6 months, not
of married status, spouse unwilling or unable to participate, inability to complete the
assessment questionnaire and understand the treatment components
Interventions 1) Cognitive behaviour therapy was delivered in groups by a psychologist and rheuma-
tologist. 2 hour sessions, held weekly, for 15 weeks. The content of the sessions included
a focus on the patient’s thinking, problem solving, stress and pain management and
relaxation techniques. The sessions were supported by weekly homework tasks
2) The attention placebo group received group discussion sessions that lasted for 2 hours
and were held weekly for 15 weeks. Sessions were guided by therapists and discussions
focused on medical and psychosocial problems resulting from fibromyalgia
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, West Haven-Yale
Multidimensional Pain Inventory, Pain Related Self Statements Scale
Assessment time points: baseline, post-intervention and 6 month follow up (12 month
follow-up outside timeframe of this review)
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Notes The study was funded by the Deutsche Forschungsgemeinschaft to KT (Th 899-1/2
and 899-2/2 and HF (FL 156/26 Clinical Research Unit), Max-Planck Award for In-
ternational Cooperation to HF and the National Institutes of Health/National Institute
of Arthritis and Musculo and Skin Diseases to DCT (AR44724 and AR 47298). The
authors report no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is stated that participants were randomly assigned but
no details of random component provided
Allocation concealment (selection bias) Unclear risk Nodetails of the randomisation procedure usedwere pro-
vided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk No details of the blinding of the assessors were provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk A 20% total attrition rate, imbalance between attrition
rates between groups for deterioration of symptoms evi-
dent in the control group
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Van Santen 2002
Methods Randomised controlled trial
Participants Female participants were recruited from a registry for rheumatic diseases if they lived
within 30 km of either treatment centre. Diagnosis of fibromyalgia was verified according
to the ACR criteria before commencement of the study
Total participants = 85 randomised (65 completed)
Age range = 18 to 60 years
Exclusions: male gender, known co-morbidity and localised myalgia
Interventions 1) Multi-component (relaxation and biofeedback). Biofeedback was delivered in indi-
vidual, 30 sessions, held twice weekly, for 8 weeks . Participants received feedback on
their level of relaxation from electrodes placed on the forehead. All participants received
training in progressive muscle relaxation from a psychologist or physiotherapist and were
encouraged to practice the technique in between sessions using an audio tape with in-
structions
2) Usual care
3) The fitness training group data were not included in this review
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Outcomes Measures relevant to this review: 0 to 100 visual analog scale for pain and fatigue,
Arthiritis Impact Measurement Scales, tender points, Symptom Checklist-90 revised
Assessment time-points: Baseline and post-intervention
Notes The study was funded by the Dutch Arthritis Association
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is stated “after randomisation” however no details of
the random component were provided
Allocation concealment (selection bias) Unclear risk Nodetails of the randomisation procedure usedwere pro-
vided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Outcome assessors were blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 23% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Vlaeyen 1996
Methods Randomised clinical trial
Participants Participants meeting the ACR criteria for diagnosis of fibromyalgia were referred from
the department of rheumatology at the regional general hospital
Total participants N = 131 randomised (67 completed)
Age range = 18 to 65 years
N = 350 female, N = 50 male
Exclusions: illiteracy, pregnancy, substance abuse, involvement in any litigation concern-
ing disability income, medical disorders and diseases making immediate treatment nec-
essary and that may prevent participants performing physical exercise, use of supportive
equipment for ambulation and severe psychopathology
Interventions 1) Cognitive education consisted of 90 minutes, held twice weekly, over 6 weeks. The
treatment aimed at decreasing distorted pain perceptions and increasing self efficacy.
Applied relaxation and biofeedback techniques were introduced to participants as part
of the skills acquisition phase. Tasks to complete in between sessions were given to
participants
2) Educational discussion (attention control). Participants were asked to read parts of a
book about pain and then to share the information and their thoughts in group discussion
100Mind and body therapy for fibromyalgia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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sessions. Participants were also asked to listen to music on audiotapes
3) Wait-list control
Outcomes Measures relevant to this review: McGill Pain Questionnaire, BeckDepression Inventory
Assessment time points: baseline, post-intervention, 6 and 12 month follow-up
Notes The study was funded by the Dutch Prevention Fund, grant number 28-2055
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is stated that participants were “randomly assigned” but
no details of random component provided
Allocation concealment (selection bias) Unclear risk No details of the randomisation procedure used were pro-
vided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk No details of the blinding of the assessors were provided
Incomplete outcome data (attrition bias)
All outcomes
High risk A 48% total attrition rate at 6 months
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary) out-
comes that are of interest in the review have been reported
in the pre-specified way
Wang 2010
Methods Randomised clinical trial
Participants Partiicpants meeting the ACR diagnostic criteria for fibromyalgia were recruited through
a tertiary academic hospital
Total participants = 66 randomised (59 completed)
N = 57 female, N = 9 male
Age range = 21 years and over
Exclusions: Particpation in tai chi in previous 6 months, serious medical conditions
that might preclude participation in the trial, co-morbid medical conditions known
to contribute to fibromyalgia symptoms, pregnancy or plans to become pregnant and
cognitive impairment (score ≤ 24)
Interventions 1)Tai chi consisted of group sessions delivered by a tai chi master. 60 minute sessions,
held twice weekly, for 12 weeks. The theory of tai chi was explained and participants
practiced 10 forms from the classic Yang style of tai chi. Each session included a warm up,
self massage and breathing techniques. Participants were asked to practice themovements
in-between sessions
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2) The education and stretching programme consisted of group sessions. 60 minute
sessions, held twice weekly, for 12 weeks. Sessions were delivered by a range of health
professionals on topics related to fibromyalgia including coping and problem solving
strategies, diet and nutrition, sleep disorders, painmanagement, exercise andmedication.
Stretches were also completed within the group sessions and held for 15 to 20 seconds
Outcomes Measures relevant to this review: Medical Outcomes Study (SF36), visual analog pain
scale 0 to 10, Center for Epidemiologic Studies - Depression scale, Fibromyalgia Impact
questionnaire, Pittsburgh Sleep Quality Index
Assessment time points: baseline, post-intervention and 3 month follow-up
Notes The study was funded by the National Center for Complementary and Alternative
Medicine of the National Institutes of Health, the American College of Rheumatology
Research and Education Foundation Health Professional Investigator Award and the
Boston Claude D. Pepper Older Americans Independence Center Research Career De-
velopment Award
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomcomponent is included in the sequence generation
process used
Allocation concealment (selection bias) Low risk Three randomisation cycles using computer generated num-
bers placed in opaque sealed envelopes
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Research staff were unaware of the group assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 10% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary) out-
comes that are of interest in the review have been reported
in the pre-specified way
Wicksell 2013
Methods Randomised controlled trial
Participants Female patients aged between 18 and 55 years old diagnosed with FMS according to
the ACR criteria with a weekly average pain score of > 40 (on a scale of 0 to 100) were
recruited
Total participants = 43 randomised (36 completed)
Exclusions: left handed, pregnant and breast feeding participants were excluded
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Interventions 1) Acceptance and commitment therapy delivered by psychologists and clinicians in a
group based format 90 minute sessions, held weekly for 12 weeks
2) Wait-list control
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Beck Depression
Inventory, State-trait Anxiety Inventory, Short Form Health Survey
Assessment time points: baseline, post-intervention and 3 months
Notes The study was supported by the Swedish Research Council K2009-53x-21070-01-3,
the Stcokholm County Council and the Swedish Rheumatism Association. The authors
report no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the sequence gen-
eration process used
Allocation concealment (selection bias) Low risk “sealed enveloped with codes for the different study con-
ditions”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk No details specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 10% attrition
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary)
outcomes that are of interest in the review have been
reported in the pre-specified way
Wigers 1996
Methods Randomised clinical trial
Participants Participants were recruited through local patient association and a hospital outpatient
clinic
Total participants = 60 randomised (57 completed)
N = 55 female, N = 5 male
Age range = 23 to 73 years
Exclusions: not meeting ACR criteria for fibromyalgia
Interventions 1) Stress management, 90 minute sessions held twice weekly for 6 weeks, followed by
once weekly for 8 weeks (30 hours of active treatment)
2) Treatment as usual (aerobic exercise group data not included)
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Outcomes Measures relevant to this review: 0 to 100 visual analog scales for pain, fatigue, mood
and depression
Assessment time points: baseline and post-intervention (4 year follow-up data not in-
cluded in this review)
Notes The study was supported by the Research Council of Norway 101417/320 and the
Norwegian Fibromyalgia Association
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomcomponent is included in the sequence generation
process used
Allocation concealment (selection bias) Low risk Randomised by drawing lots
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk E-mail confirmation received from author that outcomes
assessors were blind to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 26% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary) out-
comes that are of interest in the review have been reported
in the pre-specified way
Williams 2002
Methods Randomised clinical trial
Participants Participants who had been in standard medical care for at least 6 months were identified
through a patient registry held by a rheumatology clinic specialising in the treatment of
fibromyalgia
Total participants = 124 randomised (122 completed)
N = 130 female and N = 15 men
Mean age 47.7 years (SD 11.4)
Exclusions: under 18 years of age, severe physical impairment, co-morbid medical con-
dition causing a worsening in physical functioning, uncontrolled endocrine or allergic
disorders, malignancy within 2 years, present psychiatric disorder, current suicide risk or
attempt, or substance abuse within 2 years of the study
Interventions 1) Cognitive behaviour therapywas delivered in group sessions by a doctoral level clinical
psychologist, six one hour sessions, held over 4 weeks. The intervention comprised of in-
formation on the gate theory of pain, progressive muscle relaxation, pacing skills, activity
scheduling, communication skills and assertiveness training and cognitive restructuring
2) Usual care
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Outcomes Measures relevant to this review: McGill Pain Questionnaire, Medical Outcomes Study
(SF36)
Assessment time points: baseline (12 month follow-up not included in this review)
Notes The study was funded by the National Institutes of Health R29MH54877 and DAMD
17-00-02-0018
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail on randomisation provided
Allocation concealment (selection bias) Unclear risk No details of the randomisation procedure provided
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Unclear risk The questionnaire measures outlined in this study were de-
scribed as being self assessment tools but it was not clear
from manuscript if the questionnaires were indeed self ad-
ministered by participants or whether they were conducted
over the telephone by a researcher where it would be impor-
tant to know if they were blinded to the treatment allocation
of the participant
Incomplete outcome data (attrition bias)
All outcomes
High risk A 1% total attrition rate. Means and standard deviations
could not be extracted from data provided
Selective reporting (reporting bias) High risk Findings were provided on both outcome measures (al-
though means and standard deviations could not be ex-
tracted from information provided)
Williams 2010
Methods Randomised clinical trial
Participants Participants receiving standard care for fibromyalgiawere recruited into the study through
their treating clinician
Total participants = 118 randomised (106 completed)
Age range =
N = female, N = male
Exclusions: no fulfilment of ACR criteria, < 18 years of age, been in receipt of treatment
for < 3 months, severe physical impairment, co-morbid medical condition, psychiatric
disorder, receipt of CBT prior to participation in study, pending status with disability
compensation or receipt of disability compensation for < 2 years
Interventions 1) Cognitive behaviour therapy was delivered using an online resource. The website
contained 13 modules encompassing education about fibromyalgia, behavioural and
cognitive skills to assist in symptom management. Video lectures, self-monitoring forms
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and written summaries were provided
2) Usual care
Outcomes Measures relevant to this review: SF36 health survey, Brief Pain Inventory, Multidimen-
sional Fatigue Inventory, Center for Epidemiologic Studies -Depression Scale, Medical
Outcomes Study Sleep Scale, State-Trait Anxiety Inventory
Assessment time points: baseline and 6 month follow-up
Notes The study was supported by the NIAMS/NIH (R01-AR050044) and the Department
of Defence (DAMD 17-00-2-0018)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomcomponent is included in the sequence generation
process used
Allocation concealment (selection bias) Low risk 1:1 ratio. A computerised randomisation program was used
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk Outcome assessors were blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk A 10% total attrition rate
Selective reporting (reporting bias) Low risk All of the study’s pre-specified (primary and secondary) out-
comes that are of interest in the review have been reported
in the pre-specified way
Woolfolk 2012
Methods Randomised controlled trial with an additive design
Participants Participants diagnosed with FMS according to the ACR criteria were referred into the
study by their rheumatologist
Total participants = 76 randomised (70 completed)
Exclusions: pain from traumatic injury, structural or regional disease, rheumatoid arthri-
tis inflammatory arthritis, autoimmune disease, unstable medical or psychiatric illness
or active suicidal ideation
Interventions 1) Affective cognitive behavioural therapy delivered on an individual basis, 10 sessions
were delivered
2) Usual care
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Woolfolk 2012 (Continued)
Outcomes Measures relevant to this review: 10 point visual analog scale, BeckDepression Inventory,
Beck Anxiety Inventory, Chronic Pain Efficacy Scale, Medical Outcomes Study SF36
Assessment time points: baseline, post-intervention and 6 month follow-up
Notes There was no reference to sources of funding or conflicts of interest declared in the article
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random component is included in the
sequence generation process used
Allocation concealment (selection bias) Low risk “Computer generated random number se-
quence. Neither blocking nor stratification
used”
Blinding of outcome assessment (detection
bias)
Questionnaire assessors blind?
Low risk “Study personnel administering the ques-
tionnaires were masked to participant’s
treatment conditions”
Incomplete outcome data (attrition bias)
All outcomes
Low risk An 8% attrition
Selective reporting (reporting bias) High risk Means and standard deviations are not
available for the Beck Depression Ivenotry
or Beck Anxiety Inventory or for all com-
ponents of the SF36
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvarez-Nemegyei 2006 The intervention of providing Ericksonian hypnosis was not deemed to meet the mind and body
criteria as participants were not actively engaged in the intervention as the intervention and did not
aim to provide a tool for self management
Ang 2013b The exercise component was more substantial than the motivational interviewing component of the
intervention and therefore was not deemed to meet the 80% criterion for the intervention to be based
on mind-body principles
Arcos-Carmona 2011 The relaxation component of the intervention was deemed to be less than the 80% mind-body focus
that was required for inclusion in the review
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(Continued)
Bieber 2004 The intervention of providing shared decision making communication programme for clinicians for
inclusion as the intervention of providing information was not considered to provide tools or to increase
self management directly for patients but as a consultation tool
Bieber 2008 The intervention of providing shared decision making communication programme for clinicians for
inclusion as the intervention of providing information was not considered to provide tools or to increase
self management directly for patients but as a consultation tool
Bosch-Romero 2002 The health education sessions were not deemed to meet the 80% criteria for being based on mind and
body principles including only two sessions based on mind and body principles
Casanueva-Fernandez 2012 The intervention was not deemed to meet the 80% criteria for the intervention to be based on mind-
body principles due to the substantial inclusion of massage, thermal therapy and exercise components
Castel 2013 The intervention was based on 50% on cognitive behavioural therapy and 50% on physical therapy and
was therefore deemed not to meet the 80% criteria for being based on mind-body therapy principles
Cedraschi 2004 The intervention programme was not deemed to meet the 80% criteria based on mind-body principles
as 10/22 sessions were based on exercise
Gowans 1999 The intervention of providing exercise and education was not deemed to meet the mind and body
criteria as 50% of the intervention was specifically focused on exercise
Hochlehnert 2006 The intervention of providing shared decision making communication programme for clinicians for
inclusion as the intervention of providing information was not considered to provide tools or to increase
self management directly for patients but as a consultation tool
Hunt 2000 The intervention of providing exercise and education was not deemed to meet the 80% mind and
body criteria as there was a substantial focus on exercise
King 2002a The intervention of providing exercise and education was not deemed to meet the 80% mind and
body criteria as there was a substantial focus on exercise
King 2002b The intervention was not deemed to meet the 80% mind and body criteria as there was a substantial
focus on exercise
Kravitz 2006 The intervention of providing neuro feedback was not deemed to meet the mind and body criteria as
participants were not actively engage in the intervention and did not provide a tool for self management
Lemstra 2005 The intervention was not deemed to meet the 80% mind and body criteria as there was a substantial
focus on exercise
Mannerkorpi 2000 The intervention was not deemed to meet the 80% mind and body criteria as there was a substantial
focus on exercise
McBeth 2012 The intervention was not deemed to meet the 80% mind-body criteria for intervention content as just
under half of the sessions focuses on physical activity
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(Continued)
McVeigh 2006 The intervention was not deemed to meet the 80% mind and body criteria as there was a substantial
focus on exercise
Nelson 2010 The intervention of low energy neuro feedback was not deemed to meet the mind and body criteria as
the participants were not consciously learning to change brain wave activity
Van Eijk-Hustings 2013 Themultidisciplinary programme including psychological, physiological and sociological elements was
not deemed to meet the criterion of 80% of the intervention based on mind-body principles due to a
substantial component of physiotherapy
van Koulil 2010 The intervention was not deemed to meet the 80% mind and body therapy criteria as only 50% of
the intervention focused on CBT the other 50% focused on exercise
Zhang 2009 The intervention was not deemed to meet the 80% mind and body criteria as there was at lease a 50%
focus on massage
Characteristics of studies awaiting assessment [ordered by study ID]
Thorsell 2011
Methods Randomised controlled trial
Participants Adults participants diagnosed with fibromyalgia (unclear if diagnosis was according to the ACR diagnostic criteria)
Total participants N = 115 randomised (55 completed post-intervention measures)
Interventions 1) Acceptance Commitment Therapy 2 face to face sessions of 90 minutes and 7 30 minutes telephone sessions.
Email contact with the therapist was also available
2) Applied relaxation 2 x 90 minutes face to face sessions and 7 weekly sessions of telephone support
Outcomes Measures relevant to this review: Hospital Anxiety and Depression Scale, 10 point Visual Analog Scale
Assessment time points: baseline, post-intervention, 6 and 12 month follow-up
Notes
Toussaint 2012
Methods Randomised controlled trial
Participants Adults participants diagnosed with fibromyalgia (unclear if diagnosis was according to the ACR diagnostic criteria)
Total participants = 57 randomised (21 completed post-intervention measures)
Interventions 1) Amygdala retraining delivered during a 2.5 hour training programme
2) Usual care including a 1.5 day multi-disciplinary programme
Outcomes Measures relevant to this review:Multi-dimensional Fatigue Inventory,MedicalOutcomes Study (SF36) Fibromyalgia
Impact Questionnaire
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Toussaint 2012 (Continued)
Assessment time points: baseline and post-intervention
Notes
Wang 2012
Methods Randomised controlled trial
Participants People diagnosed with fibromyalgia (unclear if diagnosis was according to the ACR diagnostic criteria and the age
range of participants was not specified)
Total participants (N = 66)
Interventions 1) Yang-style Tai Chi
2) Wellness education and stretching control
Outcomes Measures relevant to this review: Fibromyalgia Impact Questionnaire, Medical Outcomes Study 36-item Short Form
Health Survey, Visual Analog Scale for pain
Assessment time points: baseline to week 24
Notes
Characteristics of ongoing studies [ordered by study ID]
Garcia-Campayo 2009
Trial name or title Effectiveness of the psychological and pharmacological treatment of catastrophisation in patients with fi-
bromyalgia
Methods Randomised Controlled Trial
Participants 180 adults (aged 18-70) diagnosed with fibromyalgia according to the ACR classification criteria for fi-
bromyalgia. To be eligible participants needed to be able to provide informed consent
Total participants = 180
Exclusions: Previous psychological or pharmacological treatment
Interventions 1) Cognitive behaviour therapy delivered in 10 weekly group sessions
2) Usual care
Outcomes Measures relevant to this review: Hamilton Anxiety Rating Scale, Hamilton Rating Scale for Depression,
Fibromyalgia Impact Questionnaire, EuroQol 5D questionnaire
Assessment time-points: Baseline, post-intervention, 3 and 6 month follow-up
Starting date Unknown
Contact information jgarcamp@arrakis.es
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Garcia-Campayo 2009 (Continued)
Notes The results of this study will be included in the review once completed
Miles 2010
Trial name or title Effects of gentle yoga versus CBT on fibromyalgia symptoms
Methods Randomised Controlled Trial
Participants Female participants who met the ACR criteria for diagnosis of fibromyalgia
Interventions 1) Gentle yoga
2) Cognitive behaviour therapy
Outcomes Measures relevant to this review: measures not specified but domains include fibromyalgia symptoms, anxiety,
depression and self-efficacy
Assessment time-points: Baseline and post-intervention
Starting date Unknown
Contact information Not provided
Notes Need to ascertain eligibility of control group. A preliminary report of 10 people has since been published in
International Journal of Yoga Therapy 2012
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D A T A A N D A N A L Y S E S
Comparison 1. Psychological therapies versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
10 733 Std. Mean Difference (IV, Fixed, 95% CI) -0.43 [-0.57, -0.28]
2 Functioning as assessed at 3
month follow-up
3 148 Std. Mean Difference (IV, Fixed, 95% CI) -0.54 [-0.87, -0.21]
3 Functioning as assessed at 6
month follow-up
1 112 Mean Difference (IV, Fixed, 95% CI) -3.66 [-7.29, -0.03]
4 Pain as assessed post-intervention 9 453 Std. Mean Difference (IV, Fixed, 95% CI) -0.33 [-0.52, -0.15]
5 Pain as assessed at 3 month
follow-up
2 115 Mean Difference (IV, Fixed, 95% CI) -0.85 [-1.76, 0.06]
6 Pain as assessed at 6 month
follow-up
5 371 Std. Mean Difference (IV, Fixed, 95% CI) -0.51 [-0.72, -0.30]
7 Mood as assessed
post-intervention
8 492 Std. Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.64, -0.26]
8 Mood as assessed at 3 month
follow-up
4 182 Std. Mean Difference (IV, Fixed, 95% CI) -1.15 [-1.50, -0.80]
9 Mood as assessed at 6 month
follow-up
2 213 Std. Mean Difference (IV, Fixed, 95% CI) -0.17 [-0.44, 0.10]
10 All cause attrition
post-intervention
22 1687 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.12, 1.69]
11 Adverse events
post-intervention
2 126 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.06, 2.50]
12 Fatigue as assessed
post-intervention
2 82 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.53, 0.34]
13 Fatigue as assessed at 6 months
post-intervention
2 160 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.38, 0.24]
14 Self-efficacy as assessed
post-intervention
4 255 Std. Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.50, -0.00]
15 Tender point count as assessed
at 6 month follow-up
1 42 Mean Difference (IV, Fixed, 95% CI) -0.38 [-0.88, 0.12]
16 Quality of life as assessed
post-intervention
6 276 Std. Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.44, 0.06]
17 Quality of life as assessed at 3
month follow-up
1 33 Mean Difference (IV, Fixed, 95% CI) -15.10 [-21.90, -8.
30]
18 Quality of life as assessed at 6
month follow-up
1 42 Mean Difference (IV, Fixed, 95% CI) -2.50 [-7.95, 2.95]
19 Sleep as assessed
post-intervention
5 222 Std. Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.80, -0.25]
20 Sleep as assessed at 3 month
follow-up
1 64 Mean Difference (IV, Fixed, 95% CI) -11.30 [-15.44, -7.
16]
21 Sleep as assessed at 6 month
follow-up
3 224 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.42, 0.12]
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22 Self-efficacy as assessed at 3
month follow-up
1 33 Mean Difference (IV, Fixed, 95% CI) -15.10 [-44.95, 14.
75]
Comparison 2. Psychological therapies versus usual care sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mood as assessed
post-intervention
7 428 Std. Mean Difference (IV, Fixed, 95% CI) -0.29 [-0.48, -0.10]
2 Mood as assessed at 3 month
follow-up
3 118 Std. Mean Difference (IV, Fixed, 95% CI) -0.63 [-1.00, -0.26]
3 Fatigue as assessed
post-intervention
1 42 Std. Mean Difference (IV, Fixed, 95% CI) -0.42 [-1.04, 0.19]
4 Sleep as assessed
post-intervention
4 158 Std. Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.50, 0.13]
5 Sleep as assessed at 6 month
follow-up
2 160 Std. Mean Difference (IV, Fixed, 95% CI) 0.22 [-0.09, 0.53]
Comparison 3. Psychological therapies versus attention control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
7 561 Std. Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.27, 0.07]
2 Functioning as assessed at 3
month follow-up
4 447 Std. Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.17, 0.20]
3 Functioning as assessed at 6
month follow-up
3 326 Std. Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.22, 0.23]
4 Pain as assessed post-intervention 5 324 Std. Mean Difference (IV, Fixed, 95% CI) -0.28 [-0.51, -0.06]
5 Pain as assessed at 3 month
follow-up
2 115 Std. Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.24, 0.50]
6 Pain as assessed at 6 month
follow-up
1 60 Mean Difference (IV, Fixed, 95% CI) -0.34 [-0.89, 0.21]
7 Mood as assessed
post-intervention
5 330 Std. Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.33, 0.10]
8 Mood as assessed at 3 month
follow-up
2 115 Std. Mean Difference (IV, Fixed, 95% CI) 0.24 [-0.13, 0.61]
9 All cause attrition
post-intervention
8 669 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.54, 0.87]
10 Fatigue as assessed
post-intervention
2 153 Std. Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.44, 0.20]
11 Fatigue as assessed at 3 month
follow-up
1 69 Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.73, 0.37]
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12 Self-efficacy as assessed
post-intervention
1 105 Mean Difference (IV, Fixed, 95% CI) 0.48 [-0.27, 1.23]
13 Self efficacy as assessed at 3
month follow-up
2 151 Std. Mean Difference (IV, Fixed, 95% CI) -0.27 [-0.59, 0.05]
14 Self-efficacy as assessed at 6
month follow-up
1 32 Mean Difference (IV, Fixed, 95% CI) 0.01 [-1.31, 1.33]
15 Tender point score as assessed
post-intervention
2 150 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.62, 0.02]
16 Quality of life as assessed
post-intervention
3 308 Std. Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.35, 0.10]
17 Quality of life as assessed at 3
month follow-up
2 218 Std. Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.31, 0.22]
18 Quality of life as assessed at 6
month follow-up
1 171 Std. Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.34, 0.26]
19 Sleep as assessed
post-intervention
2 109 Std. Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.50, 0.25]
20 Sleep as assessed at 3 month
follow-up
1 69 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.45, 0.47]
Comparison 4. Psychological therapies versus attention control sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
6 390 Std. Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.45, -0.05]
2 Functioning as assessed at 6
month follow-up
2 266 Std. Mean Difference (IV, Fixed, 95% CI) 0.14 [-0.10, 0.38]
3 Pain as assessed post-intervention 4 255 Std. Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.66, -0.15]
4 Sleep as assessed
post-intervention
1 40 Std. Mean Difference (IV, Fixed, 95% CI) -0.51 [-1.14, 0.12]
Comparison 5. Biofeedback versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
2 106 Std. Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.44, 0.33]
2 Functioning as assessed at 3
month follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -0.41 [-8.88, 8.06]
3 Pain as assessed post-intervention 1 65 Mean Difference (IV, Fixed, 95% CI) -2.60 [-91.29, 86.
09]
4 Mood as assessed
post-intervention
2 104 Std. Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.26, 0.52]
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5 Mood as assessed at 3 month
follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) 4.61 [-0.16, 9.38]
6 All cause attrition
post-intervention
3 125 Risk Ratio (M-H, Fixed, 95% CI) 4.08 [1.43, 11.62]
7 Tender point score as assessed
post-intervention
2 101 Mean Difference (IV, Fixed, 95% CI) -0.92 [-2.29, 0.45]
8 Tender point score as assessed at
3 month follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.85, 0.67]
9 Quality of life (Physical
functioning) as assessed
post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) -4.92 [-19.30, 9.46]
10 Quality of life (Role-Physical)
as assessed post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) -19.27 [-41.03, 2.
49]
11 Quality of life (Bodily Pain) as
assessed post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) 6.27 [-4.49, 17.03]
12 Quality of life (General Health)
as assessed post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) -8.14 [-20.47, 4.19]
13 Quality of life (Vitality) as
assessed post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) -13.43 [-24.06, -2.
80]
14 Quality of life (Social
Functioning) as assessed
post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) -10.42 [-26.61, 5.
77]
15Quality of life (Role-Emotional)
as assessed post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) -9.49 [-39.26, 20.
28]
16 Quality of life (Mental Health)
as assessed post-intervention
1 36 Mean Difference (IV, Fixed, 95% CI) -9.32 [-22.93, 4.29]
17 Quality of life (Physical
functioning) as assessed at 3
month follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) 0.0 [-13.73, 13.73]
18 Quality of life (Role-Physical)
as assessed at 3 month
follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -5.21 [-24.28, 13.
86]
19 Quality of life (Bodily Pain) as
assessed at 3 month follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) 0.71 [-8.15, 9.57]
20 Quality of life (Social
Functioning) as assessed at 3
month follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -7.43 [-24.21, 9.35]
21 Quality of life (General
Health) as assessed at 3 month
follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -0.94 [-12.33, 10.
45]
22 Quality of life (Vitality) as
assessed at 3 month follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -10.17 [-20.57, 0.
23]
23Quality of life (Role-Emotional)
as assessed at 3 month
follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -23.84 [-53.57, 5.
89]
24 Quality of life (Mental
Health) as assessed at 3 month
follow-up
1 36 Mean Difference (IV, Fixed, 95% CI) -6.44 [-18.27, 5.39]
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Comparison 6. Biofeedback versus attention control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
1 30 Mean Difference (IV, Fixed, 95% CI) 13.60 [1.05, 26.15]
2 Pain as assessed post-intervention 1 30 Mean Difference (IV, Fixed, 95% CI) 2.66 [1.21, 4.11]
3 All cause attrition
post-intervention
2 74 Risk Ratio (M-H, Fixed, 95% CI) 3.46 [0.44, 27.19]
4 Tender point score as assessed
post-intervention
1 30 Mean Difference (IV, Fixed, 95% CI) 2.93 [0.15, 5.71]
Comparison 7. Mindfulness versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
2 128 Std. Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.60, 0.09]
2 Functioning assessed at 3 month
follow-up
1 103 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.78, 0.66]
3 Pain as assessed post-intervention 2 128 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.44, 0.26]
4 Pain as assessed at 3 month
follow-up
1 103 Mean Difference (IV, Fixed, 95% CI) -0.28 [-2.37, 1.81]
5 Mood as assessed
post-intervention
3 218 Std. Mean Difference (IV, Fixed, 95% CI) -0.24 [-0.51, 0.03]
6 Mood as assessed at 3 month
follow-up
2 193 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.50, 0.07]
7 All cause attrition
post-intervention
3 195 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.67, 1.72]
8 Sleep as assessed
post-intervention
1 97 Mean Difference (IV, Fixed, 95% CI) -0.64 [-2.27, 0.99]
9 Sleep as assessed at 3 month
follow-up
2 134 Std. Mean Difference (IV, Fixed, 95% CI) -0.24 [-0.59, 0.10]
Comparison 8. Mindfulness versus usual care - sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mood as assessed at 3 month
follow-up
1 90 Mean Difference (IV, Fixed, 95% CI) -1.5 [-4.77, 1.77]
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Comparison 9. Movement therapies versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
4 143 Std. Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.53, 0.15]
2 Pain as assessed post-intervention 1 28 Mean Difference (IV, Fixed, 95% CI) -2.3 [-4.19, -0.41]
3 Mood as assessed
post-intervention
1 29 Mean Difference (IV, Fixed, 95% CI) -9.84 [-18.51, -1.17]
4 All cause attrition
post-intervention
5 240 Risk Ratio (M-H, Fixed, 95% CI) 1.95 [1.13, 3.38]
5 Adverse events post-intervention 1 98 Risk Ratio (M-H, Fixed, 95% CI) 4.62 [0.23, 93.72]
6 Fatigue as assessed
post-intervention
1 29 Mean Difference (IV, Fixed, 95% CI) -10.8 [-18.57, -3.03]
7 Tender point count as assessed
post-intervention
2 93 Std. Mean Difference (IV, Fixed, 95% CI) 0.18 [-0.25, 0.60]
8 Sleep as assessed
post-intervention
1 29 Mean Difference (IV, Fixed, 95% CI) -4.68 [-8.14, -1.22]
Comparison 10. Movement therapies versus usual care - sensitivity analyses intervention type
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
3 121 Std. Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.63, 0.11]
Comparison 11. Movement therapies versus usual care - sensitivity analyses quality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
3 115 Std. Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.44, 0.31]
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Comparison 12. Movement therapies versus attention control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
3 191 Std. Mean Difference (IV, Fixed, 95% CI) -0.65 [-0.94, -0.35]
2 Functioning as assessed at 3
month follow-up
3 189 Std. Mean Difference (IV, Fixed, 95% CI) -0.53 [-0.82, -0.23]
3 Pain as assessed by a 10-point
VAS scale post-intervention
3 172 Mean Difference (IV, Fixed, 95% CI) -1.45 [-2.08, -0.81]
4 Pain as assessed by a 10-point
VAS scale at 3 month follow-up
3 165 Mean Difference (IV, Fixed, 95% CI) -1.19 [-1.87, -0.52]
5 Mood as assessed
post-intervention
2 141 Std. Mean Difference (IV, Fixed, 95% CI) -0.49 [-0.83, -0.15]
6 Mood as assessed at 3 month
follow-up
2 140 Std. Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.69, -0.01]
7 All cause attrition
post-intervention
5 279 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.65, 2.09]
8 Adverse events post-intervention 1 78 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.37, 131.17]
9 Self-efficacy as assessed
post-intervention
1 60 Mean Difference (IV, Fixed, 95% CI) -1.60 [-2.54, -0.66]
10 Self-efficacy as assessed at 3
month follow-up
1 59 Mean Difference (IV, Fixed, 95% CI) -1.20 [-2.25, -0.15]
11 Tender points as assessed
post-intervention
2 130 Mean Difference (IV, Fixed, 95% CI) 0.09 [-1.16, 1.33]
12 Tender points as assessed at 3
month follow-up
2 130 Mean Difference (IV, Fixed, 95% CI) -0.39 [-1.63, 0.85]
13 Quality of life as assessed
post-intervention
2 109 Std. Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.09, -0.31]
14 Quality of life as assessed at 3
month follow-up
2 108 Std. Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.91, -0.14]
15 Sleep quality as assessed by the
Pittsburgh Sleep Quality Index
post-intervention
2 141 Mean Difference (IV, Fixed, 95% CI) -1.88 [-3.27, -0.48]
16 Sleep quality as assessed by the
Pittsburgh Sleep Quality Index
at 3 month follow-up
2 140 Mean Difference (IV, Fixed, 95% CI) -1.35 [-2.77, 0.07]
Comparison 13. Movement therapies versus attention control - sensitivity analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
2 110 Std. Mean Difference (IV, Fixed, 95% CI) -0.99 [-1.39, -0.59]
2 Functioning as assessed at 3
month follow-up
2 108 Std. Mean Difference (IV, Fixed, 95% CI) -0.83 [-1.23, -0.43]
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3 Pain as assessed by a 10-point
VAS scale post-intervention
2 110 Mean Difference (IV, Fixed, 95% CI) -2.18 [-2.96, -1.40]
4 Pain as assessed by a 10-point
VAS scale at 3 month follow-up
2 108 Mean Difference (IV, Fixed, 95% CI) -1.94 [-2.77, -1.10]
5 Mood as assessed
post-intervention
1 60 Std. Mean Difference (IV, Fixed, 95% CI) -1.28 [-1.84, -0.72]
6 Mood as assessed at 3 month
follow-up
1 59 Std. Mean Difference (IV, Fixed, 95% CI) -0.96 [-1.51, -0.42]
Comparison 14. Relaxation versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functioning as assessed
post-intervention
2 67 Mean Difference (IV, Fixed, 95% CI) -8.33 [-10.14, -6.53]
2 Pain as assessed post-intervention 2 67 Std. Mean Difference (IV, Fixed, 95% CI) -1.02 [-1.55, -0.50]
3 Mood as assessed
post-intervention
1 19 Mean Difference (IV, Fixed, 95% CI) -4.44 [-14.46, 5.58]
4 All cause attrition
post-intervention
1 21 Risk Ratio (M-H, Fixed, 95% CI) 4.4 [0.59, 33.07]
5 Self-efficacy as assessed
post-intervention
2 67 Std. Mean Difference (IV, Fixed, 95% CI) -1.54 [-2.13, -0.95]
6 Fatigue as assessed
post-intervention
1 19 Mean Difference (IV, Fixed, 95% CI) -0.82 [-2.91, 1.27]
7 Sleep as assessed
post-intervention
1 19 Mean Difference (IV, Fixed, 95% CI) 1.03 [-2.23, 4.29]
Comparison 15. Relaxation versus attention control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain as assessed post-intervention 1 39 Mean Difference (IV, Fixed, 95% CI) -23.17 [-36.73, -9.
61]
2 Mood as assessed
post-intervention
1 39 Mean Difference (IV, Fixed, 95% CI) -32.1 [-46.35, -17.
85]
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Analysis 1.1. Comparison 1 Psychological therapies versus usual care, Outcome 1 Functioning as assessed
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alda 2011 56 46.21 (9.18) 53 48.64 (6.77) 15.3 % -0.30 [ -0.68, 0.08 ]
Castel 2009 16 60.96 (22.69) 7 66.14 (18.81) 2.8 % -0.23 [ -1.12, 0.66 ]
Castel 2012 34 52.2 (16.57) 30 64.6 (19.11) 8.5 % -0.69 [ -1.19, -0.18 ]
Falcao 2008 25 31.65 (23.56) 26 36.06 (20.26) 7.2 % -0.20 [ -0.75, 0.35 ]
Hamnes 2012 58 55.9 (185.9764) 60 61 (146.3259) 16.8 % -0.03 [ -0.39, 0.33 ]
Luciano 2011 108 46.87 (16.77) 108 54.72 (15.95) 29.9 % -0.48 [ -0.75, -0.21 ]
Maddali-Bongh 2010 22 34.1 (17.03) 19 48 (18.82) 5.4 % -0.76 [ -1.40, -0.12 ]
Scheidt 2013 20 46.7 (2.8) 20 50.9 (2.8) 4.4 % -1.47 [ -2.18, -0.76 ]
Soares 2002 18 2.25 (0.73) 17 2.65 (0.56) 4.7 % -0.60 [ -1.28, 0.08 ]
Wicksell 2013 20 39 (12.5) 16 43.8 (10.5) 5.0 % -0.40 [ -1.07, 0.26 ]
Total (95% CI) 377 356 100.0 % -0.43 [ -0.57, -0.28 ]
Heterogeneity: Chi2 = 16.78, df = 9 (P = 0.05); I2 =46%
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Psychological therapies versus usual care, Outcome 2 Functioning as assessed
at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 2 Functioning as assessed at 3 month follow-up
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Castel 2012 34 52.8 (18.5) 30 66.3 (17.2) 42.3 % -0.74 [ -1.25, -0.24 ]
Falcao 2008 25 36.68 (24.81) 26 42.76 (27.24) 36.0 % -0.23 [ -0.78, 0.32 ]
Wicksell 2013 19 37.4 (13.4) 14 45.7 (11.1) 21.7 % -0.65 [ -1.36, 0.06 ]
Total (95% CI) 78 70 100.0 % -0.54 [ -0.87, -0.21 ]
Heterogeneity: Chi2 = 1.93, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.19 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Psychological therapies versus usual care, Outcome 3 Functioning as assessed
at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 3 Functioning as assessed at 6 month follow-up
Study or subgroup
Psychological
therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alda 2011 57 40.68 (10.93) 55 44.34 (8.56) 100.0 % -3.66 [ -7.29, -0.03 ]
Total (95% CI) 57 55 100.0 % -3.66 [ -7.29, -0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Psychological therapies versus usual care, Outcome 4 Pain as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 4 Pain as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alda 2011 56 36.88 (8.29) 53 38.68 (7.48) 24.7 % -0.23 [ -0.60, 0.15 ]
Castel 2009 16 6.1 (2.52) 7 7 (1.01) 4.4 % -0.39 [ -1.29, 0.50 ]
Castel 2012 34 5.6 (1.1) 30 6.5 (2.3) 14.1 % -0.50 [ -1.00, 0.00 ]
de Souza 2008 29 3.09 (1.1847) 26 4.03 (0.9688) 11.4 % -0.85 [ -1.41, -0.30 ]
Falcao 2008 25 3.28 (3.58) 26 3.53 (2.88) 11.6 % -0.08 [ -0.63, 0.47 ]
Hsu 2010 21 4.43 (2.69) 21 5.01 (1.8) 9.5 % -0.25 [ -0.86, 0.36 ]
Jensen 2012 19 49 (19) 15 59 (26) 7.4 % -0.44 [ -1.12, 0.25 ]
Soares 2002 18 27.14 (22.57) 17 25.65 (15.5) 8.0 % 0.07 [ -0.59, 0.74 ]
Wigers 1996 20 64 (19) 20 72 (24) 9.0 % -0.36 [ -0.99, 0.26 ]
Total (95% CI) 238 215 100.0 % -0.33 [ -0.52, -0.15 ]
Heterogeneity: Chi2 = 6.60, df = 8 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.48 (P = 0.00050)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Psychological therapies versus usual care, Outcome 5 Pain as assessed at 3
month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 5 Pain as assessed at 3 month follow-up
Study or subgroup
Psychological
therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Castel 2012 34 5.9 (1.9) 30 6.8 (2.2) 80.9 % -0.90 [ -1.91, 0.11 ]
Falcao 2008 25 4.44 (3.65) 26 5.07 (3.94) 19.1 % -0.63 [ -2.71, 1.45 ]
Total (95% CI) 59 56 100.0 % -0.85 [ -1.76, 0.06 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Psychological therapies versus usual care, Outcome 6 Pain as assessed at 6
month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 6 Pain as assessed at 6 month follow-up
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alda 2011 49 40.68 (10.93) 46 44.34 (8.56) 26.2 % -0.37 [ -0.77, 0.04 ]
Castel 2012 34 5.6 (1.8) 30 6.7 (2.7) 17.4 % -0.48 [ -0.98, 0.02 ]
de Souza 2008 28 3.05 (1.217) 24 4.26 (0.8818) 12.5 % -1.11 [ -1.70, -0.52 ]
Hsu 2010 21 4.38 (2.16) 21 5.43 (1.31) 11.3 % -0.58 [ -1.20, 0.04 ]
Williams 2010 59 4.3 (1.6) 59 4.9 (1.5) 32.6 % -0.38 [ -0.75, -0.02 ]
Total (95% CI) 191 180 100.0 % -0.51 [ -0.72, -0.30 ]
Heterogeneity: Chi2 = 4.95, df = 4 (P = 0.29); I2 =19%
Test for overall effect: Z = 4.80 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Psychological therapies versus usual care, Outcome 7 Mood as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 7 Mood as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alda 2011 56 7.78 (2.46) 53 8.17 (2.25) 25.0 % -0.16 [ -0.54, 0.21 ]
Castel 2012 34 16.1 (1.4) 30 23.1 (1.5) 3.6 % -4.78 [ -5.76, -3.79 ]
Falcao 2008 25 7.56 (7.71) 26 13.96 (11.37) 11.1 % -0.65 [ -1.21, -0.08 ]
Hamnes 2012 58 25 (72.2608) 60 24.6 (56.5174) 27.2 % 0.01 [ -0.35, 0.37 ]
Jensen 2012 19 11 (5) 15 16 (10) 7.3 % -0.64 [ -1.34, 0.05 ]
Scheidt 2013 20 8.7 (0.9) 20 9.2 (0.9) 8.8 % -0.54 [ -1.18, 0.09 ]
Wicksell 2013 20 11.7 (6) 16 14.8 (7.8) 8.0 % -0.44 [ -1.11, 0.22 ]
Wigers 1996 20 24 (22) 20 36 (35) 9.0 % -0.40 [ -1.03, 0.22 ]
Total (95% CI) 252 240 100.0 % -0.45 [ -0.64, -0.26 ]
Heterogeneity: Chi2 = 83.30, df = 7 (P<0.00001); I2 =92%
Test for overall effect: Z = 4.71 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Psychological therapies versus usual care, Outcome 8 Mood as assessed at 3
month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 8 Mood as assessed at 3 month follow-up
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Castel 2012 34 15.4 (1.3) 30 22.3 (1.4) 11.6 % -5.06 [ -6.09, -4.03 ]
Falcao 2008 25 10.56 (9.28) 26 15.61 (12.15) 39.8 % -0.46 [ -1.02, 0.10 ]
Jensen 2012 19 10 (4) 15 18 (12) 24.1 % -0.92 [ -1.64, -0.20 ]
Wicksell 2013 19 10.7 (4.8) 14 16.4 (12.5) 24.5 % -0.63 [ -1.33, 0.08 ]
Total (95% CI) 97 85 100.0 % -1.15 [ -1.50, -0.80 ]
Heterogeneity: Chi2 = 63.80, df = 3 (P<0.00001); I2 =95%
Test for overall effect: Z = 6.40 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Psychological therapies versus usual care, Outcome 9 Mood as assessed at 6
month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 9 Mood as assessed at 6 month follow-up
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alda 2011 49 7.91 (2.5) 46 8.57 (2.47) 44.4 % -0.26 [ -0.67, 0.14 ]
Williams 2010 59 16.4 (11.9) 59 17.5 (11.5) 55.6 % -0.09 [ -0.45, 0.27 ]
Total (95% CI) 108 105 100.0 % -0.17 [ -0.44, 0.10 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Psychological therapies versus usual care, Outcome 10 All cause attrition
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 10 All cause attrition post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alda 2011 1/56 3/53 2.5 % 0.32 [ 0.03, 2.94 ]
Ang 2010 2/15 2/13 1.7 % 0.87 [ 0.14, 5.32 ]
Ang 2013 3/16 2/17 1.5 % 1.59 [ 0.30, 8.33 ]
Brattberg 2008 13/17 7/29 4.1 % 3.17 [ 1.58, 6.36 ]
Burckhardt 1994 7/28 6/25 5.1 % 1.04 [ 0.40, 2.69 ]
Castel 2012 2/32 7/23 6.5 % 0.21 [ 0.05, 0.90 ]
de Souza 2008 1/29 4/26 3.4 % 0.22 [ 0.03, 1.88 ]
Edinger 2005 3/15 2/16 1.5 % 1.60 [ 0.31, 8.29 ]
Falcao 2008 5/20 4/22 3.0 % 1.38 [ 0.43, 4.42 ]
Hamnes 2012 17/58 12/60 9.4 % 1.47 [ 0.77, 2.79 ]
Hsu 2010 3/21 0/21 0.4 % 7.00 [ 0.38, 127.69 ]
Jensen 2012 6/19 3/15 2.7 % 1.58 [ 0.47, 5.29 ]
Luciano 2011 16/92 15/93 11.9 % 1.08 [ 0.57, 2.05 ]
Maddali-Bongh 2010 0/22 3/19 3.0 % 0.12 [ 0.01, 2.26 ]
Oliver 2001 42/165 23/170 18.1 % 1.88 [ 1.19, 2.98 ]
Scheidt 2013 4/20 3/20 2.4 % 1.33 [ 0.34, 5.21 ]
Vlaeyen 1996 4/19 3/14 2.8 % 0.98 [ 0.26, 3.71 ]
Wicksell 2013 7/13 4/16 2.9 % 2.15 [ 0.80, 5.78 ]
Wigers 1996 4/55 8/51 6.6 % 0.46 [ 0.15, 1.45 ]
Williams 2002 14/62 9/60 7.3 % 1.51 [ 0.71, 3.21 ]
Williams 2010 4/34 3/35 2.4 % 1.37 [ 0.33, 5.68 ]
Woolfolk 2012 10/39 1/42 0.8 % 10.77 [ 1.44, 80.29 ]
Total (95% CI) 847 840 100.0 % 1.38 [ 1.12, 1.69 ]
Total events: 168 (Experimental), 124 (Control)
Heterogeneity: Chi2 = 31.86, df = 21 (P = 0.06); I2 =34%
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Psychological Favours Control
128Mind and body therapy for fibromyalgia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.11. Comparison 1 Psychological therapies versus usual care, Outcome 11 Adverse events post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 11 Adverse events post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ang 2013 0/19 2/17 71.2 % 0.18 [ 0.01, 3.50 ]
Vlaeyen 1996 1/48 1/42 28.8 % 0.88 [ 0.06, 13.56 ]
Total (95% CI) 67 59 100.0 % 0.38 [ 0.06, 2.50 ]
Total events: 1 (Experimental), 3 (Control)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Psychological therapies versus usual care, Outcome 12 Fatigue as assessed
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 12 Fatigue as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hsu 2010 21 14.3 (4.14) 21 15.8 (2.62) 50.8 % -0.42 [ -1.04, 0.19 ]
Wigers 1996 20 70 (21) 20 63 (33) 49.2 % 0.25 [ -0.37, 0.87 ]
Total (95% CI) 41 41 100.0 % -0.09 [ -0.53, 0.34 ]
Heterogeneity: Chi2 = 2.28, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Psychological therapies versus usual care, Outcome 13 Fatigue as assessed at 6
months post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 13 Fatigue as assessed at 6 months post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hsu 2010 21 16.2 (3.17) 21 16.1 (3.73) 26.3 % 0.03 [ -0.58, 0.63 ]
Williams 2010 59 66.3 (11) 59 67.6 (12.2) 73.7 % -0.11 [ -0.47, 0.25 ]
Total (95% CI) 80 80 100.0 % -0.07 [ -0.38, 0.24 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Psychological therapies versus usual care, Outcome 14 Self-efficacy as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 14 Self-efficacy as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brattberg 2008 30 8.4 (4.8) 36 11.4 (6.2) 25.2 % -0.53 [ -1.02, -0.04 ]
Hamnes 2012 58 38.6 (13.6915) 60 42.1 (72.7759) 47.2 % -0.07 [ -0.43, 0.30 ]
Soares 2002 18 47.6 (21.95) 17 59.9 (20.35) 13.4 % -0.57 [ -1.24, 0.11 ]
Wicksell 2013 20 72.7 (36.5) 16 74.7 (24.1) 14.2 % -0.06 [ -0.72, 0.60 ]
Total (95% CI) 126 129 100.0 % -0.25 [ -0.50, 0.00 ]
Heterogeneity: Chi2 = 3.38, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Psychological therapies versus usual care, Outcome 15 Tender point count as
assessed at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 15 Tender point count as assessed at 6 month follow-up
Study or subgroup
Psychological
therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hsu 2010 21 0.96 (0.86) 21 1.34 (0.78) 100.0 % -0.38 [ -0.88, 0.12 ]
Total (95% CI) 21 21 100.0 % -0.38 [ -0.88, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Psychological therapies versus usual care, Outcome 16 Quality of life as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 16 Quality of life as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brattberg 2008 30 46.6 (16.3) 36 53.9 (18.8) 25.6 % -0.41 [ -0.90, 0.08 ]
Falcao 2008 25 31 (26.49) 26 33.47 (22.52) 20.4 % -0.10 [ -0.65, 0.45 ]
Hsu 2010 21 60.7 (10) 21 67.2 (10) 15.9 % -0.64 [ -1.26, -0.02 ]
Maddali-Bongh 2010 22 55.2 (8.01) 19 64.29 (9.37) 14.2 % -1.03 [ -1.69, -0.37 ]
Scheidt 2013 20 39.1 (2) 20 34.7 (2) 9.7 % 2.16 [ 1.36, 2.95 ]
Wicksell 2013 20 28.4 (8) 16 30.1 (9.9) 14.2 % -0.19 [ -0.85, 0.47 ]
Total (95% CI) 138 138 100.0 % -0.19 [ -0.44, 0.06 ]
Heterogeneity: Chi2 = 42.59, df = 5 (P<0.00001); I2 =88%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Psychological therapies versus usual care, Outcome 17 Quality of life as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 17 Quality of life as assessed at 3 month follow-up
Study or subgroup
Psychological
therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wicksell 2013 19 74.7 (8.4) 14 89.8 (10.8) 100.0 % -15.10 [ -21.90, -8.30 ]
Total (95% CI) 19 14 100.0 % -15.10 [ -21.90, -8.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.35 (P = 0.000014)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Psychological therapies versus usual care, Outcome 18 Quality of life as
assessed at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 18 Quality of life as assessed at 6 month follow-up
Study or subgroup
Psychological
therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hsu 2010 21 63.6 (9.58) 21 66.1 (8.41) 100.0 % -2.50 [ -7.95, 2.95 ]
Total (95% CI) 21 21 100.0 % -2.50 [ -7.95, 2.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Psychological therapies versus usual care, Outcome 19 Sleep as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 19 Sleep as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Castel 2012 34 60.2 (7.7) 30 72.2 (6.7) 23.5 % -1.64 [ -2.21, -1.06 ]
Hsu 2010 21 42.5 (20.8) 21 47.9 (18.8) 20.7 % -0.27 [ -0.88, 0.34 ]
Maddali-Bongh 2010 22 2.73 (3.41) 19 4.86 (1.66) 18.8 % -0.76 [ -1.40, -0.12 ]
Soares 2002 18 3.64 (0.91) 17 3.74 (0.8) 17.4 % -0.11 [ -0.78, 0.55 ]
Wigers 1996 20 57 (30) 20 44 (33) 19.5 % 0.40 [ -0.22, 1.03 ]
Total (95% CI) 115 107 100.0 % -0.52 [ -0.80, -0.25 ]
Heterogeneity: Chi2 = 25.63, df = 4 (P = 0.00004); I2 =84%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Psychological therapies versus usual care, Outcome 20 Sleep as assessed at 3
month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 20 Sleep as assessed at 3 month follow-up
Study or subgroup
Psychological
therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Castel 2012 30 59.9 (8.1) 34 71.2 (8.8) 100.0 % -11.30 [ -15.44, -7.16 ]
Total (95% CI) 30 34 100.0 % -11.30 [ -15.44, -7.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Psychological therapies versus usual care, Outcome 21 Sleep as assessed at 6
month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 21 Sleep as assessed at 6 month follow-up
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Castel 2012 30 60.1 (9.5) 34 72 (8.6) 24.7 % -1.30 [ -1.84, -0.76 ]
Hsu 2010 21 51.6 (18.3) 21 49.2 (19.5) 19.9 % 0.12 [ -0.48, 0.73 ]
Williams 2010 59 51.1 (16.5) 59 46.8 (16.7) 55.5 % 0.26 [ -0.11, 0.62 ]
Total (95% CI) 110 114 100.0 % -0.15 [ -0.42, 0.12 ]
Heterogeneity: Chi2 = 22.90, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Psychological therapies versus usual care, Outcome 22 Self-efficacy as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 1 Psychological therapies versus usual care
Outcome: 22 Self-efficacy as assessed at 3 month follow-up
Study or subgroup
Psychological
therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wicksell 2013 19 74.7 (24.1) 14 89.8 (53.1) 100.0 % -15.10 [ -44.95, 14.75 ]
Total (95% CI) 19 14 100.0 % -15.10 [ -44.95, 14.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Psychological therapies versus usual care sensitivity analyses, Outcome 1 Mood
as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 2 Psychological therapies versus usual care sensitivity analyses
Outcome: 1 Mood as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alda 2011 56 7.78 (2.46) 53 8.17 (2.25) 25.9 % -0.16 [ -0.54, 0.21 ]
Falcao 2008 25 7.56 (7.71) 26 13.96 (11.37) 11.5 % -0.65 [ -1.21, -0.08 ]
Hamnes 2012 58 25 (72.2608) 60 24.6 (56.5174) 28.2 % 0.01 [ -0.35, 0.37 ]
Jensen 2012 19 11 (5) 15 16 (10) 7.6 % -0.64 [ -1.34, 0.05 ]
Scheidt 2013 20 8.7 (0.9) 20 9.2 (0.9) 9.2 % -0.54 [ -1.18, 0.09 ]
Wicksell 2013 20 11.7 (6) 16 14.8 (7.8) 8.3 % -0.44 [ -1.11, 0.22 ]
Wigers 1996 20 24 (22) 20 36 (35) 9.3 % -0.40 [ -1.03, 0.22 ]
Total (95% CI) 218 210 100.0 % -0.29 [ -0.48, -0.10 ]
Heterogeneity: Chi2 = 6.48, df = 6 (P = 0.37); I2 =7%
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Psychological therapies versus usual care sensitivity analyses, Outcome 2 Mood
as assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 2 Psychological therapies versus usual care sensitivity analyses
Outcome: 2 Mood as assessed at 3 month follow-up
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Falcao 2008 25 10.56 (9.28) 26 15.61 (12.15) 45.0 % -0.46 [ -1.02, 0.10 ]
Jensen 2012 19 10 (4) 15 18 (12) 27.2 % -0.92 [ -1.64, -0.20 ]
Wicksell 2013 19 10.7 (4.8) 14 16.4 (12.5) 27.8 % -0.63 [ -1.33, 0.08 ]
Total (95% CI) 63 55 100.0 % -0.63 [ -1.00, -0.26 ]
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.31 (P = 0.00093)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Psychological therapies versus usual care sensitivity analyses, Outcome 3
Fatigue as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 2 Psychological therapies versus usual care sensitivity analyses
Outcome: 3 Fatigue as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hsu 2010 21 14.3 (4.14) 21 15.8 (2.62) 100.0 % -0.42 [ -1.04, 0.19 ]
Total (95% CI) 21 21 100.0 % -0.42 [ -1.04, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Psychological therapies versus usual care sensitivity analyses, Outcome 4 Sleep
as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 2 Psychological therapies versus usual care sensitivity analyses
Outcome: 4 Sleep as assessed post-intervention
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hsu 2010 21 42.5 (20.8) 21 47.9 (18.8) 27.1 % -0.27 [ -0.88, 0.34 ]
Maddali-Bongh 2010 22 2.73 (3.41) 19 4.86 (1.66) 24.6 % -0.76 [ -1.40, -0.12 ]
Soares 2002 18 3.64 (0.91) 17 3.74 (0.8) 22.8 % -0.11 [ -0.78, 0.55 ]
Wigers 1996 20 57 (30) 20 44 (33) 25.5 % 0.40 [ -0.22, 1.03 ]
Total (95% CI) 81 77 100.0 % -0.18 [ -0.50, 0.13 ]
Heterogeneity: Chi2 = 6.64, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Psychological therapies versus usual care sensitivity analyses, Outcome 5 Sleep
as assessed at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 2 Psychological therapies versus usual care sensitivity analyses
Outcome: 5 Sleep as assessed at 6 month follow-up
Study or subgroup
Psychological
therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hsu 2010 21 51.6 (18.3) 21 49.2 (19.5) 26.4 % 0.12 [ -0.48, 0.73 ]
Williams 2010 59 51.1 (16.5) 59 46.8 (16.7) 73.6 % 0.26 [ -0.11, 0.62 ]
Total (95% CI) 80 80 100.0 % 0.22 [ -0.09, 0.53 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Psychological therapies versus attention control, Outcome 1 Functioning as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Miro 2011 20 49.25 (21.38) 20 63.67 (16.08) 6.8 % -0.75 [ -1.39, -0.10 ]
Fontaine 2010 46 56.7 (20.6) 38 67 (18.6) 14.8 % -0.52 [ -0.95, -0.08 ]
Lera 2009 35 53.2 (13.4) 31 57.2 (11.3) 12.0 % -0.32 [ -0.80, 0.17 ]
Thieme 2006 40 3.64 (2.3) 20 4.03 (2.09) 9.8 % -0.17 [ -0.71, 0.37 ]
Langford 2009 41 51.24 (19.28) 30 52.7 (15.7) 12.8 % -0.08 [ -0.55, 0.39 ]
Gillis 2006 37 56.6 (20.42) 32 53.31 (17.79) 12.6 % 0.17 [ -0.31, 0.64 ]
Stuifbergen 2010 88 58.86 (15.9) 83 54.9 (19.3) 31.3 % 0.22 [ -0.08, 0.52 ]
Total (95% CI) 307 254 100.0 % -0.10 [ -0.27, 0.07 ]
Heterogeneity: Chi2 = 13.91, df = 6 (P = 0.03); I2 =57%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Psychological therapies versus attention control, Outcome 2 Functioning as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 2 Functioning as assessed at 3 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gillis 2006 36 52.7 (20.35) 32 53.79 (18.13) 15.2 % -0.06 [ -0.53, 0.42 ]
Hammond 2006 53 53.6 (14.55) 51 53.18 (11.39) 23.3 % 0.03 [ -0.35, 0.42 ]
Langford 2009 54 54 (18.02) 51 53.96 (13.86) 23.5 % 0.00 [ -0.38, 0.39 ]
Stuifbergen 2010 87 56 (19.7) 83 55 (19.5) 38.0 % 0.05 [ -0.25, 0.35 ]
Total (95% CI) 230 217 100.0 % 0.02 [ -0.17, 0.20 ]
Heterogeneity: Chi2 = 0.15, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Psychological therapies versus attention control, Outcome 3 Functioning as
assessed at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 3 Functioning as assessed at 6 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hammond 2006 52 55.66 (15.26) 49 51.36 (12.57) 31.7 % 0.30 [ -0.09, 0.70 ]
Stuifbergen 2010 84 54 (19.6) 81 53.2 (20.5) 52.4 % 0.04 [ -0.27, 0.34 ]
Thieme 2006 40 3 (2.43) 20 4.77 (2.6) 16.0 % -0.70 [ -1.25, -0.15 ]
Total (95% CI) 176 150 100.0 % 0.00 [ -0.22, 0.23 ]
Heterogeneity: Chi2 = 8.59, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Psychological therapies versus attention control, Outcome 4 Pain as assessed
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 4 Pain as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fontaine 2010 46 46.3 (24.2) 38 62.4 (24.5) 25.8 % -0.66 [ -1.10, -0.21 ]
Gillis 2006 37 3.32 (0.98) 32 3.2 (0.88) 22.4 % 0.13 [ -0.35, 0.60 ]
Langford 2009 41 203.1 (68.9) 30 203.86 (66.57) 22.6 % -0.01 [ -0.48, 0.46 ]
Miro 2011 20 6.5 (2.46) 20 8.26 (1.48) 11.9 % -0.85 [ -1.50, -0.20 ]
Thieme 2006 40 3.54 (1.03) 20 3.79 (1.07) 17.3 % -0.24 [ -0.78, 0.30 ]
Total (95% CI) 184 140 100.0 % -0.28 [ -0.51, -0.06 ]
Heterogeneity: Chi2 = 9.84, df = 4 (P = 0.04); I2 =59%
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Psychological therapies versus attention control, Outcome 5 Pain as assessed at
3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 5 Pain as assessed at 3 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gillis 2006 36 3.51 (0.91) 32 3.34 (0.87) 59.5 % 0.19 [ -0.29, 0.67 ]
Langford 2009 27 201.3 (75.33) 20 198.43 (62.85) 40.5 % 0.04 [ -0.54, 0.62 ]
Total (95% CI) 63 52 100.0 % 0.13 [ -0.24, 0.50 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Psychological therapies versus attention control, Outcome 6 Pain as assessed at
6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 6 Pain as assessed at 6 month follow-up
Study or subgroup
Psychological
Therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Thieme 2006 40 3.73 (0.94) 20 4.07 (1.07) 100.0 % -0.34 [ -0.89, 0.21 ]
Total (95% CI) 40 20 100.0 % -0.34 [ -0.89, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 Psychological therapies versus attention control, Outcome 7 Mood as assessed
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 7 Mood as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fontaine 2010 46 21.6 (9.8) 38 21.2 (11.3) 25.7 % 0.04 [ -0.39, 0.47 ]
Gillis 2006 37 2.88 (0.78) 32 3.06 (0.7) 21.0 % -0.24 [ -0.71, 0.24 ]
Langford 2009 41 1.51 (0.97) 30 1.36 (0.78) 21.3 % 0.17 [ -0.31, 0.64 ]
Lera 2009 35 55.8 (9.2) 31 58.7 (7.4) 20.0 % -0.34 [ -0.83, 0.15 ]
Miro 2011 20 9.65 (4.39) 20 11.3 (4.61) 12.1 % -0.36 [ -0.98, 0.27 ]
Total (95% CI) 179 151 100.0 % -0.12 [ -0.33, 0.10 ]
Heterogeneity: Chi2 = 3.52, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Psychological therapies versus attention control, Outcome 8 Mood as assessed
at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 8 Mood as assessed at 3 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gillis 2006 36 3.09 (0.71) 32 2.86 (0.78) 59.4 % 0.31 [ -0.17, 0.78 ]
Langford 2009 27 1.56 (0.94) 20 1.44 (0.76) 40.6 % 0.14 [ -0.44, 0.71 ]
Total (95% CI) 63 52 100.0 % 0.24 [ -0.13, 0.61 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Psychological therapies versus attention control, Outcome 9 All cause attrition
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 9 All cause attrition post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fontaine 2010 6/40 5/33 5.2 % 0.99 [ 0.33, 2.96 ]
Gillis 2006 1/37 2/32 2.0 % 0.43 [ 0.04, 4.55 ]
Hammond 2006 18/53 26/36 29.6 % 0.47 [ 0.31, 0.72 ]
Langford 2009 5/49 1/50 0.9 % 5.10 [ 0.62, 42.11 ]
Lera 2009 8/35 7/33 6.9 % 1.08 [ 0.44, 2.64 ]
Miro 2011 2/20 2/20 1.9 % 1.00 [ 0.16, 6.42 ]
Stuifbergen 2010 35/88 28/83 27.5 % 1.18 [ 0.79, 1.75 ]
Thieme 2006 2/40 20/20 25.9 % 0.06 [ 0.02, 0.21 ]
Total (95% CI) 362 307 100.0 % 0.68 [ 0.54, 0.87 ]
Total events: 77 (Experimental), 91 (Control)
Heterogeneity: Chi2 = 30.66, df = 7 (P = 0.00007); I2 =77%
Test for overall effect: Z = 3.13 (P = 0.0017)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Psychological therapies versus attention control, Outcome 10 Fatigue as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 10 Fatigue as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fontaine 2010 46 50.6 (9.9) 38 51.4 (10.1) 54.9 % -0.08 [ -0.51, 0.35 ]
Gillis 2006 37 5.49 (1.33) 32 5.7 (1.09) 45.1 % -0.17 [ -0.64, 0.30 ]
Total (95% CI) 83 70 100.0 % -0.12 [ -0.44, 0.20 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Psychological therapies versus attention control, Outcome 11 Fatigue as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 11 Fatigue as assessed at 3 month follow-up
Study or subgroup
Psychological
Therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gillis 2006 37 5.66 (1.24) 32 5.84 (1.11) 100.0 % -0.18 [ -0.73, 0.37 ]
Total (95% CI) 37 32 100.0 % -0.18 [ -0.73, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 Psychological therapies versus attention control, Outcome 12 Self-efficacy as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 12 Self-efficacy as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Langford 2009 54 5.8 (2.18) 51 5.32 (1.7) 100.0 % 0.48 [ -0.27, 1.23 ]
Total (95% CI) 54 51 100.0 % 0.48 [ -0.27, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Psychological therapies versus attention control, Outcome 13 Self efficacy as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 13 Self efficacy as assessed at 3 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hammond 2006 53 45.15 (2.03) 51 45.92 (1.65) 68.9 % -0.41 [ -0.80, -0.02 ]
Langford 2009 27 44.76 (2.03) 20 44.67 (1.6) 31.1 % 0.05 [ -0.53, 0.63 ]
Total (95% CI) 80 71 100.0 % -0.27 [ -0.59, 0.05 ]
Heterogeneity: Chi2 = 1.67, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 Psychological therapies versus attention control, Outcome 14 Self-efficacy as
assessed at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 14 Self-efficacy as assessed at 6 month follow-up
Study or subgroup
Psychological
Therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hammond 2006 13 4.23 (1.85) 19 4.22 (1.9) 100.0 % 0.01 [ -1.31, 1.33 ]
Total (95% CI) 13 19 100.0 % 0.01 [ -1.31, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 3.15. Comparison 3 Psychological therapies versus attention control, Outcome 15 Tender point
score as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 15 Tender point score as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fontaine 2010 46 16 (2.3) 38 16.8 (2) 79.9 % -0.80 [ -1.72, 0.12 ]
Lera 2009 35 12.1 (4.2) 31 12.9 (3.4) 20.1 % -0.80 [ -2.64, 1.04 ]
Total (95% CI) 81 69 100.0 % -0.80 [ -1.62, 0.02 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.057)
Test for subgroup differences: Not applicable
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Analysis 3.16. Comparison 3 Psychological therapies versus attention control, Outcome 16 Quality of life as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 16 Quality of life as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Langford 2009 41 30.2 (14.58) 30 32.42 (11.07) 22.7 % -0.17 [ -0.64, 0.31 ]
Lera 2009 35 60.5 (20.4) 31 69.3 (14.4) 21.0 % -0.49 [ -0.98, 0.00 ]
Stuifbergen 2010 88 67.8 (8.9) 83 67.6 (9.5) 56.3 % 0.02 [ -0.28, 0.32 ]
Total (95% CI) 164 144 100.0 % -0.13 [ -0.35, 0.10 ]
Heterogeneity: Chi2 = 3.04, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.11 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 3.17. Comparison 3 Psychological therapies versus attention control, Outcome 17 Quality of life as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 17 Quality of life as assessed at 3 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Langford 2009 27 31.57 (15.2) 20 32.07 (10.52) 21.2 % -0.04 [ -0.61, 0.54 ]
Stuifbergen 2010 88 44 (19.7) 83 45 (19.5) 78.8 % -0.05 [ -0.35, 0.25 ]
Total (95% CI) 115 103 100.0 % -0.05 [ -0.31, 0.22 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 3.18. Comparison 3 Psychological therapies versus attention control, Outcome 18 Quality of life as
assessed at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 18 Quality of life as assessed at 6 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stuifbergen 2010 88 46 (19.6) 83 46.8 (20.5) 100.0 % -0.04 [ -0.34, 0.26 ]
Total (95% CI) 88 83 100.0 % -0.04 [ -0.34, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 3.19. Comparison 3 Psychological therapies versus attention control, Outcome 19 Sleep as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 19 Sleep as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gillis 2006 37 4.28 (1.05) 32 4.19 (0.83) 64.0 % 0.09 [ -0.38, 0.57 ]
Miro 2011 20 11.25 (4.29) 20 13.2 (3.12) 36.0 % -0.51 [ -1.14, 0.12 ]
Total (95% CI) 57 52 100.0 % -0.12 [ -0.50, 0.25 ]
Heterogeneity: Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 3.20. Comparison 3 Psychological therapies versus attention control, Outcome 20 Sleep as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 3 Psychological therapies versus attention control
Outcome: 20 Sleep as assessed at 3 month follow-up
Study or subgroup
Psychological
Therapies Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gillis 2006 37 4.23 (1.06) 32 4.22 (0.9) 100.0 % 0.01 [ -0.45, 0.47 ]
Total (95% CI) 37 32 100.0 % 0.01 [ -0.45, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Psychological therapies versus attention control sensitivity analyses, Outcome 1
Functioning as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 4 Psychological therapies versus attention control sensitivity analyses
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Miro 2011 20 49.25 (21.38) 20 63.67 (16.08) 9.9 % -0.75 [ -1.39, -0.10 ]
Fontaine 2010 46 56.7 (20.6) 38 67 (18.6) 21.6 % -0.52 [ -0.95, -0.08 ]
Lera 2009 35 53.2 (13.4) 31 57.2 (11.3) 17.4 % -0.32 [ -0.80, 0.17 ]
Thieme 2006 40 3.64 (2.3) 20 4.03 (2.09) 14.2 % -0.17 [ -0.71, 0.37 ]
Langford 2009 41 51.24 (19.28) 30 52.7 (15.7) 18.6 % -0.08 [ -0.55, 0.39 ]
Gillis 2006 37 56.6 (20.42) 32 53.31 (17.79) 18.3 % 0.17 [ -0.31, 0.64 ]
Total (95% CI) 219 171 100.0 % -0.25 [ -0.45, -0.05 ]
Heterogeneity: Chi2 = 7.38, df = 5 (P = 0.19); I2 =32%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Psychological therapies versus attention control sensitivity analyses, Outcome 2
Functioning as assessed at 6 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 4 Psychological therapies versus attention control sensitivity analyses
Outcome: 2 Functioning as assessed at 6 month follow-up
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hammond 2006 52 55.66 (15.26) 49 51.36 (12.57) 37.7 % 0.30 [ -0.09, 0.70 ]
Stuifbergen 2010 84 54 (19.6) 81 53.2 (20.5) 62.3 % 0.04 [ -0.27, 0.34 ]
Total (95% CI) 136 130 100.0 % 0.14 [ -0.10, 0.38 ]
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Psychological therapies versus attention control sensitivity analyses, Outcome 3
Pain as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 4 Psychological therapies versus attention control sensitivity analyses
Outcome: 3 Pain as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fontaine 2010 46 46.3 (24.2) 38 62.4 (24.5) 33.2 % -0.66 [ -1.10, -0.21 ]
Langford 2009 41 203.1 (68.9) 30 203.86 (66.57) 29.2 % -0.01 [ -0.48, 0.46 ]
Miro 2011 20 6.5 (2.46) 20 8.26 (1.48) 15.3 % -0.85 [ -1.50, -0.20 ]
Thieme 2006 40 3.54 (1.03) 20 3.79 (1.07) 22.3 % -0.24 [ -0.78, 0.30 ]
Total (95% CI) 147 108 100.0 % -0.40 [ -0.66, -0.15 ]
Heterogeneity: Chi2 = 6.10, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 3.11 (P = 0.0019)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Psychological therapies versus attention control sensitivity analyses, Outcome 4
Sleep as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 4 Psychological therapies versus attention control sensitivity analyses
Outcome: 4 Sleep as assessed post-intervention
Study or subgroup
Psychological
Therapies Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Miro 2011 20 11.25 (4.29) 20 13.2 (3.12) 100.0 % -0.51 [ -1.14, 0.12 ]
Total (95% CI) 20 20 100.0 % -0.51 [ -1.14, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Biofeedback versus usual care, Outcome 1 Functioning as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Biofeedback Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 37.11 (14.89) 18 35.23 (17.16) 34.9 % 0.11 [ -0.54, 0.77 ]
Van Santen 2002 42 2.7 (8.9852) 28 4.6 (16.5051) 65.1 % -0.15 [ -0.63, 0.33 ]
Total (95% CI) 60 46 100.0 % -0.06 [ -0.44, 0.33 ]
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Biofeedback versus usual care, Outcome 2 Functioning as assessed at 3 month
follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 2 Functioning as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 37.87 (9.65) 18 38.28 (15.58) 100.0 % -0.41 [ -8.88, 8.06 ]
Total (95% CI) 18 18 100.0 % -0.41 [ -8.88, 8.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Biofeedback versus usual care, Outcome 3 Pain as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 3 Pain as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Van Santen 2002 38 58.5 (197.7536) 27 61.1 (165.8296) 100.0 % -2.60 [ -91.29, 86.09 ]
Total (95% CI) 38 27 100.0 % -2.60 [ -91.29, 86.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Biofeedback versus usual care, Outcome 4 Mood as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 4 Mood as assessed post-intervention
Study or subgroup Biofeedback Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 16.11 (8.78) 18 12.89 (7.3) 34.9 % 0.39 [ -0.27, 1.05 ]
Van Santen 2002 40 167.1 (594.0925) 28 175.8 (504.4364) 65.1 % -0.02 [ -0.50, 0.47 ]
Total (95% CI) 58 46 100.0 % 0.13 [ -0.26, 0.52 ]
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Biofeedback versus usual care, Outcome 5 Mood as assessed at 3 month follow-
up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 5 Mood as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 16.91 (8.33) 18 12.3 (6.1) 100.0 % 4.61 [ -0.16, 9.38 ]
Total (95% CI) 18 18 100.0 % 4.61 [ -0.16, 9.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Biofeedback versus usual care, Outcome 6 All cause attrition post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 6 All cause attrition post-intervention
Study or subgroup Biofeedback Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baumuller 2009 1/19 1/19 25.1 % 1.00 [ 0.07, 14.85 ]
Kayiran 2010 2/18 2/18 50.2 % 1.00 [ 0.16, 6.35 ]
Van Santen 2002 13/25 1/26 24.6 % 13.52 [ 1.91, 95.83 ]
Total (95% CI) 62 63 100.0 % 4.08 [ 1.43, 11.62 ]
Total events: 16 (Biofeedback), 4 (Control)
Heterogeneity: Chi2 = 4.71, df = 2 (P = 0.10); I2 =58%
Test for overall effect: Z = 2.64 (P = 0.0084)
Test for subgroup differences: Not applicable
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Analysis 5.7. Comparison 5 Biofeedback versus usual care, Outcome 7 Tender point score as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 7 Tender point score as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 14.74 (1.91) 18 15.68 (2.29) 98.9 % -0.94 [ -2.32, 0.44 ]
Van Santen 2002 38 8.4 (32.8575) 27 7.8 (20.9815) 1.1 % 0.60 [ -12.51, 13.71 ]
Total (95% CI) 56 45 100.0 % -0.92 [ -2.29, 0.45 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours biofeedback Favours usual care
165Mind and body therapy for fibromyalgia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.8. Comparison 5 Biofeedback versus usual care, Outcome 8 Tender point score as assessed at 3
month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 8 Tender point score as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 3.08 (1.27) 18 3.17 (1.06) 100.0 % -0.09 [ -0.85, 0.67 ]
Total (95% CI) 18 18 100.0 % -0.09 [ -0.85, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 5.9. Comparison 5 Biofeedback versus usual care, Outcome 9 Quality of life (Physical functioning)
as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 9 Quality of life (Physical functioning) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 49.31 (19.41) 18 54.23 (24.34) 100.0 % -4.92 [ -19.30, 9.46 ]
Total (95% CI) 18 18 100.0 % -4.92 [ -19.30, 9.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 5.10. Comparison 5 Biofeedback versus usual care, Outcome 10 Quality of life (Role-Physical) as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 10 Quality of life (Role-Physical) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 14.06 (27.34) 18 33.33 (38.35) 100.0 % -19.27 [ -41.03, 2.49 ]
Total (95% CI) 18 18 100.0 % -19.27 [ -41.03, 2.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.083)
Test for subgroup differences: Not applicable
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Analysis 5.11. Comparison 5 Biofeedback versus usual care, Outcome 11 Quality of life (Bodily Pain) as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 11 Quality of life (Bodily Pain) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 36.71 (16) 18 30.44 (16.92) 100.0 % 6.27 [ -4.49, 17.03 ]
Total (95% CI) 18 18 100.0 % 6.27 [ -4.49, 17.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 5.12. Comparison 5 Biofeedback versus usual care, Outcome 12 Quality of life (General Health) as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 12 Quality of life (General Health) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 36.53 (19.21) 18 44.67 (18.53) 100.0 % -8.14 [ -20.47, 4.19 ]
Total (95% CI) 18 18 100.0 % -8.14 [ -20.47, 4.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 5.13. Comparison 5 Biofeedback versus usual care, Outcome 13 Quality of life (Vitality) as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 13 Quality of life (Vitality) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 28.24 (17.58) 18 41.67 (14.85) 100.0 % -13.43 [ -24.06, -2.80 ]
Total (95% CI) 18 18 100.0 % -13.43 [ -24.06, -2.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 5.14. Comparison 5 Biofeedback versus usual care, Outcome 14 Quality of life (Social Functioning)
as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 14 Quality of life (Social Functioning) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 50 (22.1) 18 60.42 (27.2) 100.0 % -10.42 [ -26.61, 5.77 ]
Total (95% CI) 18 18 100.0 % -10.42 [ -26.61, 5.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 5.15. Comparison 5 Biofeedback versus usual care, Outcome 15 Quality of life (Role-Emotional) as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 15 Quality of life (Role-Emotional) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 47.92 (47.09) 18 57.41 (43.99) 100.0 % -9.49 [ -39.26, 20.28 ]
Total (95% CI) 18 18 100.0 % -9.49 [ -39.26, 20.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 5.16. Comparison 5 Biofeedback versus usual care, Outcome 16 Quality of life (Mental Health) as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 16 Quality of life (Mental Health) as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 51.35 (20.14) 18 60.67 (21.49) 100.0 % -9.32 [ -22.93, 4.29 ]
Total (95% CI) 18 18 100.0 % -9.32 [ -22.93, 4.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 5.17. Comparison 5 Biofeedback versus usual care, Outcome 17 Quality of life (Physical
functioning) as assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 17 Quality of life (Physical functioning) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 51.64 (21.01) 18 51.64 (21.01) 100.0 % 0.0 [ -13.73, 13.73 ]
Total (95% CI) 18 18 100.0 % 0.0 [ -13.73, 13.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.18. Comparison 5 Biofeedback versus usual care, Outcome 18 Quality of life (Role-Physical) as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 18 Quality of life (Role-Physical) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 15.62 (25.62) 18 20.83 (32.37) 100.0 % -5.21 [ -24.28, 13.86 ]
Total (95% CI) 18 18 100.0 % -5.21 [ -24.28, 13.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 5.19. Comparison 5 Biofeedback versus usual care, Outcome 19 Quality of life (Bodily Pain) as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 19 Quality of life (Bodily Pain) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 36.88 (11.52) 18 36.17 (15.34) 100.0 % 0.71 [ -8.15, 9.57 ]
Total (95% CI) 18 18 100.0 % 0.71 [ -8.15, 9.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 5.20. Comparison 5 Biofeedback versus usual care, Outcome 20 Quality of life (Social Functioning)
as assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 20 Quality of life (Social Functioning) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 53.68 (25.68) 18 61.11 (25.69) 100.0 % -7.43 [ -24.21, 9.35 ]
Total (95% CI) 18 18 100.0 % -7.43 [ -24.21, 9.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 5.21. Comparison 5 Biofeedback versus usual care, Outcome 21 Quality of life (General Health) as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 21 Quality of life (General Health) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 43.5 (16.5) 18 44.44 (18.33) 100.0 % -0.94 [ -12.33, 10.45 ]
Total (95% CI) 18 18 100.0 % -0.94 [ -12.33, 10.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 5.22. Comparison 5 Biofeedback versus usual care, Outcome 22 Quality of life (Vitality) as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 22 Quality of life (Vitality) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 28.63 (16.35) 18 38.8 (15.49) 100.0 % -10.17 [ -20.57, 0.23 ]
Total (95% CI) 18 18 100.0 % -10.17 [ -20.57, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 5.23. Comparison 5 Biofeedback versus usual care, Outcome 23 Quality of life (Role-Emotional) as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 23 Quality of life (Role-Emotional) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 35.42 (42.98) 18 59.26 (47.9) 100.0 % -23.84 [ -53.57, 5.89 ]
Total (95% CI) 18 18 100.0 % -23.84 [ -53.57, 5.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 5.24. Comparison 5 Biofeedback versus usual care, Outcome 24 Quality of life (Mental Health) as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 5 Biofeedback versus usual care
Outcome: 24 Quality of life (Mental Health) as assessed at 3 month follow-up
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Baumuller 2009 18 51.06 (17.86) 18 57.5 (18.36) 100.0 % -6.44 [ -18.27, 5.39 ]
Total (95% CI) 18 18 100.0 % -6.44 [ -18.27, 5.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Biofeedback versus attention control, Outcome 1 Functioning as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 6 Biofeedback versus attention control
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Babu 2007 15 52.66 (16.95) 15 39.06 (18.09) 100.0 % 13.60 [ 1.05, 26.15 ]
Total (95% CI) 15 15 100.0 % 13.60 [ 1.05, 26.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Biofeedback versus attention control, Outcome 2 Pain as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 6 Biofeedback versus attention control
Outcome: 2 Pain as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Babu 2007 15 5.46 (2.32) 15 2.8 (1.69) 100.0 % 2.66 [ 1.21, 4.11 ]
Total (95% CI) 15 15 100.0 % 2.66 [ 1.21, 4.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Biofeedback versus attention control, Outcome 3 All cause attrition post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 6 Biofeedback versus attention control
Outcome: 3 All cause attrition post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Babu 2007 0/15 0/15 Not estimable
Bakker 1995 5/26 1/18 100.0 % 3.46 [ 0.44, 27.19 ]
Total (95% CI) 41 33 100.0 % 3.46 [ 0.44, 27.19 ]
Total events: 5 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Biofeedback versus attention control, Outcome 4 Tender point score as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 6 Biofeedback versus attention control
Outcome: 4 Tender point score as assessed post-intervention
Study or subgroup Biofeedback Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Babu 2007 15 9.53 (3.77) 15 6.6 (3.99) 100.0 % 2.93 [ 0.15, 5.71 ]
Total (95% CI) 15 15 100.0 % 2.93 [ 0.15, 5.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Mindfulness versus usual care, Outcome 1 Functioning as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Mindfulness Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parra-Delgado 2013 15 61.77 (13.65) 16 66.2 (17.22) 24.2 % -0.28 [ -0.98, 0.43 ]
Schmidt 2011 45 4.9 (1.74) 52 5.32 (1.62) 75.8 % -0.25 [ -0.65, 0.15 ]
Total (95% CI) 60 68 100.0 % -0.26 [ -0.60, 0.09 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Mindfulness versus usual care, Outcome 2 Functioning assessed at 3 month
follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 2 Functioning assessed at 3 month follow-up
Study or subgroup Mindfulness Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schmidt 2011 47 5.23 (2) 56 5.29 (1.66) 100.0 % -0.06 [ -0.78, 0.66 ]
Total (95% CI) 47 56 100.0 % -0.06 [ -0.78, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Mindfulness versus usual care, Outcome 3 Pain as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 3 Pain as assessed post-intervention
Study or subgroup Mindfulness Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parra-Delgado 2013 15 2.04 (0.2) 16 2.07 (0.21) 24.3 % -0.14 [ -0.85, 0.56 ]
Schmidt 2011 45 20.78 (4.98) 52 21.17 (5.75) 75.7 % -0.07 [ -0.47, 0.33 ]
Total (95% CI) 60 68 100.0 % -0.09 [ -0.44, 0.26 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Mindfulness versus usual care, Outcome 4 Pain as assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 4 Pain as assessed at 3 month follow-up
Study or subgroup Mindfulness Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schmidt 2011 47 21.16 (5.42) 56 21.44 (5.34) 100.0 % -0.28 [ -2.37, 1.81 ]
Total (95% CI) 47 56 100.0 % -0.28 [ -2.37, 1.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Mindfulness versus usual care, Outcome 5 Mood as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 5 Mood as assessed post-intervention
Study or subgroup Mindfulness Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parra-Delgado 2013 15 13 (6.35) 16 15.44 (6.88) 14.2 % -0.36 [ -1.07, 0.35 ]
Schmidt 2011 45 23.2 (9.04) 52 24.22 (10.28) 45.1 % -0.10 [ -0.50, 0.30 ]
Sephton 2007 51 12.4 (7.4) 39 15.1 (8.1) 40.7 % -0.35 [ -0.77, 0.07 ]
Total (95% CI) 111 107 100.0 % -0.24 [ -0.51, 0.03 ]
Heterogeneity: Chi2 = 0.80, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Mindfulness versus usual care, Outcome 6 Mood as assessed at 3 month follow-
up.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 6 Mood as assessed at 3 month follow-up
Study or subgroup Mindfulness Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schmidt 2011 47 21.7 (9.93) 56 24 (9.61) 53.6 % -0.23 [ -0.62, 0.16 ]
Sephton 2007 51 13.3 (7.5) 39 14.8 (8.1) 46.4 % -0.19 [ -0.61, 0.23 ]
Total (95% CI) 98 95 100.0 % -0.21 [ -0.50, 0.07 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 7.7. Comparison 7 Mindfulness versus usual care, Outcome 7 All cause attrition post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 7 All cause attrition post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Parra-Delgado 2013 2/15 0/16 2.0 % 5.31 [ 0.28, 102.38 ]
Schmidt 2011 14/45 8/51 31.7 % 1.98 [ 0.92, 4.29 ]
Sephton 2007 10/41 13/27 66.3 % 0.51 [ 0.26, 0.99 ]
Total (95% CI) 101 94 100.0 % 1.07 [ 0.67, 1.72 ]
Total events: 26 (Experimental), 21 (Control)
Heterogeneity: Chi2 = 8.44, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 7.8. Comparison 7 Mindfulness versus usual care, Outcome 8 Sleep as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 8 Sleep as assessed post-intervention
Study or subgroup Mindfulness Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Schmidt 2011 45 10.04 (3.76) 52 10.68 (4.42) 100.0 % -0.64 [ -2.27, 0.99 ]
Total (95% CI) 45 52 100.0 % -0.64 [ -2.27, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 7.9. Comparison 7 Mindfulness versus usual care, Outcome 9 Sleep as assessed at 3 month follow-
up.
Review: Mind and body therapy for fibromyalgia
Comparison: 7 Mindfulness versus usual care
Outcome: 9 Sleep as assessed at 3 month follow-up
Study or subgroup Mindfulness Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parra-Delgado 2013 15 13.13 (5.34) 16 17.75 (5.86) 21.7 % -0.80 [ -1.54, -0.07 ]
Schmidt 2011 47 10.01 (3.6) 56 10.37 (4.42) 78.3 % -0.09 [ -0.48, 0.30 ]
Total (95% CI) 62 72 100.0 % -0.24 [ -0.59, 0.10 ]
Heterogeneity: Chi2 = 2.82, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Mindfulness versus usual care - sensitivity analyses, Outcome 1 Mood as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 8 Mindfulness versus usual care - sensitivity analyses
Outcome: 1 Mood as assessed at 3 month follow-up
Study or subgroup Mindfulness Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sephton 2007 51 13.3 (7.5) 39 14.8 (8.1) 100.0 % -1.50 [ -4.77, 1.77 ]
Total (95% CI) 51 39 100.0 % -1.50 [ -4.77, 1.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Movement therapies versus usual care, Outcome 1 Functioning as assessed
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carson 2010 19 35.49 (17.61) 26 48.69 (18.88) 30.7 % -0.71 [ -1.32, -0.10 ]
Carson 2012 22 34.5 (16.8) 26 28.3 (13.3) 34.7 % 0.41 [ -0.17, 0.98 ]
Holmer 2004 11 11.33 (2.77) 17 14.24 (4.16) 18.4 % -0.77 [ -1.55, 0.02 ]
Mannerkorpi 2004 12 7.3 (0.9) 10 7.1 (1.7) 16.2 % 0.15 [ -0.69, 0.99 ]
Total (95% CI) 64 79 100.0 % -0.19 [ -0.53, 0.15 ]
Heterogeneity: Chi2 = 9.55, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Movement therapies versus usual care, Outcome 2 Pain as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 2 Pain as assessed post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Holmer 2004 11 4.08 (2.25) 17 6.38 (2.84) 100.0 % -2.30 [ -4.19, -0.41 ]
Total (95% CI) 11 17 100.0 % -2.30 [ -4.19, -0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Movement therapies versus usual care, Outcome 3 Mood as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 3 Mood as assessed post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Holmer 2004 12 14.75 (12.2) 17 24.59 (11.02) 100.0 % -9.84 [ -18.51, -1.17 ]
Total (95% CI) 12 17 100.0 % -9.84 [ -18.51, -1.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Movement therapies versus usual care, Outcome 4 All cause attrition post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 4 All cause attrition post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bojner-Horwitz 2003 0/20 0/16 Not estimable
Carson 2010 6/19 2/26 12.9 % 4.11 [ 0.93, 18.16 ]
Carson 2012 3/22 2/26 14.0 % 1.77 [ 0.32, 9.67 ]
Lynch 2012 9/44 2/45 15.1 % 4.60 [ 1.05, 20.11 ]
Mannerkorpi 2004 7/12 7/10 58.1 % 0.83 [ 0.45, 1.56 ]
Total (95% CI) 117 123 100.0 % 1.95 [ 1.13, 3.38 ]
Total events: 25 (Experimental), 13 (Control)
Heterogeneity: Chi2 = 9.35, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Movement therapies versus usual care, Outcome 5 Adverse events post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 5 Adverse events post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lynch 2012 2/51 0/47 100.0 % 4.62 [ 0.23, 93.72 ]
Total (95% CI) 51 47 100.0 % 4.62 [ 0.23, 93.72 ]
Total events: 2 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Movement Favours Control
Analysis 9.6. Comparison 9 Movement therapies versus usual care, Outcome 6 Fatigue as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 6 Fatigue as assessed post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Holmer 2004 12 24.98 (10.78) 17 35.78 (10.11) 100.0 % -10.80 [ -18.57, -3.03 ]
Total (95% CI) 12 17 100.0 % -10.80 [ -18.57, -3.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
Test for subgroup differences: Not applicable
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Analysis 9.7. Comparison 9 Movement therapies versus usual care, Outcome 7 Tender point count as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 7 Tender point count as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carson 2010 19 2.68 (2.59) 26 4.14 (2.19) 49.6 % -0.61 [ -1.21, 0.00 ]
Carson 2012 22 15.5 (2.5) 26 11.9 (4.5) 50.4 % 0.95 [ 0.35, 1.55 ]
Total (95% CI) 41 52 100.0 % 0.18 [ -0.25, 0.60 ]
Heterogeneity: Chi2 = 12.78, df = 1 (P = 0.00035); I2 =92%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Movement therapies versus usual care, Outcome 8 Sleep as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 9 Movement therapies versus usual care
Outcome: 8 Sleep as assessed post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Holmer 2004 12 9.08 (5.23) 17 13.76 (3.78) 100.0 % -4.68 [ -8.14, -1.22 ]
Total (95% CI) 12 17 100.0 % -4.68 [ -8.14, -1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Movement therapies versus usual care - sensitivity analyses intervention type,
Outcome 1 Functioning as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 10 Movement therapies versus usual care - sensitivity analyses intervention type
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carson 2010 19 35.49 (17.61) 26 48.69 (18.88) 36.6 % -0.71 [ -1.32, -0.10 ]
Carson 2012 22 34.5 (16.8) 26 28.3 (13.3) 41.4 % 0.41 [ -0.17, 0.98 ]
Holmer 2004 11 11.33 (2.77) 17 14.24 (4.16) 22.0 % -0.77 [ -1.55, 0.02 ]
Total (95% CI) 52 69 100.0 % -0.26 [ -0.63, 0.11 ]
Heterogeneity: Chi2 = 8.81, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Movement therapies versus usual care - sensitivity analyses quality, Outcome
1 Functioning as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 11 Movement therapies versus usual care - sensitivity analyses quality
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carson 2010 19 35.49 (17.61) 26 48.69 (18.88) 37.6 % -0.71 [ -1.32, -0.10 ]
Carson 2012 22 34.5 (16.8) 26 28.3 (13.3) 42.6 % 0.41 [ -0.17, 0.98 ]
Mannerkorpi 2004 12 7.3 (0.9) 10 7.1 (1.7) 19.9 % 0.15 [ -0.69, 0.99 ]
Total (95% CI) 53 62 100.0 % -0.06 [ -0.44, 0.31 ]
Heterogeneity: Chi2 = 7.07, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Movement therapies versus attention control, Outcome 1 Functioning as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 63.5 (19.6) 24 77.5 (21.4) 26.2 % -0.67 [ -1.25, -0.09 ]
Calandre 2009 42 51.7 (16.6) 39 55.5 (14.1) 45.5 % -0.24 [ -0.68, 0.19 ]
Wang 2010 32 34.6 (18.8) 29 58.6 (18.3) 28.3 % -1.28 [ -1.83, -0.72 ]
Total (95% CI) 99 92 100.0 % -0.65 [ -0.94, -0.35 ]
Heterogeneity: Chi2 = 8.22, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 4.31 (P = 0.000017)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Movement therapies versus attention control, Outcome 2 Functioning as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 2 Functioning as assessed at 3 month follow-up
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 69.3 (24.7) 24 77.6 (22.2) 27.3 % -0.35 [ -0.91, 0.22 ]
Calandre 2009 42 54.7 (14.3) 39 57 (13.2) 45.6 % -0.17 [ -0.60, 0.27 ]
Wang 2010 30 32.1 (20.1) 29 57.7 (18.3) 27.1 % -1.31 [ -1.88, -0.75 ]
Total (95% CI) 97 92 100.0 % -0.53 [ -0.82, -0.23 ]
Heterogeneity: Chi2 = 10.43, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 3.50 (P = 0.00047)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 Movement therapies versus attention control, Outcome 3 Pain as assessed by
a 10-point VAS scale post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 3 Pain as assessed by a 10-point VAS scale post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 4.1 (1.7) 24 6 (2.1) 35.1 % -1.90 [ -2.97, -0.83 ]
Calandre 2009 32 6.6 (2.3) 30 6.6 (2.1) 33.7 % 0.0 [ -1.10, 1.10 ]
Wang 2010 32 3.3 (2.1) 29 5.8 (2.4) 31.2 % -2.50 [ -3.64, -1.36 ]
Total (95% CI) 89 83 100.0 % -1.45 [ -2.08, -0.81 ]
Heterogeneity: Chi2 = 10.69, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.4. Comparison 12 Movement therapies versus attention control, Outcome 4 Pain as assessed by
a 10-point VAS scale at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 4 Pain as assessed by a 10-point VAS scale at 3 month follow-up
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 5.2 (2.5) 24 6.5 (2.1) 27.3 % -1.30 [ -2.59, -0.01 ]
Calandre 2009 29 7.1 (2.2) 28 6.9 (2.2) 34.9 % 0.20 [ -0.94, 1.34 ]
Wang 2010 30 3.3 (2.2) 29 5.7 (2.1) 37.8 % -2.40 [ -3.50, -1.30 ]
Total (95% CI) 84 81 100.0 % -1.19 [ -1.87, -0.52 ]
Heterogeneity: Chi2 = 10.39, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 3.47 (P = 0.00053)
Test for subgroup differences: Not applicable
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Analysis 12.5. Comparison 12 Movement therapies versus attention control, Outcome 5 Mood as assessed
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 5 Mood as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Calandre 2009 42 18.1 (10.1) 39 18.2 (8) 62.2 % -0.01 [ -0.45, 0.43 ]
Wang 2010 31 13.5 (8.9) 29 25.8 (10.1) 37.8 % -1.28 [ -1.84, -0.72 ]
Total (95% CI) 73 68 100.0 % -0.49 [ -0.83, -0.15 ]
Heterogeneity: Chi2 = 12.28, df = 1 (P = 0.00046); I2 =92%
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Not applicable
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Analysis 12.6. Comparison 12 Movement therapies versus attention control, Outcome 6 Mood as assessed
at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 6 Mood as assessed at 3 month follow-up
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Calandre 2009 42 18.3 (9.9) 39 17.8 (8.7) 60.7 % 0.05 [ -0.38, 0.49 ]
Wang 2010 30 15 (10.5) 29 25.6 (11.2) 39.3 % -0.96 [ -1.51, -0.42 ]
Total (95% CI) 72 68 100.0 % -0.35 [ -0.69, -0.01 ]
Heterogeneity: Chi2 = 8.23, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 2.00 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 12.7. Comparison 12 Movement therapies versus attention control, Outcome 7 All cause attrition
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 7 All cause attrition post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Altan 2009 0/25 1/23 9.5 % 0.31 [ 0.01, 7.20 ]
Calandre 2009 12/30 7/32 41.1 % 1.83 [ 0.83, 4.02 ]
Jones 2012 0/51 3/47 22.1 % 0.13 [ 0.01, 2.49 ]
Liu 2012 2/5 0/7 2.6 % 6.67 [ 0.39, 114.78 ]
Wang 2010 3/30 4/29 24.7 % 0.73 [ 0.18, 2.96 ]
Total (95% CI) 141 138 100.0 % 1.16 [ 0.65, 2.09 ]
Total events: 17 (Experimental), 15 (Control)
Heterogeneity: Chi2 = 5.94, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 0.50 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 12.8. Comparison 12 Movement therapies versus attention control, Outcome 8 Adverse events
post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 8 Adverse events post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Calandre 2009 3/39 0/39 100.0 % 7.00 [ 0.37, 131.17 ]
Total (95% CI) 39 39 100.0 % 7.00 [ 0.37, 131.17 ]
Total events: 3 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 12.9. Comparison 12 Movement therapies versus attention control, Outcome 9 Self-efficacy as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 9 Self-efficacy as assessed post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wang 2010 31 3.3 (1.9) 29 4.9 (1.8) 100.0 % -1.60 [ -2.54, -0.66 ]
Total (95% CI) 31 29 100.0 % -1.60 [ -2.54, -0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Not applicable
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Analysis 12.10. Comparison 12 Movement therapies versus attention control, Outcome 10 Self-efficacy as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 10 Self-efficacy as assessed at 3 month follow-up
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wang 2010 30 3.6 (2.2) 29 4.8 (1.9) 100.0 % -1.20 [ -2.25, -0.15 ]
Total (95% CI) 30 29 100.0 % -1.20 [ -2.25, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 12.11. Comparison 12 Movement therapies versus attention control, Outcome 11 Tender points as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 11 Tender points as assessed post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 13.2 (3.6) 24 14.1 (4.5) 29.6 % -0.90 [ -3.19, 1.39 ]
Calandre 2009 42 15.1 (3.7) 39 14.6 (3.1) 70.4 % 0.50 [ -0.98, 1.98 ]
Total (95% CI) 67 63 100.0 % 0.09 [ -1.16, 1.33 ]
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 12.12. Comparison 12 Movement therapies versus attention control, Outcome 12 Tender points as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 12 Tender points as assessed at 3 month follow-up
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 13.5 (3.8) 24 14.6 (3.6) 35.8 % -1.10 [ -3.17, 0.97 ]
Calandre 2009 42 15.1 (3.8) 39 15.1 (3.3) 64.2 % 0.0 [ -1.55, 1.55 ]
Total (95% CI) 67 63 100.0 % -0.39 [ -1.63, 0.85 ]
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 12.13. Comparison 12 Movement therapies versus attention control, Outcome 13 Quality of life as
assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 13 Quality of life as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 196.6 (111.3) 24 256.5 (112.4) 46.3 % -0.53 [ -1.10, 0.04 ]
Wang 2010 31 62.5 (10.6) 29 70.5 (7.7) 53.7 % -0.85 [ -1.38, -0.32 ]
Total (95% CI) 56 53 100.0 % -0.70 [ -1.09, -0.31 ]
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 3.53 (P = 0.00042)
Test for subgroup differences: Not applicable
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Analysis 12.14. Comparison 12 Movement therapies versus attention control, Outcome 14 Quality of life as
assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 14 Quality of life as assessed at 3 month follow-up
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 224.2 (129.2) 24 246.3 (128.1) 47.5 % -0.17 [ -0.73, 0.39 ]
Wang 2010 30 62.3 (10.3) 29 70.4 (8.5) 52.5 % -0.85 [ -1.38, -0.31 ]
Total (95% CI) 55 53 100.0 % -0.52 [ -0.91, -0.14 ]
Heterogeneity: Chi2 = 2.92, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 2.65 (P = 0.0080)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours movement Favours attention control
198Mind and body therapy for fibromyalgia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.15. Comparison 12 Movement therapies versus attention control, Outcome 15 Sleep quality as
assessed by the Pittsburgh Sleep Quality Index post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 15 Sleep quality as assessed by the Pittsburgh Sleep Quality Index post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Calandre 2009 42 12.9 (4.9) 39 13.9 (4.3) 48.4 % -1.00 [ -3.00, 1.00 ]
Wang 2010 31 9.9 (3.4) 29 12.6 (4.2) 51.6 % -2.70 [ -4.64, -0.76 ]
Total (95% CI) 73 68 100.0 % -1.88 [ -3.27, -0.48 ]
Heterogeneity: Chi2 = 1.43, df = 1 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.64 (P = 0.0083)
Test for subgroup differences: Not applicable
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Analysis 12.16. Comparison 12 Movement therapies versus attention control, Outcome 16 Sleep quality as
assessed by the Pittsburgh Sleep Quality Index at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 12 Movement therapies versus attention control
Outcome: 16 Sleep quality as assessed by the Pittsburgh Sleep Quality Index at 3 month follow-up
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Calandre 2009 42 13.7 (4.4) 39 13.7 (4.4) 54.9 % 0.0 [ -1.92, 1.92 ]
Wang 2010 30 9.1 (4.2) 29 12.1 (4.1) 45.1 % -3.00 [ -5.12, -0.88 ]
Total (95% CI) 72 68 100.0 % -1.35 [ -2.77, 0.07 ]
Heterogeneity: Chi2 = 4.24, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.86 (P = 0.062)
Test for subgroup differences: Not applicable
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Analysis 13.1. Comparison 13 Movement therapies versus attention control - sensitivity analyses, Outcome
1 Functioning as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 13 Movement therapies versus attention control - sensitivity analyses
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 63.5 (19.6) 24 77.5 (21.4) 48.0 % -0.67 [ -1.25, -0.09 ]
Wang 2010 32 34.6 (18.8) 29 58.6 (18.3) 52.0 % -1.28 [ -1.83, -0.72 ]
Total (95% CI) 57 53 100.0 % -0.99 [ -1.39, -0.59 ]
Heterogeneity: Chi2 = 2.19, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 4.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 Movement therapies versus attention control - sensitivity analyses, Outcome
2 Functioning as assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 13 Movement therapies versus attention control - sensitivity analyses
Outcome: 2 Functioning as assessed at 3 month follow-up
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 69.3 (24.7) 24 77.6 (22.2) 50.1 % -0.35 [ -0.91, 0.22 ]
Wang 2010 30 32.1 (20.1) 29 57.7 (18.3) 49.9 % -1.31 [ -1.88, -0.75 ]
Total (95% CI) 55 53 100.0 % -0.83 [ -1.23, -0.43 ]
Heterogeneity: Chi2 = 5.60, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 4.06 (P = 0.000048)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Movement therapies versus attention control - sensitivity analyses, Outcome
3 Pain as assessed by a 10-point VAS scale post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 13 Movement therapies versus attention control - sensitivity analyses
Outcome: 3 Pain as assessed by a 10-point VAS scale post-intervention
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 4.1 (1.7) 24 6 (2.1) 52.9 % -1.90 [ -2.97, -0.83 ]
Wang 2010 32 3.3 (2.1) 29 5.8 (2.4) 47.1 % -2.50 [ -3.64, -1.36 ]
Total (95% CI) 57 53 100.0 % -2.18 [ -2.96, -1.40 ]
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.48 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Movement therapies versus attention control - sensitivity analyses, Outcome
4 Pain as assessed by a 10-point VAS scale at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 13 Movement therapies versus attention control - sensitivity analyses
Outcome: 4 Pain as assessed by a 10-point VAS scale at 3 month follow-up
Study or subgroup Movement therapy Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Altan 2009 25 5.2 (2.5) 24 6.5 (2.1) 41.9 % -1.30 [ -2.59, -0.01 ]
Wang 2010 30 3.3 (2.2) 29 5.7 (2.1) 58.1 % -2.40 [ -3.50, -1.30 ]
Total (95% CI) 55 53 100.0 % -1.94 [ -2.77, -1.10 ]
Heterogeneity: Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.5. Comparison 13 Movement therapies versus attention control - sensitivity analyses, Outcome
5 Mood as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 13 Movement therapies versus attention control - sensitivity analyses
Outcome: 5 Mood as assessed post-intervention
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wang 2010 31 13.5 (8.9) 29 25.8 (10.1) 100.0 % -1.28 [ -1.84, -0.72 ]
Total (95% CI) 31 29 100.0 % -1.28 [ -1.84, -0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.6. Comparison 13 Movement therapies versus attention control - sensitivity analyses, Outcome
6 Mood as assessed at 3 month follow-up.
Review: Mind and body therapy for fibromyalgia
Comparison: 13 Movement therapies versus attention control - sensitivity analyses
Outcome: 6 Mood as assessed at 3 month follow-up
Study or subgroup Movement therapy Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wang 2010 30 15 (10.5) 29 25.6 (11.2) 100.0 % -0.96 [ -1.51, -0.42 ]
Total (95% CI) 30 29 100.0 % -0.96 [ -1.51, -0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.49 (P = 0.00048)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 Relaxation versus usual care, Outcome 1 Functioning as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 14 Relaxation versus usual care
Outcome: 1 Functioning as assessed post-intervention
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Menzies 2006 24 40.49 (3.25) 24 48.83 (3.16) 99.0 % -8.34 [ -10.15, -6.53 ]
Riedel 2012 9 52.42 (16.51) 10 60.2 (23.25) 1.0 % -7.78 [ -25.78, 10.22 ]
Total (95% CI) 33 34 100.0 % -8.33 [ -10.14, -6.53 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 9.05 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 Relaxation versus usual care, Outcome 2 Pain as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 14 Relaxation versus usual care
Outcome: 2 Pain as assessed post-intervention
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Menzies 2006 24 14.27 (1.95) 24 17.25 (1.86) 65.7 % -1.54 [ -2.19, -0.89 ]
Riedel 2012 9 11 (8.9) 10 11.3 (6.22) 34.3 % -0.04 [ -0.94, 0.86 ]
Total (95% CI) 33 34 100.0 % -1.02 [ -1.55, -0.50 ]
Heterogeneity: Chi2 = 7.01, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 3.80 (P = 0.00014)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 Relaxation versus usual care, Outcome 3 Mood as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 14 Relaxation versus usual care
Outcome: 3 Mood as assessed post-intervention
Study or subgroup Relaxation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Riedel 2012 9 18.56 (7.02) 10 23 (14.38) 100.0 % -4.44 [ -14.46, 5.58 ]
Total (95% CI) 9 10 100.0 % -4.44 [ -14.46, 5.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 14.4. Comparison 14 Relaxation versus usual care, Outcome 4 All cause attrition post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 14 Relaxation versus usual care
Outcome: 4 All cause attrition post-intervention
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Riedel 2012 4/10 1/11 100.0 % 4.40 [ 0.59, 33.07 ]
Total (95% CI) 10 11 100.0 % 4.40 [ 0.59, 33.07 ]
Total events: 4 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 14.5. Comparison 14 Relaxation versus usual care, Outcome 5 Self-efficacy as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 14 Relaxation versus usual care
Outcome: 5 Self-efficacy as assessed post-intervention
Study or subgroup Relaxation Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Menzies 2006 24 41.75 (4.82) 24 54.25 (4.61) 56.9 % -2.61 [ -3.39, -1.82 ]
Riedel 2012 9 44.01 (19.34) 10 46.79 (19.22) 43.1 % -0.14 [ -1.04, 0.76 ]
Total (95% CI) 33 34 100.0 % -1.54 [ -2.13, -0.95 ]
Heterogeneity: Chi2 = 16.38, df = 1 (P = 0.00005); I2 =94%
Test for overall effect: Z = 5.11 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 14.6. Comparison 14 Relaxation versus usual care, Outcome 6 Fatigue as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 14 Relaxation versus usual care
Outcome: 6 Fatigue as assessed post-intervention
Study or subgroup Relaxation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Riedel 2012 9 4.63 (1.64) 10 5.45 (2.9) 100.0 % -0.82 [ -2.91, 1.27 ]
Total (95% CI) 9 10 100.0 % -0.82 [ -2.91, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 14.7. Comparison 14 Relaxation versus usual care, Outcome 7 Sleep as assessed post-intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 14 Relaxation versus usual care
Outcome: 7 Sleep as assessed post-intervention
Study or subgroup Relaxation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Riedel 2012 9 12.33 (2.65) 10 11.3 (4.45) 100.0 % 1.03 [ -2.23, 4.29 ]
Total (95% CI) 9 10 100.0 % 1.03 [ -2.23, 4.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 Relaxation versus attention control, Outcome 1 Pain as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 15 Relaxation versus attention control
Outcome: 1 Pain as assessed post-intervention
Study or subgroup Relaxation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fors 2000 17 28.12 (19.23) 22 51.29 (23.96) 100.0 % -23.17 [ -36.73, -9.61 ]
Total (95% CI) 17 22 100.0 % -23.17 [ -36.73, -9.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 Relaxation versus attention control, Outcome 2 Mood as assessed post-
intervention.
Review: Mind and body therapy for fibromyalgia
Comparison: 15 Relaxation versus attention control
Outcome: 2 Mood as assessed post-intervention
Study or subgroup Relaxation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fors 2000 17 18.03 (17.99) 22 50.13 (27.28) 100.0 % -32.10 [ -46.35, -17.85 ]
Total (95% CI) 17 22 100.0 % -32.10 [ -46.35, -17.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.41 (P = 0.000010)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. National Center for Complementatry and Alternative Medicine Overview Statement
The National Center for Complementary and Alternative Medicine Overview Statement on mind-body medicine that “mind-body
medicine focuses on interactions among the brain, mind, body and behavior, and the powerful ways in which emotional, mental,
social and spiritual and behavioral factors can directly affect health. It regards as fundamental an approach that respects and enhances
each person’s capacity for self-knowledge and self-care, and it emphasizes techniques that are grounded in this approach. Mind-body
medicine typically focuses on intervention strategies that are thought to promote health, such as relaxation, yoga, biofeedback, tai chi,
qi gong and cognitive behavioral therapies. NCCAM 2005 page 1.
Appendix 2. Full search strategy
Search Strategies:
Cochrane Library Issue 10, 2013
#1 (fibromyalgia):ti,ab,kw or (fibromyalg*):ti,ab,kw or (muscular rheumatism):ti,ab,kw or (fibrositi*):ti,ab,kw
#2 (mind near body):ti,ab,kw or (hypnosis):ti,ab,kw or (meditat*):ti,ab,kw or (relax*):ti,ab,kw or (mindful*):ti,ab,kw
#3 (yoga):ti,ab,kw or (tai chi):ti,ab,kw or (breath* near exercise*):ti,ab,kw or (massage*):ti,ab,kw or (imagery):ti,ab,kw
#4 (biofeedback):ti,ab,kw or (hypno*):ti,ab,kw or (suggest*):ti,ab,kw or (autosuggest*):ti,ab,kw or (aromatherapy):ti,ab,kw
#5 MeSH descriptor Mind-Body Therapies explode all trees
#6 MeSH descriptor Yoga explode all trees
#7 MeSH descriptor Biofeedback, Psychology explode all trees
#8 MeSH descriptor Counseling explode all trees
#9 MeSH descriptor Aromatherapy explode all trees
#10 MeSH descriptor Tai Ji explode all trees
#11 MeSH descriptor Cognitive Therapy explode all trees
#12 MeSH descriptor Psychotherapy explode all trees
#13 MeSH descriptor Relaxation explode all trees
#14 MeSH descriptor Relaxation Therapy explode all trees
#15 (#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 (#1 AND #15)
(OVID) AMED (Allied and Complementary Medicine) <1985 to 31 October 2013>
1 exp Fibromyalgia/ (1437)
2 fibrositi$.tw. (21)
3 fibromyalgia.tw. (1604)
4 (chronic adj2 pain).tw. (2457)
5 or/1-4 (3805)
6 Psychosomatic therapies/ (1468)
7 (mind adj2 body).tw. (767)
8 Yoga/ (335)
9 exp Tai chi/ (202)
10 Exercise therapy/ (4804)
11 Tai ji.tw. (6)
12 autosuggestion.tw. (6)
13 exp Suggestion/ (129)
14 exp Hypnosis/ (3515)
15 hypnoti$.tw. (1398)
16 exp Imagery/ (162)
17 exp Visualization/ (171)
18 exp Mental healing/ (420)
19 guided imagery.tw. (99)
20 exp Relaxation/ (936)
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21 relax$.tw. (2677)
22 ((relax$ or relaxation) and (training or therapy or technique$)).ti,ab. (875)
23 exp Mind body relations/ (277)
24 exp Counseling/ (1589)
25 counsel$.tw. (2681)
26 exp Biofeedback/ (1005)
27 biofeedback.tw. (1194)
28 exp Aroma therapy/ (531)
29 aromatherap$.tw. (390)
30 or/6-29 (17221)
31 5 and 30 (448)
(OVID) Embase Classic+Embase <1947 to 31 October 2013>
--------------------------------------------------------------------------------
1 exp fibromyalgia/ (10187)
2 fibromyalg$.tw. (7904)
3 exp fibromatosis/ (3124)
4 fibrositi$.tw. (733)
5 muscular rheumatism.tw. (82)
6 or/1-5 (14475)
7 exp autogenic training/ (1411)
8 guided imagery/ (407)
9 relaxation training/ (7541)
10 imagery/ (4040)
11 exp suggestion/ (2495)
12 exp hypnosis/ (14958)
13 hypnoti$.tw. (16211)
14 exp meditation/ (2747)
15 meditat$.tw. (3100)
16 (auto adj2 suggestion).tw. (25)
17 (mind adj2 body).tw. (2861)
18 exp Tai Chi/ (876)
19 tai ji.tw. (12)
20 ((relax or relaxation) and (therapy or training or technique$)).tw. (16976)
21 directive counseling/ or patient counseling/ or counseling/ (59696)
22 biofeedback.tw. (6026)
23 awareness/ (25450)
24 bodywork/ (48)
25 exp massage/ (10249)
26 mindful$.tw. (2274)
27 or/7-26 (157692)
28 random$.tw. (693382)
29 factorial$.tw. (18501)
30 crossover$.tw. (42003)
31 cross over.tw. (19245)
32 cross-over.tw. (19245)
33 placebo$.tw. (172180)
34 (doubl$ adj blind$).tw. (129772)
35 (singl$ adj blind$).tw. (11667)
36 assign$.tw. (195232)
37 allocat$.tw. (65592)
38 volunteer$.tw. (158289)
39 crossover procedure/ (31641)
40 double blind procedure/ (106689)
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41 randomized controlled trial/ (296329)
42 single blind procedure/ (14559)
43 or/28-42 (1170580)
44 6 and 27 and 43 (170)
(OVID) MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1948 to 31 October 2013>
-------------------------------------------------------------------------------
1 Fibromyalgia/ (5292)
2 fibromyalg$.tw. (5521)
3 muscular rheumatism.tw. (38)
4 fibrositi$.tw. (484)
5 exp Mind-Body Therapies/ (37799)
6 (mind adj2 body).tw. (2139)
7 exp Psychophysiology/ (573224)
8 Relaxation/ (1670)
9 Relaxation Therapy/ (5474)
10 relax$.tw. (110666)
11 exp Meditation/ (1112)
12 meditat$.tw. (2330)
13 mindful.tw. (855)
14 exp Breathing Exercises/ (2457)
15 (breathing adj3 exercises).tw. (456)
16 respiratory muscle training.tw. (170)
17 (progressive adj muscle).tw. (1127)
18 exp Massage/ (4261)
19 massag$.tw. (6607)
20 exp ”Imagery (Psychotherapy)“/ (951)
21 imagery.tw. (7207)
22 exp Biofeedback, Psychology/ (6311)
23 biofeedback.tw. (4492)
24 aromatherap$.tw. (488)
25 exp Aromatherapy/ (455)
26 essential oils.tw. (2920)
27 exp Hypnosis/ (10256)
28 hypnoti$.tw. (10876)
29 hypnosis.tw. (5787)
30 hypnotherap$.tw. (876)
31 exp suggestion/ (2986)
32 autosuggest$.tw. (33)
33 ((mind or mental) adj heal$).tw. (63093)
34 exp Yoga/ (1173)
35 yoga.tw. (1287)
36 exp Tai Ji/ (458)
37 (tai ji or tai chi).tw. (615)
38 (qigong or (qi adj gong) or (gi adj gong)).tw. (343)
39 (chi adj kung).tw. (6)
40 exp Psychotherapy/ (137463)
41 psychotherap$.tw. (28690)
42 exp Cognitive Therapy/ (12610)
43 cbt.tw. (3704)
44 (behav$ adj2 therap$).tw. (11218)
45 (cognitive adj2 therap$).tw. (8028)
46 exp Counseling/ (29617)
47 counsel$.tw. (58972)
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48 exp Counseling/ (29617)
49 Directive Counseling/ (827)
50 (supportive adj2 (therap* or psychotherap*)).tw. (3914)
51 humanistic.tw. (1715)
52 randomized controlled trial.pt. (323095)
53 controlled clinical trial.pt. (84091)
54 randomized.ab. (239369)
55 placebo.ab. (135087)
56 clinical trials as topic.sh. (159645)
57 randomly.ab. (175198)
58 trial.ti. (102635)
59 or/52-58 (776419)
60 exp animals/ not humans.sh. (3722514)
61 59 not 60 (718473)
62 or/1-4 (6807)
63 or/5-51 (954295)
64 61 and 62 and 63 (439)
(OVID) PsycINFO <1806 to 31 October 2013>
-------------------------------------------------------------------------------
1 exp Fibromyalgia/ (902)
2 fibrositi$.tw. (44)
3 fibromyalg$.tw. (1813)
4 muscular rheumatism.tw. (3)
5 (chronic adj2 pain).ti,ab. (9336)
6 or/1-5 (10671)
7 exp Autogenic Training/ (591)
8 exp RELAXATION THERAPY/ (3274)
9 exp Guided Imagery/ (551)
10 exp HYPNOTHERAPY/ (4264)
11 exp MEDITATION/ (2405)
12 exp YOGA/ (777)
13 autosuggestion.tw. (185)
14 exp HYPNOSIS/ (6685)
15 exp Meditation/ (2405)
16 meditat$.tw. (4718)
17 auto suggestion.tw. (95)
18 Posthypnotic Suggestions/ (241)
19 exp Biofeedback Training/ or exp Biofeedback/ (4577)
20 exp Counseling/ (60325)
21 ((relax$ or relaxation) and (training or therapy or technique$)).ti,ab. (7026)
22 Dualism/ (2474)
23 (mind adj2 body).tw. (5676)
24 or/7-23 (92232)
25 6 and 24 (719)
EbscoHost CINAHL 1981 to 31 October 2013
S16 S3 and S15
S15 S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14
S14 (MM ”Autogenic Training (Iowa NIC)“)
S13 (MM ”Counseling“)
S12 (MM ”Massage“)
S11 (MM ”Tai Chi“)
S10 (MM ”Yoga“)
S9 (MM ”Meditation“)
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S8 (MM ”Relaxation“)
S7 (MM ”Biofeedback“)
S6 (MM ”Hypnosis“)
S5 (MM ”Guided Imagery“) OR (MM ”Simple Guided Imagery (Iowa NIC)“)
S4 (MM ”Mind Body Techniques“)
S3 S1 or S2
S2 (MM ”Chronic Pain/DH/NU/PR/PC/PF/RT/RH/TH“)
S1 (MH ”Fibromyalgia“) OR ”fibromyalgia“
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Alice Theadom is a psychologist who specialises in conducting research of psychological interventions in health care.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Further refinement of the definition of what constitutes a mind-body intervention was required to provided clear criteria on what types
of interventions would and would not meet the criteria for inclusion in the review.
Outcomes have been presented to facilitate standardisation of outcomes between reviews on fibromyalgia within Cochrane.
Adverse events and withdrawals between groups have been added to the major outcomes to reflect other important potential harmful
outcomes of mind-body interventions.
No studies made reference to early stopping or indicated any variations in intervention delivery, and therefore these other risks of bias
were not included in the risk of bias assessment.
214Mind and body therapy for fibromyalgia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
